Compounds > mesalamine
Page last updated: 2024-10-30

mesalamine and Bowel Diseases, Inflammatory

mesalamine has been researched along with Bowel Diseases, Inflammatory in 510 studies

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Research Excerpts

ExcerptRelevanceReference
"Patients who received mesalamine plus the mixture of beta-glucan, inositol and digestive enzymes (group A) reported a reduction in abdominal pain together with reduction in bloating and flatulence after four weeks of treatment."9.24Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome. ( Cosco, C; Cosco, V; Doldo, P; Garieri, P; Mancina, RM; Ruggiero, G; Spagnuolo, R, 2017)
"Some patients with inflammatory bowel disease (IBD) who were under mesalamine treatment develop adverse reactions called "mesalamine allergy," which includes high fever and worsening diarrhea."9.22Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease. ( Andoh, A; Araki, H; Fujii, T; Fujiya, M; Hanai, H; Hiraoka, S; Hisamatsu, T; Hokari, R; Ishiguro, Y; Kakuta, Y; Katsurada, T; Kawai, Y; Kinouchi, Y; Kobayashi, T; Kudo, H; Kuroha, M; Li, D; Masamune, A; Matsumoto, T; Matsuura, M; McGovern, DPB; Minegishi, N; Moroi, R; Motoya, S; Nagasaki, M; Naito, T; Nakase, H; Noguchi, M; Ohta, Y; Okamoto, D; Onodera, M; Oshima, N; Otsuka, T; Sakuraba, H; Sasaki, M; Sasaki, Y; Sato, Y; Shiga, H; Shimoyama, Y; Shinozaki, M; Suzuki, K; Suzuki, Y; Takagawa, T; Tokunaga, K, 2022)
"The Motherisk Program prospectively enrolled and followed up 165 women exposed to mesalamine during pregnancy, 146 of whom had first trimester exposure."9.08The safety of mesalamine in human pregnancy: a prospective controlled cohort study. ( Bologa, M; Diav-Citrin, O; Koren, G; Park, YH; Pastuszak, A; Polachek, H; Veerasuntharam, G, 1998)
"To examine serum C-reactive protein levels and the prevalence of leukopenia in patients with Crohn's disease or ulcerative colitis undergoing treatment with azathioprine and/or mesalazine."8.12C-reactive protein levels and prevalence of leukopenia in patients with inflammatory bowel disease treated with azathioprine and/or mesalazine: a real-life study. ( Catapani, WR; Santos, RCFD; Takahashi, AAR; Waisberg, J, 2022)
"Mesalamine (5-ASA) is one of the drugs indicated as first line therapy in ulcerative colitis for induction and maintenance of remission."7.83Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases. ( Kandula, M; Palanichamy, S; Rampal, A; Sunil Kumar, KB, 2016)
"A 38-year-old Caucasian man with a medical history significant for inflammatory bowel disease (IBD) and mesalamine use presented to the emergency department with stabbing, pleuritic, substernal chest pain over the previous 2 days."7.81Cardiac MRI-confirmed mesalamine-induced myocarditis. ( Baker, WL; Elliott, K; Parker, MW; Saulsberry, WJ, 2015)
"This observation suggests that the higher frequency of lymphopenia may be associated with the elevated 6-TGN concentrations recovered in patients treated with aminosalicylates."7.76High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine. ( Boulieu, R; Lachaux, A; Le Gall, C; Nguyen, TM, 2010)
"We prospectively investigated colonoscopic biopsies from five groups of 20 subjects each: patients with ulcerative or indeterminate colitis treated with azathioprine (group 1), azathioprine and 5-ASA (group 2), 5-ASA (group 3), untreated IBD (group 4), and healthy controls."7.74Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis. ( Bengmark, S; Dörffel, Y; Lochs, H; Loening-Baucke, V; Swidsinski, A, 2007)
"Colitis was induced in mice by intracolonic (i."5.51Evaluation of the effect of liposomes loaded with chlorogenic acid in treatment of 2,4,6-trinitrobenzenesulfonic acid-induced murine colitis. ( Chen, C; Czapor-Irzabek, H; Fichna, J; Gorniak, A; Karolewicz, B; Krajewska, JB; Owczarek, A; Pietruszka, P; Tomczyk, D, 2019)
"Evaluate factors influencing risk of colorectal cancer development in inflammatory bowel disease patients."5.36Mesalamine protects against colorectal cancer in inflammatory bowel disease. ( Pai, C; Sharif, O; Silverman, AL; Tang, J, 2010)
"Pancreatitis is a potentially severe condition."5.35Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. ( Algaba, A; Bermejo, F; Calvo, M; Carneros, JA; Gisbert, JP; López, P; Lopez-Sanroman, A; Luna, M; Martín-Arranz, MD; Menchén, L; Mendoza, JL; Opio, V; Pérez-Calle, JL; Taxonera, C; Van-Domselaar, M; Vera, I, 2008)
"Patients who received mesalamine plus the mixture of beta-glucan, inositol and digestive enzymes (group A) reported a reduction in abdominal pain together with reduction in bloating and flatulence after four weeks of treatment."5.24Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome. ( Cosco, C; Cosco, V; Doldo, P; Garieri, P; Mancina, RM; Ruggiero, G; Spagnuolo, R, 2017)
"Some patients with inflammatory bowel disease (IBD) who were under mesalamine treatment develop adverse reactions called "mesalamine allergy," which includes high fever and worsening diarrhea."5.22Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease. ( Andoh, A; Araki, H; Fujii, T; Fujiya, M; Hanai, H; Hiraoka, S; Hisamatsu, T; Hokari, R; Ishiguro, Y; Kakuta, Y; Katsurada, T; Kawai, Y; Kinouchi, Y; Kobayashi, T; Kudo, H; Kuroha, M; Li, D; Masamune, A; Matsumoto, T; Matsuura, M; McGovern, DPB; Minegishi, N; Moroi, R; Motoya, S; Nagasaki, M; Naito, T; Nakase, H; Noguchi, M; Ohta, Y; Okamoto, D; Onodera, M; Oshima, N; Otsuka, T; Sakuraba, H; Sasaki, M; Sasaki, Y; Sato, Y; Shiga, H; Shimoyama, Y; Shinozaki, M; Suzuki, K; Suzuki, Y; Takagawa, T; Tokunaga, K, 2022)
"The Motherisk Program prospectively enrolled and followed up 165 women exposed to mesalamine during pregnancy, 146 of whom had first trimester exposure."5.08The safety of mesalamine in human pregnancy: a prospective controlled cohort study. ( Bologa, M; Diav-Citrin, O; Koren, G; Park, YH; Pastuszak, A; Polachek, H; Veerasuntharam, G, 1998)
"The package inserts for products containing 5-aminosalicylic acid, or mesalamine, include the following language regarding the risk of adverse kidney effects: "renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and rarely renal failure, has been reported in patients given products such as mesalamine delayed-release tablets that contain mesalamine or are converted to mesalamine."5.05The Association of Mesalamine With Kidney Disease. ( Adiga, A; Goldfarb, DS, 2020)
"Data from both basic research and clinical experience continue to suggest that mesalamines and thiopurines are effective and efficient for the maintenance of remission of inflammatory bowel diseases."4.85Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease. ( Actis, GC; Ayoubi, M; Leone, N; Pazienza, P; Pellicano, R; Rizzetto, M; Rosina, F; Tappero, G, 2009)
"To examine serum C-reactive protein levels and the prevalence of leukopenia in patients with Crohn's disease or ulcerative colitis undergoing treatment with azathioprine and/or mesalazine."4.12C-reactive protein levels and prevalence of leukopenia in patients with inflammatory bowel disease treated with azathioprine and/or mesalazine: a real-life study. ( Catapani, WR; Santos, RCFD; Takahashi, AAR; Waisberg, J, 2022)
"Bronchiectasis was treated with inhaled oral steroids and sputum expectoration while she continued mesalamine and azathioprine for ulcerative colitis."4.12Ulcerative colitis-associated bronchiectasis: A rare extraintestinal manifestation of inflammatory bowel disease: A case report. ( Abbas, A; Alhalabi, M; Ali Deeb, S; Ali, F, 2022)
" The strong inhibitory activity of compound 55 against an in vivo colitis model was confirmed by its dose-dependent inhibitory activity in a rat model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis, demonstrating compound 55 as a new potential candidate for the development of therapeutics against IBD."3.85Discovery and structure-activity relationship studies of 2-benzylidene-2,3-dihydro-1H-inden-1-one and benzofuran-3(2H)-one derivatives as a novel class of potential therapeutics for inflammatory bowel disease. ( Banskota, S; Bist, G; Gurung, P; Kadayat, TM; Kim, JA; Lee, ES; Shrestha, A; Thapa Magar, TB, 2017)
"), with that of 5-aminosalicylic acid (5-ASA), a first-line drug in IBD, in a 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis rat model."3.85Comparison of anti-inflammatory activities of an anthocyanin-rich fraction from Portuguese blueberries (Vaccinium corymbosum L.) and 5-aminosalicylic acid in a TNBS-induced colitis rat model. ( Almeida, LM; Dinis, TC; Figueiredo, I; Freitas, V; Pereira, R; Pereira, SR, 2017)
"In this work, thiolated chitosan/alginate composite microparticulates (CMPs) coated by Eudragit S-100 were developed for colon-specific delivery of 5-aminosalicylic acid (5-ASA) and curcumin (CUR), and the use of it as a multi drug delivery system for the treatment of colitis."3.83Mucoadhesive microparticulates based on polysaccharide for target dual drug delivery of 5-aminosalicylic acid and curcumin to inflamed colon. ( Bai, X; Duan, H; Gao, C; Liu, M; Lü, S; Qin, H; Wei, Y; Wu, X, 2016)
"Mesalamine (5-ASA) is one of the drugs indicated as first line therapy in ulcerative colitis for induction and maintenance of remission."3.83Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases. ( Kandula, M; Palanichamy, S; Rampal, A; Sunil Kumar, KB, 2016)
"A 38-year-old Caucasian man with a medical history significant for inflammatory bowel disease (IBD) and mesalamine use presented to the emergency department with stabbing, pleuritic, substernal chest pain over the previous 2 days."3.81Cardiac MRI-confirmed mesalamine-induced myocarditis. ( Baker, WL; Elliott, K; Parker, MW; Saulsberry, WJ, 2015)
"Mesalamine and thiopurines (6-mercaptopurine and azathioprine) have been shown to increase the risk of developing acute pancreatitis in inflammatory bowel disease (IBD) patients."3.80Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease. ( Deepak, P; Stobaugh, DJ, 2014)
" Subsequently, its protective effect in indomethacin and iodoacetamide induced colitis in rats (45, 90, 180, 270 mg/kg) and acetic acid induced colitis in mice (65, 130, 250, 500 mg/kg) was assessed."3.77Protective effect of aqueous extract of Bombax malabaricum DC on experimental models of inflammatory bowel disease in rats and mice. ( Jagtap, AG; Niphadkar, PV; Phadke, AS, 2011)
"This observation suggests that the higher frequency of lymphopenia may be associated with the elevated 6-TGN concentrations recovered in patients treated with aminosalicylates."3.76High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine. ( Boulieu, R; Lachaux, A; Le Gall, C; Nguyen, TM, 2010)
"Film coatings based on blends of Eurylon 6 HP-PG (a hydroxypropylated and pregelatinized high amylose starch) and ethylcellulose were to be evaluated as promising coating materials for site-specific drug delivery to the colon of patients suffering from inflammatory bowel diseases."3.76Enzymatically degraded Eurylon 6 HP-PG: ethylcellulose film coatings for colon targeting in inflammatory bowel disease patients. ( Deremaux, L; Desreumaux, P; Dubreuil, L; Flament, MP; Karrout, Y; Lemdani, M; Neut, C; Ravaux, P; Siepmann, F; Siepmann, J; Wils, D, 2010)
" The prodrugs exhibited comparable ameliorating effect as that of sulfasalazine on trinitrobenzenesulfonic acid-induced experimental colitis in rats with a better safety profile."3.75Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease. ( Bhatt, L; Dhaneshwar, SS; Gairola, N; Kadam, SS; Kandpal, M; Rathi, B; Vadnerkar, G, 2009)
"We prospectively investigated colonoscopic biopsies from five groups of 20 subjects each: patients with ulcerative or indeterminate colitis treated with azathioprine (group 1), azathioprine and 5-ASA (group 2), 5-ASA (group 3), untreated IBD (group 4), and healthy controls."3.74Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis. ( Bengmark, S; Dörffel, Y; Lochs, H; Loening-Baucke, V; Swidsinski, A, 2007)
"Our understanding of coronavirus disease 2019 (COVID-19) and its implications for patients with inflammatory bowel diseases (IBD) is rapidly evolving."2.82COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. ( Godoy Brewer, G; Limketkai, BN; Parian, AM; Saleh Ismail, M; Sauk, JS; Singh, Y; Thu Nguyen, M; Tripathi, K, 2022)
"The risk of acute pancreatitis in patients with IBD is increased due to the higher incidence of cholelithiasis and drug-induced pancreatitis in this population."2.82Pancreatic Disorders in Patients with Inflammatory Bowel Disease. ( Bi, Y; Corral, JE; Farraye, FA; Ji, B; Kröner, PT; Lukens, FJ; Montenegro, ML, 2022)
" Given the high use of complementary alternative medicines in pediatric IBD, a prospective tolerability study of curcumin, an herbal therapy with known anti-inflammatory effects, was conducted to assess possible dosage in children with IBD."2.78Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. ( Burpee, T; Christie, D; Cohen, M; Suskind, DL; Wahbeh, G; Weber, W, 2013)
"Inflammatory bowel diseases such as ulcerative colitis (UC) may be complicated by several extraintestinal manifestations."2.72Recurrent myocarditis in a patient with active ulcerative colitis: a case report and review of the literature. ( Caio, G; Caputo, F; De Giorgio, R; Lungaro, L; Marcello, MC; Muccinelli, M; Volta, U; Zoli, E; Zoli, G, 2021)
" In children, pharmacokinetic data are scarce, and dosage recommendations are largely extrapolated from studies in adults."2.71Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. ( Benninga, MA; Dilger, K; Escher, JC; Taminiau, J; Trenk, D; van Boxtel, CJ; Wiersma, H, 2004)
"Mean mercaptopurine dose was 0."2.71The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. ( Bierau, J; Bos, LP; Derijks, LJ; Engels, LG; Gilissen, LP; Hooymans, PM; Stockbrügger, RW; van Gennip, A, 2005)
"Tubular proteinuria is an extra-intestinal manifestation of inflammatory bowel disease irrespective of 5-ASA treatment."2.70Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. ( Fraser, JS; Lamb, EJ; Muller, AF; Newman, DJ; Smith, DJ, 2001)
"Although leukopenia was associated with higher 6-TG levels (P < 0."2.69Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. ( Dubinsky, MC; Lamothe, S; Seidman, EG; Sinnett, D; Targan, SR; Théorêt, Y; Yang, HY, 2000)
"pylori."2.69Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease. ( Duncan, HD; Green, JR; Pearce, CB; Timmis, L, 2000)
"Management of inflammatory bowel diseases has witnessed paradigm shift from 5-aminosalicylic acid and glucocorticoids to various immunosuppressant and biological agents."2.61Mucosal healing in inflammatory bowel disease: Expanding horizon. ( Dutta, U; Shah, J; Thakur, ML, 2019)
"The presence of concomitant primary sclerosing cholangitis (PSC) with inflammatory bowel disease (IBD) represents a distinct disease phenotype that carries a higher risk of colorectal cancer (CRC) than the average IBD patient."2.58Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. ( Kowdley, KV; Lashner, B; Rao, BB, 2018)
" In IBD patients, mesalazine dosage ≥ 1."2.55Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. ( Ma, J; Qiu, X; Wang, K; Zhang, H, 2017)
"When we look at the natural history of Crohn's disease (CD), it first begins with inflammation of the intestinal mucosa and this inflammatory reaction proceeds to stenosing or penetrating reaction if not adequately controlled."2.52[Changing paradigm in the management of inflammatory bowel disease]. ( Jang, BI, 2015)
"Mesalamine was associated with a modest reduction in the odds ratio (OR) of CRN (OR = 0."2.52Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis. ( Akbari, M; Moss, AC; OʼConnor, A; Packey, CD, 2015)
" As long-term administration of medications is often necessary, the safety of drug therapy during pregnancy and breast-feeding needs to be considered in daily clinical practice."2.50IBD medications during pregnancy and lactation. ( Hendel, J; Maxwell, C; Nielsen, OH, 2014)
" The older patient with IBD is more susceptible to disease-related complications and also to adverse events with therapy, particularly immunosuppression."2.50Medical management of inflammatory bowel disease in the elderly: balancing safety and efficacy. ( Ha, CY, 2014)
"The risk of developing colorectal cancer is increased in patients with inflammatory bowel disease."2.50[Chemoprevention of colorectal cancer in inflammatory bowel disease]. ( Han, SH; Lee, J, 2014)
"An increased risk of colorectal cancer (CRC) is present also after LT in IBD patients with primary sclerosing cholangitis (PSC)."2.50Clinical management of inflammatory bowel disease in the organ recipient. ( Indriolo, A; Ravelli, P, 2014)
"Diarrhea is a common clinical feature of inflammatory bowel diseases and may be accompanied by abdominal pain, urgency, and fecal incontinence."2.48Diarrhea in chronic inflammatory bowel diseases. ( Wenzl, HH, 2012)
"This article is a review of recently published research dealing with new 5-ASA dosage forms."2.47Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease. ( Bautzová, T; Lamprecht, A; Rabišková, M, 2011)
"Crohn's disease and ulcerative colitis, together popularly known as inflammatory bowel disease (IBD), are characterized by a number of extraintestinal manifestations."2.46Pancreatitis in inflammatory bowel diseases. ( Das, K; Pitchumoni, CS; Rubin, A, 2010)
"Inflammatory bowel diseases are chronic diseases that affect the gastrointestinal tract."2.46New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. ( Danese, S; De La Rue, SA; Fiorino, G; Fries, W; Malesci, AC; Repici, A, 2010)
" Patients often take only 40 to 80% of their prescribed dosage of medication."2.45[The problems of compliance and adherence, using the example of chronic inflammatory bowel disease]. ( Siegmund, SV; Singer, MV; Zimmerer, T, 2009)
" Recently, attention has focused on optimizing dosing strategies for biologic agents; however, of equal importance are recent advances in the optimization of conventional IBD therapies."2.45Optimizing conventional therapies for inflammatory bowel disease. ( Hanauer, SB; Irving, PM; Sparrow, MP, 2009)
"ulcerative colitis and Crohn's disease), for both active disease and the control of remission."2.44Drug insight: aminosalicylates for the treatment of IBD. ( Munck, LK; Nielsen, OH, 2007)
"The therapy of inflammatory bowel diseases is based on 5-aminosalicylates (5-ASAs) that are the forefront of treatment of mild-to-moderate active disease and maintenance; steroids are used for the treatment of moderate-to-severe active disease; immunosuppressives and sometimes antibiotics in moderate-to-severe disease; maintenance and for the treatment of selected complications."2.44[Medical therapy of inflammatory bowel diseases: Crohn's disease]. ( Lakatos, L; Lakatos, PL, 2007)
" For patients with severe ulcerative colitis (UC), steroid dosing has been clarified, and a mega-analysis of steroid outcomes and toxicities has been reported."2.44Optimizing drug therapy in inflammatory bowel disease. ( Kornbluth, A; Swaminath, A, 2007)
"Medication non-adherence is multifactorial involving factors other than dosing frequency."2.44Review article: medication non-adherence in ulcerative colitis--strategies to improve adherence with mesalazine and other maintenance therapies. ( Ghosh, S; Hawthorne, AB; Rubin, G, 2008)
"The same drugs are used to treat hemorrhagic rectocolitis (HRC) and Crohn's disease (CD), although the aims are very different."2.44[Treatment of chronic inflammatory bowel diseases]. ( Lémann, M, 2007)
" Retrospective correlative studies have suggested that the long-term use of 5-ASA in IBD patients may significantly reduce the risk of development of colorectal cancer."2.435-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. ( Cheng, Y; Desreumaux, P, 2005)
"Treatment of ulcerative colitis has changed little in recent years, except for our improved ability to deliver mesalazine to the large bowel via the recent availability of several oral and rectal preparations."2.43Inflammatory bowel disease. ( Gibson, PR; Iser, J, 2005)
"Most of these cases had a history of ulcerative colitis (76 patients)."2.435-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. ( Card, T; Leufkens, HG; Logan, RF; van Staa, TP, 2005)
"The main risk factors for colorectal cancer are not suitable targets for therapeutic intervention, and primary chemoprevention is an intriguing therapeutic option."2.435-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'? ( Giannini, EG; Kane, SV; Savarino, V; Testa, R, 2005)
"Balsalazide is a mesalamine prodrug that is generally well tolerated and useful in the treatment of inflammatory bowel disease (IBD)."2.43Safety of balsalazide therapy in the treatment of inflammatory bowel disease. ( Baker, DE, 2005)
" However, the minimal dosage to achieve this chemopreventive effect remains unclear."2.43Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates. ( Esendal, B; Kornbluth, A; Loftus, EV; Mittmann, U; Munkholm, P; Reinacher-Schick, A, 2006)
"Crohn's disease (CD) and ulcerative colitis (UC) are common and heterogeneous chronic inflammatory bowel disorders of childhood that account for up to 25% of all patients with inflammatory bowel disease (IBD)."2.43Inflammatory bowel disease in children: a pediatrician's perspective. ( Cuffari, C, 2006)
" Therapeutic success of mesalazine may be optimized by a combination of high dose and low frequency of dosage to improve compliance."2.43Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? ( Mulder, CJ; van Bodegraven, AA, 2006)
"The relative risk of colorectal cancer in ulcerative colitis is increased, however, there're marked geographically differences."2.43[Inflammatory bowel disease and colorectal cancer]. ( Hagymási, K; Tulassay, Z, 2006)
"Although colorectal cancer (CRC), complicating ulcerative colitis and Crohn's disease, only accounts for 1-2% of all cases of CRC in the general population, it is considered a serious complication of the disease and accounts for approximately 15% of all deaths in inflammatory bowel disease (IBD) patients."2.42Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. ( Munkholm, P, 2003)
"Some cases of Crohn's disease could be treated with anti-TNFalpha antibodies that successfully treat the relapses of disease."2.42[The conservative treatment of nonspecific inflammatory bowel diseases]. ( Chojnacki, J; Gil, J; Wichan, P; Wojtuń, S, 2004)
"The risk of colorectal cancer is increased in ulcerative colitis and Crohn's colitis."2.41Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. ( Bernstein, CN; Eaden, J; Gordon, PH; Munkholm, P; Steinhart, AH, 2002)
"It describes the treatment of ulcerative colitis according to the different groups of patients and the degree of activity."2.41[Conservative therapy of inflammatory bowel diseases]. ( Nagy, F, 2002)
" Although significant differences are found between the various aminosalicylates in release patterns and the resulting pharmacokinetic parameters, no differences in therapeutic effects have been found in comparative studies."2.41Clinical pharmacokinetics of slow release mesalazine. ( De Vos, M, 2000)
" It is conceivable that reduced intracolonic pH in active ulcerative colitis impairs bioavailability of 5-aminosalicylic acid from pH dependent release formulations (Asacol, Salofalk) and those requiring cleavage by bacterial azo reductase (sulphasalazine, olsalazine, balsalazide), but further pharmacokinetic studies are needed to confirm this possibility."2.41Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. ( Evans, DF; Kumar, D; Nugent, SG; Rampton, DS, 2001)
"Often, relapse is related to the failure of maintenance therapy."2.40Factors influencing the relapse of patients with inflammatory bowel disease. ( Miner, PB, 1997)
" Little is known about the dose-response relationship and about possible dose related side effects."2.40Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease. ( Mulder, CJ; van den Hazel, SJ, 1998)
" This concept of drug targeting could be accomplished by both special galenic formulations and by utilizing the pharmacokinetic properties of the agents especially their high intestinal and hepatic presystemic elimination."2.40[Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations]. ( Klotz, U, 1999)
"Mesalamine use was associated with fewer relapses in UC/IBDU patients (aHR, 0."1.91Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease. ( Akol-Simsek, D; Colombel, JF; de Koning, DB; Fidder, HH; Goetgebuer, R; Hoentjen, F; Horjus-Talabur Horje, CS; Jansen, JM; Jharap, B; Lutgens, MWMD; Mahmmod, N; Mahmoud, R; Mares, W; Minderhoud, I; Oldenburg, B; Römkens, TEH; Savelkoul, EHJ; van Boeckel, PGA; van Schaik, FDM; van Tuyl, SAC; Witteman, BJM, 2023)
"The medical records of patients with Crohn's disease (CD) and ulcerative colitis (UC) diagnosed with IBD-associated intestinal neoplasia (dysplasia or cancer) from 1983 to 2020 were included in this study."1.91Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study. ( Ajioka, Y; Akagi, Y; Arakaki, J; Daito, K; Futami, K; Goi, T; Hanai, T; Hasegawa, J; Hida, K; Ikeuchi, H; Iseki, Y; Ishida, F; Ishihara, S; Itabashi, M; Kanemitsu, Y; Katsumata, K; Kazama, S; Kimura, H; Kinugasa, Y; Kiyomatsu, T; Komori, K; Koyama, F; Maeda, K; Maemoto, A; Matsuda, K; Nakamura, M; Nezu, R; Noake, T; Noguchi, T; Ogino, T; Ohge, H; Okabayashi, K; Okamoto, K; Okuda, J; Sasaki, S; Sato, Y; Seishima, R; Shida, D; Sugihara, K; Sunami, E; Suto, T; Takahashi, K; Toiyama, Y; Uchino, M; Uehara, K; Ueno, H; Wakai, T; Watanabe, K; Yamada, K; Yamada, T; Yamaguchi, S; Yamamoto, S; Yamamoto, T, 2023)
"Because intestinal inflammation affects the gut microbiota and 5-ASA can change the severity of inflammation, assessing the impact of inflammation and 5-ASA on the gut microbiota is not feasible in a clinical study of patients with UC."1.915-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis. ( Akimoto, Y; Hibi, N; Hibi, T; Hisamatsu, T; Kobayashi, T; Kuronuma, S; Lee, STM; Matsuura, M; Miyoshi, J; Nishinarita, Y; Oguri, N; Takeuchi, O; Wada, H, 2023)
"Ulcerative colitis is a relapsing and remitting disease that may be associated with flares."1.91Factors contributing to flares of ulcerative colitis in North India- a case-control study. ( Dutta, U; Jearth, V; Mahajan, G; Patil, AN; Rana, VS; Saroch, A; Sekar, A; Sharma, V; Singh, AK; Singh, H, 2023)
"Among 10 400 patients, ulcerative colitis (UC) was twice as common as Crohn's disease (CD), with a male predominance (UC 6678, CD 3495, IBD unclassified 227, and 58% male)."1.72Emerging inflammatory bowel disease demographics, phenotype, and treatment in South Asia, South-East Asia, and Middle East: Preliminary findings from the Inflammatory Bowel Disease-Emerging Nations' Consortium. ( Abdullah, M; Aftab, H; Ahmed, F; Al Awadhi, S; Al Mohannadi, M; Ali, E; Aniwan, S; Aye, TT; Banerjee, R; Bhatia, SJ; Chaudhuri, S; De Silva, AP; de Silva, HJ; Desai, DC; Dutta, U; Fernandopulle, N; Ghoshal, UC; Hilmi, I; Joshi, N; Kieu, TV; Limsrivilai, J; Mohiuddin, SA; Mohsin, MN; Nawarathne, M; Ngoc, PTV; Nguyen, AD; Ni, N; Niriella, MA; Omar, M; Pal, P; Philip, M; Pisespongsa, P; Rahman, MM; Ramesh, GN; Saberi, B; Shastri, YM; Sollano, JD; Travis, SPL; Wai, TM; Zeid, A, 2022)
"The difference in 6 months recurrence rates of subjects receiving or not receiving mesalazine was the primary outcome measure."1.72The role of mesalazine co-treatment in the prevention of recurrence in subjects with subclinical inflammatory bowel disease and perianal fistula who are scheduled for surgical intervention. ( Akturk, R; Serinsöz, S, 2022)
"Distal ulcerative colitis (UC) is responsible for distressing symptoms and reduces quality of life (QoL)."1.72Real-world evidence of quality of life improvement in patients with distal ulcerative colitis treated by mesalazine: the Quartz study. ( Caron, B; Gonzalez, F; Paupard, T; Peyrin-Biroulet, L; Siproudhis, L, 2022)
"Crohn's disease (CD) and ulcerative colitis (UC) are complex, inflammatory bowel diseases (IBD) with debilitating complications."1.72Thiopurine Monotherapy Is Effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease. ( Barber, GE; Choe, M; Hendler, S; Keyashian, K; Lechner, S; Limketkai, BN; Limsui, D, 2022)
"A total of 103 patients (93."1.62Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease. ( Achit, H; Ayav, C; D'Amico, F; Danese, S; Frimat, L; Guillemin, F; Guillo, L; Peyrin-Biroulet, L; Weislinger, L, 2021)
"The majority of patients had Crohn's disease (CD) (60%) and most of them were in clinical remission."1.62COVID-19 in IBD: The experience of a single tertiary IBD center. ( Belluzzi, A; Calabrese, C; Calandrini, L; Decorato, A; Dussias, N; Filippone, E; Gionchetti, P; Laureti, S; Melotti, L; Peruzzi, G; Poggioli, G; Privitera, H; Rizzello, F; Rottoli, M; Salice, M; Scaioli, E; Siniscalchi, A, 2021)
"Colitis was induced in mice by intracolonic (i."1.51Evaluation of the effect of liposomes loaded with chlorogenic acid in treatment of 2,4,6-trinitrobenzenesulfonic acid-induced murine colitis. ( Chen, C; Czapor-Irzabek, H; Fichna, J; Gorniak, A; Karolewicz, B; Krajewska, JB; Owczarek, A; Pietruszka, P; Tomczyk, D, 2019)
" This study was designed to determine transfer of mesalamine into human milk as a function of maternal dose and time, and dosage form."1.51Determination of Mesalamine levels in Human Milk as a Function of Dose. ( Baker, T; Datta, P; Hale, TW; Kallem, RR; Rewers-Felkins, K, 2019)
"The therapy of the inflammatory bowel diseases is quite complex."1.48The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets. ( Astegiano, M; Caviglia, GP; Finocchiaro, F; Pellicano, R; Ribaldone, DG; Saracco, GM; Vernero, M, 2018)
"Despite NUDT15 variants showing significant association with thiopurine-induced adverse events (AEs) in Asians, it remains unclear which variants of NUDT15 or whether additional genetic variants should be tested to predict AEs."1.48NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. ( Andoh, A; Araki, H; Endo, K; Hanai, H; Hiraoka, S; Hisamatsu, T; Hokari, R; Ikeya, K; Ishiguro, Y; Kakuta, Y; Kawai, Y; Kinouchi, Y; Kobayashi, T; Masamune, A; Matsumoto, T; Miura, M; Mizuno, S; Moroi, R; Motoya, S; Naganuma, M; Nagasaki, M; Naito, T; Nakagawa, S; Nakagawa, T; Nakamura, S; Nakase, H; Nishida, A; Okamoto, D; Onodera, K; Sakuraba, H; Sasaki, M; Shiga, H; Shimosegawa, T; Shinozaki, M; Suzuki, Y; Takagawa, T; Takahara, M; Toyonaga, T; Yanai, S, 2018)
"Mesalamine were the most frequently used medications."1.48Inflammatory bowel disease in patients over the age of 70 y. Does the disease duration influence its behavior? ( Bosca-Watts, MM; Cortes, X; Gil, R; Hervás, D; Huguet, JM; Iborra, M; Maroto, N; Paredes, JM, 2018)
" In order to obtain the maximum efficacy of 5-ASA formulations when treating inflammatory bowel diseases, it is essential that the dosage and administration are appropriate."1.465-Aminosalicylic acid. ( Iida, T; Nakase, H; Onodera, K, 2017)
"The low incidence of Mycobacterium tuberculosis infection and lack of adequate controls have prevented researchers from estimating tuberculosis (TB) risk in inflammatory bowel disease (IBD) patients."1.46Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea. ( Ahn, HS; Ahn, IM; Han, SJ; Hong, SN; Kim, HJ; Kim, KH, 2017)
"In both Crohn's disease and ulcerative colitis patients in deep remission, the incidence rate of relapse was 19% per patient-year."1.46Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. ( Aicart, M; Alcaín, G; Almela, P; Arguelles-Arias, F; Arias-Rivera, ML; Barreiro-de Acosta, M; Barrio, J; Beltrán, B; Benítez, JM; Bermejo, F; Botella, B; Bujanda, L; Busquets, D; Calvet, X; Casanova, MJ; Castaño-Milla, C; Castro, E; Castro, L; Ceballos, D; Chaparro, M; Cortés, X; Domènech, E; Domínguez, M; Domínguez-Antonaya, M; Dueñas, C; Esteve, M; Fernández-Salazar, L; García-Herola, A; García-López, S; García-Planella, E; García-Sánchez, V; García-Sepulcre, MF; Garrido, E; Gisbert, JP; Gómez-García, M; Gomollón, F; González-Lama, Y; Guardiola, J; Gutiérrez, A; Hernández-Martínez, A; Hervías, D; Hinojosa, J; Huguet, JM; Jauregui-Amezaga, A; Khorrami, S; Leo, E; Llaó, J; Lorente-Poyatos, R; Mañosa, M; Marín-Jiménez, I; Marrero, JM; Martín-Arranz, M; Martinez-Montiel, MP; Menacho, M; Merino, O; Monfort, D; Moraleja, I; Muñoz, C; Muñoz, F; Nantes, O; Navarro-Llavat, M; Novella, MT; Opio, V; Pajares, R; Pérez-Calle, JL; Pérez-Martínez, I; Pineda, JR; Ponferrada, A; Ramírez-de la Piscina, P; Ramos, L; Robles-Alonso, V; Rodríguez, C; Rodríguez, GE; Rodríguez-Pérez, A; Rojas-Feria, M; Roncedo, O; Sánchez-Torres, A; Sicilia, B; Taxonera, C; Tosca, J; Van Domselaar, M; Vázquez, JM; Vega-López, AB, 2017)
"Azathioprine was considered as the treatment for which the risks versus benefits were perceived as the highest."1.43Patients and gastroenterologists' perceptions of treatments for inflammatory bowel diseases: do their perspectives match? ( Burnand, B; Froehlich, F; Maillard, MH; Michetti, P; Pittet, V; Vaucher, C, 2016)
"To investigate knowledge and fear of colorectal cancer (CRC) risk in inflammatory bowel disease (IBD) patients."1.43Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease. ( Belle, A; Collet-Fenetrier, B; Lopez, A; Peyrin-Biroulet, L, 2016)
"Recurrent Clostridium difficile infection (rCDI) contributes to a significant burden of disease in patients with inflammatory bowel disease (IBD)."1.43Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study. ( Bahreini, Z; McGeer, A; Nguyen, GC; Razik, R; Rumman, A, 2016)
"Disease relapse was measured at each visit."1.43The Effects of Active IBD During Pregnancy in the Era of Novel IBD Therapies. ( de Lima-Karagiannis, A; van der Woude, CJ; Zelinkova-Detkova, Z, 2016)
"Half of the Crohn's disease patients were prescribed prolonged oral 5-ASAs during the study, although this decreased between era 3 and 5 from 61."1.43Steroid dependency and trends in prescribing for inflammatory bowel disease - a 20-year national population-based study. ( Cecil, E; Chhaya, V; Curcin, V; Majeed, A; Pollok, RC; Saxena, S; Subramanian, V, 2016)
"No significant risk for other intestinal cancers was found, especially for small bowel carcinoma."1.43Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study. ( Charpentier, C; Cheddani, H; Dauchet, L; Dupas, JL; Fumery, M; Gower-Rousseau, C; Marie Bouvier, A; Pariente, B; Peyrin-Biroulet, L; Savoye, G, 2016)
"For the treatment of inflammatory bowel disease, the development of pH responsive modified release dosage forms is one of the most common approaches to achieve targeted drug delivery."1.42Dissolution of mesalazine modified release tablets under standard and bio-relevant test conditions. ( Garbacz, G; Koziolek, M; Rappen, GM; Weitschies, W, 2015)
"To identify the frequency of hair loss among patients with inflammatory bowel disease (IBD) and associated clinical and disease related factors."1.42Frequency and associated factors of hair loss among patients with inflammatory bowel disease. ( Abraham, B; Hou, J; Sellin, J; Shah, R, 2015)
"Aminosalicylate (5-ASA) is effective treatment for inflammatory bowel diseases (IBDs) but requires continuous maintenance therapy."1.40Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia. ( Kemp, A; Leong, RW; Selinger, CP, 2014)
"There is a high prevalence of low bone mineral density (BMD) among patients with inflammatory bowel disease (IBD) although there is a lack of clinical data on the impact of IBD specific medications and recommended vitamin D (VD) and calcium (Ca) supplements on it."1.40Combination therapy with an immunomodulator and anti-TNFα agent improves bone mineral density in IBD patients. ( Cierny, D; Hlavaty, T; Huorka, M; Killinger, Z; Koller, T; Krajcovicova, A; Letkovsky, J; Miznerova, E; Nevidanska, M; Payer, J; Toth, J; Zelinkova, Z, 2014)
"The two main types, ulcerative colitis (UC) and Crohn's disease (CD), sometimes mimic each other and are not readily distinguishable."1.37Inflammatory bowel disease unclassified. ( Chen, SH; Chen, WX; Li, YM; Xu, CF; Zhou, N, 2011)
"Mercaptopurine is a safe alternative in patients with digestive intolerance or hepatotoxicity due to azathioprine."1.37Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. ( Chaparro, M; Gisbert, JP; Gomollón, F, 2011)
"Evaluate factors influencing risk of colorectal cancer development in inflammatory bowel disease patients."1.36Mesalamine protects against colorectal cancer in inflammatory bowel disease. ( Pai, C; Sharif, O; Silverman, AL; Tang, J, 2010)
"Pancreatitis is a potentially severe condition."1.35Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. ( Algaba, A; Bermejo, F; Calvo, M; Carneros, JA; Gisbert, JP; López, P; Lopez-Sanroman, A; Luna, M; Martín-Arranz, MD; Menchén, L; Mendoza, JL; Opio, V; Pérez-Calle, JL; Taxonera, C; Van-Domselaar, M; Vera, I, 2008)
"The 25-year cumulative rate of colorectal cancer was 23."1.35Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. ( Beaugerie, L; Chazouilleres, O; Cosnes, J; Poupon, R; Seksik, P; Sokol, H; Tiret, E, 2008)
"coli isolates from IBD, colon cancer, and controls was characterized at the cellular and molecular level."1.35Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamine. ( Campbell, BJ; Corkill, JE; Hart, CA; Rhodes, JM; Roberts, CL; Smith, SL; Subramanian, S; Tam, B; Virji, M; Winstanley, C, 2008)
"To investigate the occurrence of adverse events and efficacy of azathioprine with or without mesalazine."1.35Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome. ( Edwards, CM; Probert, CS; Shah, JA, 2008)
"A 15-year-old female with ulcerative colitis developed polyuria, polydipsia, vomiting, and fatigue."1.34Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease. ( Demir, H; Gürakan, F; Saltik-Temizel, IN; Topaloğlu, R; Uslu, N; Yüce, A, 2007)
"Pericarditis is an uncommon extraintestinal manifestation of inflammatory bowel disease (IBD), which may occur at any time during its natural course."1.34Parallel manifestation of Crohn's disease and acute pericarditis: a report of two cases. ( Kaziani, A; Mantzaris, G; Roussos, A; Skoutelis, A; Stasinopoulou, P, 2007)
"There is an increased risk of colorectal cancer in patients with inflammatory bowel disease (IBD)."1.33Distal adenomatous polyps are rare in patients with inflammatory bowel disease. ( Dixon, A; Hart, A; Robinson, R; Wurm, P, 2006)
"Microproteinuria is mainly associated with UC and its activity but not affected by 5-ASA."1.33Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid? ( Archimandritis, A; Dandakis, DC; Georgouli, A; Goumas, KE; Panagiotaki, M; Poulou, AC; Soutos, DC; Tyrmpas, I, 2006)
" Logistic regression revealed the independent predictors of non-compliance to be three-times daily dosing [odds ratio (OR), 3."1.32Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. ( Riley, SA; Shale, MJ, 2003)
"5-aminosalicylates are extensively prescribed for the treatment of ulcerative colitis but have a wide range of described adverse effects."1.31Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. ( Langman, MJ; Ransford, RA, 2002)
"Mesalamine may cause hypersensitivity pneumonitis in patients with Crohn's disease."1.30Mesalamine-induced hypersensitivity pneumonitis. A case report and review of the literature. ( Ben-Chetrit, E; Gafanovich, I; Kramer, MR; Sviri, S; Tsvang, E, 1997)
" Although the time for the first appearance of 5-ASA into the systemic circulation was almost the same value between SASP capsule and PCC containing 5-ASA, longer Tmax was observed from SASP capsule than from PCC."1.30Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs. ( Funaoka, A; Matsuda, K; Sawada, K; Suzuki, H; Takada, K; Takaya, T, 1997)
"When arachidonic acid was added to the cell suspension, it significantly stimulated LTB4 synthesis, especially in patients with active disease."1.29Arachidonic acid metabolism and intracellular calcium concentration in inflammatory bowel disease. ( Baumeister, B; Kosché, E; Schmidt, C; Vetter, H, 1995)
"Sulfasalazine is an important therapeutic agent in the management of chronic inflammatory bowel disease (CIBD)."1.28Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease. ( Tolia, V, 1992)
"An increased incidence of colonic cancer is associated with chronic inflammatory bowel disease."1.28The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model. ( Crouch, R; Davis, AE; Patterson, F, 1992)
"Drug treatment with sulfasalazine or 5-aminosalicylic acid improved enteritis score."1.28Chronic intrajejunal TNBS application in TNBS-sensitized rats: a new model of chronic inflammatory bowel diseases. ( Selve, N, 1992)
" Incubation with higher concentrations of the drugs revealed a dose-response effect on binding with complete inhibition by 100 mM 4ASA and 10 mM olsalazine, and lesser degrees of inhibition by 100 mM 5ASA, N-acetyl-5ASA, and N-acetyl-4ASA."1.28Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease. ( Aronson, JK; Crotty, B; Jewell, DP; Rosenberg, WM, 1992)
" Children are less affected by modifying conditions such as smoking, alcohol ingestion, and the long-term use of medications, and because of their specific needs for ponderal and linear growth, children might benefit most from immunological therapy that has been proven to be steroid sparing."1.28Immunology of inflammatory bowel disease: summary of the proceedings of the Subcommittee on Immunosuppressive Use in IBD. ( Cohen, SA; Daum, F; Glassman, M; Holmes, RD; Markowitz, J; Piccoli, D; Rossi, TM; Treem, WR; Ulshen, MH; Winter, HS, 1991)
" To avoid the side effects associated with sulfapyridine, researchers have developed dosage forms that deliver mesalazine to the site of inflammation."1.28Pharmaceutic development: mesalazine. ( Osterwald, HP, 1990)

Research

Studies (510)

TimeframeStudies, this research(%)All Research%
pre-199013 (2.55)18.7374
1990's95 (18.63)18.2507
2000's138 (27.06)29.6817
2010's196 (38.43)24.3611
2020's68 (13.33)2.80

Authors

AuthorsStudies
Pellicciari, R1
Garzon-Aburbeh, A1
Natalini, B1
Marinozzi, M1
Clerici, C1
Gentili, G1
Morelli, A1
Dhaneshwar, SS3
Gairola, N2
Kandpal, M2
Bhatt, L2
Vadnerkar, G2
Kadam, SS2
Rathi, B1
Banskota, S3
Kang, HE1
Kim, DG1
Park, SW1
Jang, H1
Karmacharya, U1
Jeong, BS1
Kim, JA3
Nam, TG1
Kadayat, TM2
Gurung, P2
Bist, G2
Thapa Magar, TB1
Shrestha, A2
Lee, ES2
Magar, TBT1
Rath, B1
Abul Qais, F1
Patro, R1
Mohapatra, S1
Sharma, T1
Ungaro, RC2
Brenner, EJ2
Agrawal, M1
Zhang, X2
Kappelman, MD2
Colombel, JF9
Tripathi, K1
Godoy Brewer, G1
Thu Nguyen, M1
Singh, Y1
Saleh Ismail, M1
Sauk, JS1
Parian, AM1
Limketkai, BN2
Akbar, A1
Arnott, I1
Kennedy, NA1
Nolan, J1
Peake, S1
Whiteoak, SR1
Probert, C1
Fraser, A1
Cheshire, A1
Lewis, A1
Sugrue, K1
Laird, S1
Scott, G1
Kjeldsen, S1
Nielsen, J2
Mertz Nørgård, B1
Kjeldsen, J4
Kuenzig, ME1
Manuel, DG1
Donelle, J1
Benchimol, EI1
Vaezi, Z1
Asadzadeh Aghdaei, H1
Sedghi, M1
Mahdavian, R1
Molakarimi, M1
Hashemi, N1
Naderi-Manesh, H1
Banerjee, R1
Pal, P1
Hilmi, I1
Ghoshal, UC1
Desai, DC1
Rahman, MM1
Dutta, U3
Mohiuddin, SA1
Al Mohannadi, M1
Philip, M1
Ramesh, GN1
Niriella, MA1
De Silva, AP1
de Silva, HJ1
Pisespongsa, P1
Limsrivilai, J1
Aniwan, S1
Nawarathne, M1
Fernandopulle, N1
Aye, TT1
Ni, N1
Al Awadhi, S1
Joshi, N1
Ngoc, PTV1
Kieu, TV1
Nguyen, AD1
Abdullah, M1
Ali, E1
Zeid, A1
Sollano, JD1
Saberi, B1
Omar, M1
Mohsin, MN1
Aftab, H1
Wai, TM1
Shastri, YM1
Chaudhuri, S1
Ahmed, F1
Bhatia, SJ1
Travis, SPL1
Akturk, R1
Serinsöz, S1
Moss, JG1
Parry, CM1
Holt, RCL1
McWilliam, SJ1
Santos, RCFD1
Catapani, WR1
Takahashi, AAR1
Waisberg, J1
Schmid, F1
Chao, CM1
Däbritz, J1
Park, J1
Cheon, JH3
Alhalabi, M1
Ali Deeb, S1
Ali, F1
Abbas, A1
Mahmoud, R1
Savelkoul, EHJ1
Mares, W1
Goetgebuer, R1
Witteman, BJM1
de Koning, DB1
van Tuyl, SAC1
Minderhoud, I1
Lutgens, MWMD1
Akol-Simsek, D1
van Schaik, FDM1
Fidder, HH1
Jansen, JM1
van Boeckel, PGA1
Mahmmod, N1
Horjus-Talabur Horje, CS1
Römkens, TEH1
Hoentjen, F2
Jharap, B3
Oldenburg, B2
Yao, LY1
Shao, BL1
Tian, F1
Ye, M1
Li, YQ1
Wang, XL1
Wang, L1
Yang, SQ1
Lv, XP1
Jia, Y1
Wang, XH1
Zhang, XQ1
Wei, YL1
Cao, Q2
Choi, SY2
Choi, S1
Kang, B2
Choe, BH1
Lee, YJ1
Park, JH1
Kim, YB1
Kim, JY3
Lee, K1
Lee, KJ1
Kang, KS1
Lee, YM1
Kim, HJ2
Kang, Y1
Jang, HJ1
Yi, DY1
Hong, SJ1
Choi, YJ1
Hong, J1
Kim, SC1
Paupard, T1
Gonzalez, F1
Caron, B1
Siproudhis, L1
Peyrin-Biroulet, L8
Avni-Biron, I1
Mishael, T1
Zittan, E1
Livne-Margolin, M1
Zinger, A1
Tzadok, R1
Goldenberg, R1
Kopylov, U1
Ron, Y1
Hadar, E1
Helman, S1
Granovsky, SG1
Ollech, JE1
Arazi, A1
Farkash, R1
Pauker, MH1
Yanai, H1
Dotan, I1
Shitrit, AB1
Tange, K1
Yagi, S1
Takeshita, E1
Abe, M1
Yamamoto, Y1
Tomida, H1
Kawamura, T1
Hanayama, M1
Matsuura, B1
Ikeda, Y1
Hiasa, Y1
Lee, MH2
Li, HJ2
Wasuwanich, P2
Kim, SE2
Jeong, GH2
Park, S2
Yang, JW2
Kim, MS2
Yon, DK2
Lee, SW2
Koyanagi, A2
Jacob, L2
Kim, EY2
Shin, JI2
Smith, L2
Mei, X1
Mell, B1
Manandhar, I1
Aryal, S1
Tummala, R1
Kyoung, J1
Yang, T1
Joe, B1
Moutaharrik, S1
Maroni, A1
Neut, C3
Dubuquoy, C1
Dubuquoy, L2
Foppoli, A1
Cerea, M1
Palugan, L1
Siepmann, F3
Siepmann, J3
Gazzaniga, A1
Seishima, R1
Okabayashi, K1
Ikeuchi, H1
Uchino, M1
Futami, K1
Noguchi, T1
Ohge, H1
Iseki, Y1
Watanabe, K2
Itabashi, M1
Okamoto, K1
Toiyama, Y1
Ogino, T1
Nakamura, M1
Yamada, K1
Wakai, T1
Sato, Y2
Kimura, H1
Takahashi, K2
Hida, K1
Kinugasa, Y1
Ishida, F1
Okuda, J1
Daito, K1
Koyama, F1
Ueno, H1
Yamamoto, T1
Yamamoto, S1
Hanai, T1
Maemoto, A1
Arakaki, J1
Komori, K1
Akagi, Y1
Shida, D1
Yamaguchi, S1
Matsuda, K2
Maeda, K1
Noake, T1
Nezu, R1
Sasaki, S1
Hasegawa, J1
Sunami, E1
Kanemitsu, Y1
Katsumata, K1
Uehara, K1
Kiyomatsu, T1
Suto, T1
Kazama, S1
Yamada, T1
Goi, T1
Ishihara, S1
Ajioka, Y1
Sugihara, K1
Gantzel, RH1
Vesterdal, JD1
Haase, AM1
Petersen, AJ1
Grønbæk, H1
Pedersen, ML1
Cordesse, A1
Delbet, JD1
Lemoine, A1
Dubern, B2
Tounian, P1
Lemale, J2
Giordani, AS1
Candelora, A1
Fiacca, M1
Cheng, C1
Barberio, B1
Baritussio, A1
Marcolongo, R1
Iliceto, S1
Carturan, E1
De Gaspari, M1
Rizzo, S1
Basso, C1
Tarantini, G1
Savarino, EV1
Alp, C1
Mehta, RS1
Mayers, JR1
Zhang, Y3
Bhosle, A1
Glasser, NR1
Nguyen, LH1
Ma, W1
Bae, S1
Branck, T1
Song, K1
Sebastian, L1
Pacheco, JA1
Seo, HS1
Clish, C1
Dhe-Paganon, S1
Ananthakrishnan, AN1
Franzosa, EA1
Balskus, EP1
Chan, AT1
Huttenhower, C1
Nørgård, BM1
Zegers, FD1
Knudsen, T1
Lund, K1
Brodersen, JB1
Lee, AA1
Gupta, S1
Labban, M1
Cao, FT1
Trinh, QD1
McNabb-Baltar, J1
Wada, H1
Miyoshi, J1
Kuronuma, S1
Nishinarita, Y1
Oguri, N1
Hibi, N1
Takeuchi, O1
Akimoto, Y1
Lee, STM1
Matsuura, M2
Kobayashi, T3
Hibi, T2
Hisamatsu, T3
Meunier, M1
Spillmann, A1
Rousseaux, C2
Schwamborn, K1
Hanson, M1
Qiu, L1
Shen, R1
Wei, L1
Xu, S1
Xia, W1
Hou, Y1
Cui, J1
Qu, R1
Luo, J1
Cao, J1
Yang, J1
Sun, J1
Ma, R1
Yu, Q1
Rana, VS1
Mahajan, G1
Patil, AN1
Singh, AK1
Jearth, V1
Sekar, A1
Singh, H2
Saroch, A1
Sharma, V1
Xu, J1
Fang, XH1
Liu, Y1
Huang, YB1
Ke, ZL1
Wang, Y1
Zhang, YF1
Zhou, JH1
Su, HT1
Chen, N1
Liu, YL1
Fan, H1
Du, J1
Liu, X1
Zheng, WW1
Zhuang, ZH1
Wang, CD1
Gao, R1
Krajewska, JB1
Pietruszka, P1
Tomczyk, D1
Chen, C1
Owczarek, A1
Karolewicz, B1
Czapor-Irzabek, H1
Gorniak, A1
Fichna, J1
Estill, M1
Hauser, R2
Nassan, FL2
Moss, A1
Krawetz, SA2
Choi, YI1
Kim, TJ1
Park, DK1
Chung, JW1
Kim, KO1
Kwon, KA1
Kim, YJ1
Naftali, T1
Bar-Lev Schleider, L1
Sklerovsky Benjaminov, F1
Lish, I1
Konikoff, FM1
Ringel, Y1
Martinez-Fierro, ML1
Garza-Veloz, I1
Rocha-Pizaña, MR1
Cardenas-Vargas, E1
Cid-Baez, MA1
Trejo-Vazquez, F1
Flores-Morales, V1
Villela-Ramirez, GA1
Delgado-Enciso, I1
Rodriguez-Sanchez, IP1
Ortiz-Castro, Y1
Jeong, S2
Lee, H1
Kim, S1
Ju, S1
Kim, W2
Cho, H1
Kim, HY1
Heo, G1
Im, E1
Yoo, JW1
Yoon, IS1
Jung, Y2
Lee, S2
Seow, CH3
Adhikari, K1
Metcalfe, A1
Casanova, MJ2
Chaparro, M3
Gisbert, JP7
Law, CCY1
Koh, D1
Bao, Y1
Jairath, V3
Narula, N1
Mak, JWY1
So, J1
Tang, W1
Yip, TCF1
Leung, WK2
Li, M1
Lo, FH2
Ng, KM1
Sze, SF2
Leung, CM2
Tsang, SWC2
Shan, EHS2
Chan, KH2
Lam, BCY2
Hui, AJ2
Chow, WH1
Chan, FKL1
Ng, SC2
Adiga, A1
Goldfarb, DS1
Basaranoğlu, M1
Kapsigay, M1
Kunduz, E1
Lee, JY1
Cevallos, SA1
Byndloss, MX1
Tiffany, CR1
Olsan, EE1
Butler, BP1
Young, BM1
Rogers, AWL1
Nguyen, H1
Kim, K1
Choi, SW1
Bae, E1
Lee, JH1
Min, UG1
Lee, DC1
Bäumler, AJ1
Zeng, J1
Meng, ZM1
Huang, XL1
Gan, HT1
Moreno Moraleda, I1
Lázaro Sáez, M1
Diéguez Castillo, C1
Hernández Martínez, Á1
Teruel, AH2
Gonzalez-Alvarez, I2
Bermejo, M1
Merino, V2
Marcos, MD1
Sancenon, F2
Gonzalez-Alvarez, M2
Martinez-Mañez, R2
Kubová, K1
Pigneur, B1
Focht, G1
Turner, D2
Ruemmele, FM1
Chapman, TP2
Frias Gomes, C2
Louis, E1
Satsangi, J2
Nicolaides, S1
Vasudevan, A1
van Langenberg, D1
Hufnagel, B1
Muellner, V1
Hlatky, K1
Tallian, C1
Vielnascher, R1
Guebitz, GM1
Wirth, M1
Gabor, F1
Weislinger, L1
Guillo, L1
D'Amico, F1
Danese, S2
Achit, H1
Ayav, C1
Guillemin, F1
Frimat, L2
Jeličić, ML1
Brusač, E1
Klarić, DA1
Nigović, B1
Turk, N1
Mornar, A1
Tamura, S1
Ishida, N1
Miyazu, T1
Onoue, S1
Tani, S1
Yamade, M1
Hamaya, Y1
Iwaizumi, M1
Osawa, S1
Furuta, T1
Sugimoto, K1
Matsumoto, S1
Mashima, H1
Rizzello, F1
Calabrese, C1
Salice, M1
Calandrini, L1
Privitera, H1
Melotti, L1
Peruzzi, G1
Dussias, N1
Belluzzi, A1
Scaioli, E1
Decorato, A1
Siniscalchi, A1
Filippone, E1
Laureti, S1
Rottoli, M1
Poggioli, G1
Gionchetti, P1
Suzuki, K1
Kakuta, Y2
Naito, T2
Takagawa, T2
Hanai, H2
Araki, H2
Sasaki, Y1
Sakuraba, H2
Sasaki, M3
Motoya, S2
Matsumoto, T3
Onodera, M1
Ishiguro, Y2
Nakase, H3
Andoh, A3
Hiraoka, S2
Shinozaki, M2
Fujii, T1
Katsurada, T1
Fujiya, M2
Otsuka, T1
Oshima, N1
Suzuki, Y2
Hokari, R2
Noguchi, M1
Ohta, Y1
Kawai, Y2
Tokunaga, K1
Nagasaki, M2
Kudo, H1
Minegishi, N1
Okamoto, D2
Shimoyama, Y1
Moroi, R2
Kuroha, M1
Shiga, H2
Li, D1
McGovern, DPB1
Kinouchi, Y2
Masamune, A2
Montenegro, ML1
Corral, JE1
Lukens, FJ1
Ji, B1
Kröner, PT1
Farraye, FA2
Bi, Y1
Caio, G1
Lungaro, L1
Caputo, F1
Muccinelli, M1
Marcello, MC1
Zoli, E1
Volta, U1
De Giorgio, R1
Zoli, G1
Barber, GE1
Hendler, S1
Choe, M1
Keyashian, K1
Lechner, S1
Limsui, D1
Zhou, W1
Zhang, H2
Pan, Y1
Xu, Y2
Cao, Y1
Barnhoorn, MC1
Storm, BN1
de Boer, NK4
van der Voorn, MMPJA1
Veloso, PM1
Machado, R1
Nobre, C1
Roy, S1
Sheikh, SZ1
Furey, TS1
Shi, S1
Feng, J1
Zhou, L1
Li, Y1
Shi, H1
Bernstein, CN6
Tennakoon, A1
Targownik, L1
Pereira, SR1
Pereira, R1
Figueiredo, I1
Freitas, V1
Dinis, TC2
Almeida, LM2
Taxonera, C3
Ponferrada, Á2
Bermejo, F4
Riestra, S1
Saro, C1
Martín-Arranz, MD2
Cabriada, JL1
Barreiro-de Acosta, M2
de Castro, ML1
López-Serrano, P1
Barrio, J2
Suarez, C1
Iglesias, E1
Argüelles-Arias, F2
Ferrer, I1
Marín-Jiménez, I2
Hernández-Camba, A1
Bastida, G1
Van Domselaar, M2
Martínez-Montiel, P1
Olivares, D1
Alba, C1
Kang, S1
Lee, Y1
Nam, J1
Mak, LY1
Wong, IOL1
Li, MKK1
Wong, MTL1
Hung, IFN1
Chiu, CT1
Kuo, SN1
Hung, SW1
Yang, CY1
Filipec Kanizaj, T1
Mijic, M1
Spagnuolo, R1
Cosco, C1
Mancina, RM1
Ruggiero, G1
Garieri, P1
Cosco, V1
Doldo, P2
Peña-Sánchez, JN1
Lix, LM1
Teare, GF1
Li, W1
Fowler, SA1
Jones, JL1
Yu, H1
MacIsaac, D1
Wong, JJ1
Sellers, ZM1
Wren, AA1
Bensen, R1
Kin, C1
Park, KT1
Davoudi, Z1
Peroutka-Bigus, N1
Bellaire, B1
Wannemuehler, M1
Barrett, TA1
Narasimhan, B1
Wang, Q1
Ribaldone, DG1
Vernero, M1
Saracco, GM1
Pellicano, R3
Finocchiaro, F1
Caviglia, GP1
Astegiano, M1
Tarabar, D1
Kandolf-Sekulović, L1
Tatomirović, Ž1
Mijušković, Ž1
Milenković, Z1
Tarabar, O1
Pecelj-Broćić, T1
Staatz, CE1
Martin, NS1
Kong, DP1
Hollingworth, SA1
Rao, BB1
Lashner, B1
Kowdley, KV1
Kluthe, C1
Tsui, J1
Spady, D1
Carroll, M1
Wine, E1
Huynh, HQ1
Motta, JP1
Allain, T1
Green-Harrison, LE1
Groves, RA1
Feener, T1
Ramay, H1
Beck, PL1
Lewis, IA1
Wallace, JL1
Buret, AG1
Ikeya, K1
Nishida, A2
Nakagawa, S1
Miura, M1
Toyonaga, T1
Onodera, K2
Mizuno, S1
Takahara, M1
Yanai, S1
Nakagawa, T1
Endo, K1
Naganuma, M1
Nakamura, S1
Shimosegawa, T1
Calderón, M1
Minckas, N1
Nuñez, S1
Ciapponi, A1
Carbone, F1
Bodini, G1
Brunacci, M1
Bonaventura, A1
Vecchiè, A1
Liberale, L1
Crespi, M1
Baldissarro, I1
Dallegri, F1
Savarino, V2
Montecucco, F1
Giannini, EG2
Zhang, S1
Fu, J1
Dogan, B1
Scherl, EJ1
Simpson, KW1
Paschou, SA1
Palioura, E1
Kothonas, F1
Myroforidis, A1
Loi, V1
Poulou, A1
Goumas, K1
Effraimidis, G1
Vryonidou, A1
Huguet, JM2
Iborra, M1
Bosca-Watts, MM1
Maroto, N1
Gil, R1
Cortes, X2
Hervás, D1
Paredes, JM1
Yang, X1
Gu, Y1
Cao, XC1
Wang, BM1
Cao, HL1
Datta, P1
Rewers-Felkins, K1
Kallem, RR1
Baker, T1
Hale, TW1
Stokkeland, K1
Höijer, J1
Bottai, M1
Söderberg-Löfdal, K1
Bergquist, A1
Burisch, J1
Zammit, SC1
Ellul, P1
Turcan, S1
Duricova, D2
Bortlik, M2
Andersen, KW1
Andersen, V1
Kaimakliotis, IP1
Fumery, M2
Gower-Rousseau, C2
Girardin, G1
Valpiani, D1
Goldis, A1
Brinar, M1
Čuković-Čavka, S1
Oksanen, P1
Collin, P1
Barros, L2
Magro, F3
Misra, R1
Arebi, N1
Eriksson, C1
Halfvarson, J2
Kievit, HAL1
Pedersen, N3
Myers, S1
Sebastian, S2
Katsanos, KH1
Christodoulou, DK1
Midjord, J1
Nielsen, KR1
Kiudelis, G1
Kupcinskas, L1
Nikulina, I1
Belousova, E1
Schwartz, D1
Odes, S1
Salupere, R1
Carmona, A1
Pineda, JR2
Vegh, Z1
Lakatos, PL3
Langholz, E3
Munkholm, P6
Iida, T1
Eberhardson, M1
Hedin, CRH1
Carlson, M1
Tarnawski, L1
Levine, YA1
Olofsson, PS1
Bamba, S1
Morita, Y1
Kawahara, M1
Inatomi, O1
Sugimoto, M1
Todo, K1
Osamura, T1
Imashuku, S1
Newton, AMJ1
Lakshmanan, P1
Nowak, M1
Barańska-Rybak, W1
Mehrholz, D1
Nowicki, J1
Khare, V1
Krnjic, A1
Frick, A1
Gmainer, C1
Asboth, M1
Jimenez, K1
Lang, M1
Baumgartner, M1
Evstatiev, R1
Gasche, C4
Palma, E1
Costa, N1
Molinaro, R1
Francardi, M1
Paolino, D1
Cosco, D1
Fresta, M1
Sedano Muñoz, R1
Quera Pino, R1
Ibáñez Lazo, P1
Figueroa Corona, C1
Flores Pérez, L1
Viazis, N1
Pontas, C1
Karmiris, K1
Dimas, I1
Fragaki, M1
Paspatis, G1
Drygiannakis, I1
Koutroubakis, IE1
Moschovis, D1
Tzouvala, M1
Theocharis, G1
Tsolias, C1
Thomopoulos, K1
Zampeli, E1
Axiaris, G1
Michopoulos, S1
Belesiotou, E1
Banasa, M1
Maraki, S1
Kouskoumpekou, F1
Apostolopoulos, G1
Stamouli, V1
Prifti, H1
Mantzaris, GJ3
Pérez-Esteve, É1
Costero, AM1
Ferri, D1
Gaviña, P1
Shah, J1
Thakur, ML1
Gong, SS1
Fan, YH1
Han, QQ1
Lv, B1
Lee, HS1
Cleynen, I1
Pinel Ríos, J1
Madrid Navarro, CJ1
Pérez Navarro, MJ1
Cabello Tapia, MJ1
Piña Vera, MJ1
Campos Arillo, V1
Gómez García, MR1
Mínguez Castellanos, A1
Escamilla Sevilla, F1
Simsek, M1
de Boer, NKH1
Hokkanen, SRK1
Guizzetti, L1
Boxall, N1
Campbell-Hill, S1
Patel, H1
Ma, C1
Battat, R1
Dulai, PS1
Parker, CE2
Sandborn, WJ6
Feagan, BG2
Rietdijk, ST1
D'Haens, GR1
Santos-Antunes, J1
Albuquerque, A1
Vilas-Boas, F1
Macedo, GN1
Nazareth, N1
Lopes, S1
Sobrinho-Simões, J1
Teixeira, S1
Dias, CC1
Cabral, J1
Sarmento, A1
Macedo, G1
Bessissow, T1
Bisschops, R1
Ferrante, M1
Baert, F2
Van Assche, G2
Rutgeerts, P3
Vermeire, S1
Scaldaferri, F1
Petito, V1
Lopetuso, L1
Bruno, G1
Gerardi, V1
Ianiro, G1
Sgambato, A1
Gasbarrini, A1
Cammarota, G1
Robinson, A4
Hankins, M3
Wiseman, G3
Jones, M3
Nielsen, OH2
Maxwell, C1
Hendel, J1
Suneela, D1
Gaurav, V1
Himanshu, R1
Lopez, A2
Serra, D1
Paixão, J1
Nunes, C1
Selinger, CP2
Kadiyala, I1
Jacobs, D1
Ban, L1
Tata, LJ1
Fiaschi, L1
Card, T2
Ha, CY1
Curtis, H1
Jones, S1
Treasure, P1
Han, SH1
Lee, J1
Druez, A1
Rahier, JF1
Hébuterne, X1
Kemp, A1
Leong, RW1
Devlen, J1
Beusterien, K1
Yen, L1
Ahmed, A1
Cheifetz, AS2
Moss, AC4
Kniazev, OV2
Parfenov, AI3
Ruchkina, IN3
Lazebnik, LB3
Sagynbaeva, VÉ3
Indriolo, A1
Ravelli, P1
Uchiyama, K1
Takagi, T1
Iwamoto, Y1
Kondo, N1
Okayama, T1
Yoshida, N1
Kamada, K1
Katada, K1
Handa, O1
Ishikawa, T1
Yasuda, H1
Sakagami, J1
Konishi, H1
Yagi, N1
Naito, Y1
Itoh, Y1
Greenstein, RJ1
Cameron, DW1
Brown, ST1
Chapman, CG1
Rubin, DT3
Stobaugh, DJ1
Deepak, P1
Krajcovicova, A1
Hlavaty, T1
Killinger, Z1
Miznerova, E1
Toth, J1
Letkovsky, J1
Nevidanska, M1
Cierny, D1
Koller, T1
Zelinkova, Z1
Huorka, M1
Payer, J1
Jones, KD1
Hünten-Kirsch, B1
Laving, AM1
Munyi, CW1
Ngari, M1
Mikusa, J1
Mulongo, MM1
Odera, D1
Nassir, HS1
Timbwa, M1
Owino, M1
Fegan, G1
Murch, SH2
Sullivan, PB1
Warner, JO1
Berkley, JA1
Garbacz, G1
Rappen, GM1
Koziolek, M1
Weitschies, W1
Shah, R1
Abraham, B1
Hou, J1
Sellin, J1
Petri, WA1
Naylor, C1
Haque, R1
Buderus, S2
Scholz, D1
Behrens, R1
Classen, M1
De Laffolie, J1
Keller, KM1
Zimmer, KP1
Koletzko, S2
Taleban, S1
Mohler, MJ1
Fain, MJ1
Shimizu, T1
Kijima, A1
Masuo, Y1
Ishimoto, T1
Sugiura, T1
Takahashi, S1
Nakamichi, N1
Kato, Y1
Jang, BI1
Tsironikos, D1
Tzanetakou, X1
Grispou, E1
Karatzas, P1
Kalogeropoulos, I1
Papamichael, K2
OʼConnor, A1
Packey, CD1
Akbari, M1
Lee, MN1
Kim, MJ1
Woo, SY1
Kim, JW1
Choe, YH1
Lee, SY1
Baker, WL1
Saulsberry, WJ1
Elliott, K1
Parker, MW1
Moeser, A1
Pletz, MW1
Hagel, S1
Kroegel, C1
Stallmach, A1
Onal, IK1
Alizadeh, N1
Sargin, ZG1
Chande, N1
Marshall, JK1
Nelson, S1
Heap, GA1
So, K1
Weedon, M1
Edney, N1
Bewshea, C1
Singh, A1
Annese, V1
Beckly, J1
Buurman, D1
Chaudhary, R1
Cole, AT1
Cooper, SC1
Creed, T1
Cummings, F1
D'Inca, R1
D'Souza, R1
Daneshmend, TK1
Delaney, M1
Dhar, A1
Direkze, N1
Dunckley, P1
Gaya, DR1
Gearry, R1
Gore, S1
Hart, A2
Hawkey, CJ2
Iqbal, T1
Irving, P1
Lal, S1
Lawrance, I1
Lees, CW1
Lockett, M1
Mann, S1
Mansfield, J1
Mowat, C1
Mulgrew, CJ1
Muller, F1
Murray, C1
Oram, R1
Orchard, T1
Parkes, M2
Phillips, R1
Pollok, R1
Radford-Smith, G1
Sen, S1
Shirazi, T1
Silverberg, M1
Solomon, L1
Sturniolo, GC1
Thomas, M1
Tremelling, M1
Tsianos, EV1
Watts, D1
Weaver, S1
Weersma, RK1
Wesley, E1
Holden, A1
Ahmad, T1
Vaucher, C1
Maillard, MH1
Froehlich, F1
Burnand, B1
Michetti, P1
Pittet, V1
Stiefelhagen, P1
Gasparetto, M1
Guariso, G1
Pozza, LV1
Ross, A1
Heuschkel, R2
Zilbauer, M1
Gearry, RB1
Gareb, B1
Eissens, AC1
Kosterink, JGW1
Frijlink, HW1
Wasan, SK1
Zullow, S1
Berg, A1
Ganley-Leal, L1
Collet-Fenetrier, B1
Belle, A1
Aloi, M1
Birimberg-Schwartz, L1
Hojsak, I1
Fell, JM2
Bronsky, J1
Veereman, G1
Shaoul, R1
Miele, E1
Russell, RK1
Razik, R1
Rumman, A1
Bahreini, Z1
McGeer, A1
Nguyen, GC2
Duan, H1
Lü, S1
Gao, C1
Bai, X1
Qin, H1
Wei, Y1
Wu, X2
Liu, M1
Simon, H1
Fischer, T1
Almási, A1
Fischer, E1
de Lima-Karagiannis, A1
Zelinkova-Detkova, Z1
van der Woude, CJ1
Maxwell, EC1
Grossman, AB1
Chhaya, V1
Saxena, S1
Cecil, E1
Subramanian, V1
Curcin, V1
Majeed, A1
Pollok, RC1
Cheddani, H1
Dauchet, L1
Charpentier, C1
Marie Bouvier, A1
Dupas, JL1
Pariente, B1
Savoye, G2
Coull, BA1
Skakkebaek, NE1
Williams, MA1
Dadd, R1
Mínguez-Alarcón, L1
Hait, EJ1
Korzenik, JR1
Ford, JB1
Horton, N1
Philpott, J1
Garber, A1
Achkar, JP1
Brzezinski, A1
Lashner, BA1
Shen, B1
Kandula, M1
Sunil Kumar, KB1
Palanichamy, S1
Rampal, A1
Cappello, M1
Licata, A1
Calvaruso, V1
Bravatà, I1
Aiello, A1
Torres, D1
Della Corte, V1
Tuttolomondo, A1
Perticone, M1
Licata, G1
Craxì, A1
Cammà, C1
Qiu, X1
Ma, J1
Wang, K1
Hong, SN1
Kim, KH1
Han, SJ1
Ahn, IM1
Ahn, HS1
García-Sánchez, V1
Nantes, O1
Leo, E1
Rojas-Feria, M1
Jauregui-Amezaga, A1
García-López, S1
Aicart, M1
Gómez-García, M1
Muñoz, F1
Esteve, M1
Bujanda, L1
Tosca, J1
Mañosa, M3
Llaó, J1
Guardiola, J1
Pérez-Martínez, I1
Muñoz, C2
González-Lama, Y3
Hinojosa, J1
Vázquez, JM1
Martinez-Montiel, MP1
Rodríguez, GE1
Pajares, R1
García-Sepulcre, MF2
Hernández-Martínez, A1
Pérez-Calle, JL2
Beltrán, B1
Busquets, D1
Ramos, L1
Roncedo, O1
Calvet, X1
Hervías, D1
Gomollón, F2
Domínguez-Antonaya, M1
Alcaín, G1
Sicilia, B1
Dueñas, C1
Gutiérrez, A1
Lorente-Poyatos, R1
Domínguez, M1
Khorrami, S1
Rodríguez-Pérez, A1
Arias-Rivera, ML1
Merino, O1
Castro, E1
Marrero, JM1
Martín-Arranz, M1
Botella, B1
Fernández-Salazar, L1
Monfort, D1
Opio, V2
García-Herola, A1
Menacho, M1
Ramírez-de la Piscina, P1
Ceballos, D1
Almela, P1
Navarro-Llavat, M1
Robles-Alonso, V1
Vega-López, AB1
Moraleja, I1
Novella, MT1
Castaño-Milla, C1
Sánchez-Torres, A1
Benítez, JM1
Rodríguez, C1
Castro, L1
Garrido, E1
Domènech, E3
García-Planella, E2
Carrat, F1
Seksik, P5
Beaugerie, L2
Busoni, VB1
Frangi, F1
Bourgeois, P1
Orsi, M1
Badens, C1
Fabre, A1
Yousefi, S1
Bayat, S1
Rahman, MB1
Ibrahim, Z1
Abdulmalek, E1
Moussata, D1
Allez, M1
Cazals-Hatem, D1
Treton, X1
Laharie, D1
Reimund, JM1
Bertheau, P1
Bourreille, A1
Lavergne-Slove, A1
Brixi, H1
Branche, J1
Gornet, JM1
Stefanescu, C1
Moreau, J1
Marteau, P7
Pelletier, AL1
Carbonnel, F1
Simon, M1
Fléjou, JF1
Charlois, AL1
Roblin, X1
Nancey, S1
Bouhnik, Y1
Berger, F1
Flourié, B1
Jackson, BD1
Con, D1
Liew, D1
De Cruz, P1
Lopez-Sanroman, A1
Vera, I1
Menchén, L1
Carneros, JA1
Van-Domselaar, M1
Mendoza, JL1
Luna, M2
López, P1
Calvo, M1
Algaba, A1
Sokol, H1
Cosnes, J3
Chazouilleres, O1
Tiret, E1
Poupon, R1
Thachil, J2
Scribano, ML1
Moum, B1
Pousa, ID1
Velasco, M1
Moreno-Otero, R1
Maté, J2
Ibiş, M1
Ataseven, H1
Basar, O1
Yüksel, I1
Ulker, A1
Andrews, JM3
Travis, SP4
Gibson, PR2
von Stein, P1
Ghosh, S4
Kaufman, J1
Griffiths, TA1
Surette, MG1
Ness, S1
Rioux, KP1
Zhu, Q1
Shang, Y1
Gao, M1
Si, J1
Butterworth, JR1
Usta, Y1
Ozen, H1
Gurakan, F2
Uslu, N2
Saltik-Temizel, IN2
Demir, H2
Yuce, A2
Actis, GC3
Rizzetto, M2
Ayoubi, M1
Leone, N1
Tappero, G1
Pazienza, P1
Rosina, F3
Harris, A1
Feller, ER1
Shah, SA1
Saha, S1
Esposti, SD1
Karrout, Y2
Wils, D2
Deremaux, L2
Flament, MP2
Dubreuil, L2
Desreumaux, P6
Zimmerer, T1
Siegmund, SV1
Singer, MV1
Rychlik, A1
Nieradka, R1
Kander, M1
Depta, A1
Daperno, M1
Sostegni, R1
Canaparo, R1
Serpe, L1
Lavagna, A1
Crocellà, L1
Castagno, F1
Vernetto, A1
Rigazio, C1
Ercole, E1
D'Antico, S1
Pera, A1
Zara, G1
Rocca, R1
Tang, J1
Sharif, O1
Pai, C1
Silverman, AL1
Ingerski, LM4
Baldassano, RN2
Denson, LA4
Hommel, KA6
Goodhand, J1
Dawson, R1
Hefferon, M1
Tshuma, N1
Swanson, G1
Wahed, M1
Croft, NM2
Lindsay, JO1
Lyakhovich, A1
Sparrow, MP1
Irving, PM1
Hanauer, SB4
de Silva, S1
Kaplan, GG1
Devlin, SM1
Panaccione, R1
Borniquel, S1
Jansson, EA1
Cole, MP1
Freeman, BA1
Lundberg, JO1
Rodríguez-Reyna, TS1
Martínez-Reyes, C1
Yamamoto-Furusho, JK1
Cury, DB1
Kunz, JH1
Greenley, RN1
Saijo, F1
Milsom, AB1
Bryan, NS1
Bauer, SM1
Vowinkel, T1
Ivanovic, M1
Andry, C1
Granger, DN1
Rodriguez, J1
Feelisch, M1
Allen, PB1
Lindsay, H1
Tham, TC1
Wilson, DC1
Thomas, AG1
Newby, E1
Akobeng, AK1
Sawczenko, A1
Murphy, MS1
Beattie, RM1
Sandhu, BK1
Mitton, SG1
Casson, D1
Elawad, M1
Jenkins, H1
Johnson, T1
Macdonald, S1
Pitchumoni, CS1
Rubin, A1
Das, K1
Raithel, M2
Nägel, A1
Zopf, Y1
deRossi, T1
Stengel, Ch1
Hagel, A1
Kressel, J1
Hahn, EG2
Konturek, P1
Fleming, A1
Jankowski, J1
Goldsmith, P1
Low, A1
Love, M1
Walt, R1
Kane, K1
Eksteen, B1
Goh, J1
Shahrani Muhammad, HS1
Peters, C1
Casserly, LF1
Dorman, AM1
Watts, M1
Spiller, RC1
Holzer, P1
Leal-Valdivieso, C1
Naves, JE1
Zabana, Y1
Cabré, E2
Smith, MA1
Marinaki, AM1
Sanderson, JD1
Azevedo, LF1
Portela, F1
Lago, P1
Deus, J1
Cotter, J1
Cremers, I1
Vieira, A1
Peixe, P1
Caldeira, P1
Lopes, H1
Gonçalves, R1
Reis, J1
Cravo, M1
Ministro, P1
Lurdes, M1
Duarte, A1
Campos, M1
Carvalho, L1
Costa-Pereira, A1
Fiorino, G1
Fries, W1
De La Rue, SA1
Malesci, AC1
Repici, A1
Nguyen, TM1
Le Gall, C1
Lachaux, A1
Boulieu, R1
de Graaf, P2
Wong, DR2
Karner, S1
Hooymans, PM3
Veldkamp, AI1
Mulder, CJ4
van Bodegraven, AA4
Schwab, M1
Ramos, JM1
Masiá, M1
Brotons, A1
Grau, MC1
Gutiérrez, F1
Ravaux, P1
Lemdani, M1
Mountifield, RE1
Prosser, R1
Bampton, P1
Muller, K1
Holtmann, G1
Bodger, K1
Qualtrough, D1
Smallwood, K1
Littlejohns, D1
Pignatelli, M1
Nugent, Z1
Blanchard, JF2
Bautzová, T1
Rabišková, M1
Lamprecht, A1
Lenicek, M1
Jakobsen, C1
Lukas, M3
Wewer, V1
Zhou, N1
Chen, WX1
Chen, SH1
Xu, CF1
Li, YM1
Herzer, M3
Hente, E2
van Schaik, FD1
van Oijen, MG1
Smeets, HM1
van der Heijden, GJ1
Siersema, PD1
Jagtap, AG1
Niphadkar, PV1
Phadke, AS1
Jamieson, A1
Katz, S1
Pardi, DS1
Riyaz, S1
Hamlin, J1
Everett, S1
Hente, EA1
Odell, S1
Guilfoyle, SM1
Akpınar, EE1
Gülhan, M1
Değertekin, H1
Ataoğlu, Ö1
Perito, ER1
Mileti, E1
Dalal, DH1
Cho, SJ1
Ferrell, LD1
McCracken, M1
Heyman, MB1
Velciov, S1
Gluhovschi, G1
Sporea, I1
Trandafirescu, V1
Petrica, L1
Bozdog, G1
Gluhovschi, C1
Bob, F1
Gădălean, F1
Buzaş, R1
Bobu, M1
Voicu, L1
Kane, S2
Becker, B1
Harmsen, WS1
Kurian, A1
Morisky, DE1
Zinsmeister, AR2
Klotz, U5
Juneja, M1
Baidoo, L1
Schwartz, MB1
Barrie, A1
Regueiro, M1
Dunn, M1
Binion, DG1
Adams, DJ1
Colombo, JM1
Armuzzi, A1
Reinisch, W1
Pineton de Chambrun, G1
Griffiths, A1
Sladek, M1
Preiss, JC1
D'Haens, G2
Boldyreva, ON1
Efremov, LI1
Guseĭnzade, MG1
Konopliannikov, AG1
Gribanov, II1
Trindade, AJ1
Tinsley, A1
Kornbluth, A3
Ullman, TA3
Gao, X1
Zhang, FB1
Ding, L1
Liu, H1
Wang, XD1
Chen, BL1
Bi, HC1
Xiao, YL1
Zhao, LZ1
Chen, MH1
Huang, M1
Hu, PJ1
Stolfi, C1
Pallone, F2
Monteleone, G2
Gulamhusein, A1
Strate, LL1
Modi, R1
Cohen, E1
Spiegel, BM1
Wenzl, HH1
Rungoe, C1
Basit, S1
Ranthe, MF1
Wohlfahrt, J1
Jess, T2
Knyazev, OV1
Shcherbakov, PL1
Khomeriki, SG1
Konoplyannikov, AG1
Zallot, C1
Billioud, V1
Faure, P1
Suskind, DL1
Wahbeh, G1
Burpee, T1
Cohen, M1
Christie, D1
Weber, W1
Oshitani, N2
Matsumoto, H1
Aomatsu, K1
Suwa, I1
Kohgo, Y1
Tanabe, H1
Yajima, T1
Fangbin, Z1
Xiang, G1
Minhu, C1
Liang, D1
Feng, X1
Min, H1
Pinjin, H1
Tarallo, S1
Sann, H1
Erichsen, Jv1
Hessmann, M1
Pahl, A1
Hoffmeyer, A1
Podolsky, DK1
Ransford, RA1
Langman, MJ1
Shaw, IS1
Jobson, BA1
Silverman, D1
Ford, J2
Hearing, SD1
Ball, D1
Johnson, E1
Day, A1
Probert, CS3
Eaden, J1
Steinhart, AH1
Gordon, PH1
Mouzas, IA1
Pallis, AG1
Kochiadakis, GE1
Marketou, M1
Chlouverakis, GI1
Mellisas, J1
Vardas, PE1
Kouroumalis, EA1
Nagy, F1
Edmond, LM1
Hopkins, MJ1
Magee, EA1
Cummings, JH1
Forbes, A3
Cartwright, A1
Marchant, S1
McIntyre, P1
Newton, M1
Lewis, JD1
Shale, MJ1
Riley, SA1
Allgayer, H6
Hato, F1
Kitagawa, S1
Fujiwara, Y1
Higuchi, K1
Arakawa, T1
Stone, MA1
Mayberry, JF1
Baker, R1
Wong, JM1
Wei, SC1
Itzkowitz, SH1
Harpaz, N1
Van Staa, TP2
Travis, S1
Leufkens, HG2
Logan, RF2
Romano, O2
Daniel, F1
Cacheux, W1
Jian, R2
Díaz Rodríguez, C1
Granja, E1
Vázquez Martul, E1
Sacristán, F1
Moreno Fernández, A1
González Rivero, C1
del Río Romero, D1
Trinidad, JC1
Wiersma, H1
Escher, JC1
Dilger, K1
Trenk, D1
Benninga, MA1
van Boxtel, CJ1
Taminiau, J1
Qureshi, AI1
Cohen, RD1
Silverman, DA1
Shaw, I1
Wojtuń, S1
Gil, J1
Chojnacki, J1
Wichan, P1
Cheng, Y1
Siveke, JT1
Egert, J1
Sitter, T1
Schiemann, U1
Walcher, P1
Török, HP1
Glas, J1
Folwaczny, C1
Iser, J1
Adler, SN1
Jacob, H1
López San Román, A1
Carrera, E1
Pérez-Abad, M1
Boixeda, D1
Kane, SV1
Testa, R1
Kesisoglou, F1
Zhou, SY1
Niemiec, S1
Lee, JW1
Zimmermann, EM1
Fleisher, D1
Couve, S1
Baker, DE1
Ioffe, AIu1
Gilissen, LP1
Bierau, J1
Derijks, LJ1
Bos, LP1
van Gennip, A1
Stockbrügger, RW1
Engels, LG2
Roberta, P1
Antonino, B1
Paolo, P1
Kohli, R1
Melin-Aldana, H1
Sentongo, TA1
Sari, I1
Birlik, M1
Cavdar, C1
Sarioglu, S1
Akpinar, H1
Onen, F1
Akkoc, N1
Joshi, R1
Kumar, S1
Unnikrishnan, M1
Mukherjee, T1
Brunner, M1
Lackner, E1
Exler, PS1
Fluiter, HC1
Kletter, K1
Tschurlovits, M1
Dudczak, R1
Eichler, HG1
Müller, M1
Dixon, A1
Wurm, P1
Robinson, R1
D'Argenio, G1
Valenti, M1
Scaglione, G1
Cosenza, V1
Sorrentini, I1
Di Marzo, V1
Loftus, EV2
Reinacher-Schick, A1
Mittmann, U1
Esendal, B1
Poulou, AC1
Goumas, KE1
Dandakis, DC1
Tyrmpas, I1
Panagiotaki, M1
Georgouli, A1
Soutos, DC1
Archimandritis, A1
Bergman, R1
Hande, S1
Wilson-Rich, N1
Bousvaros, A1
Zholudev, A1
Maurer, R1
Banks, P1
Makrauer, F1
Reddy, S1
Burakoff, R2
Friedman, S2
Floch, MH1
White, JA1
Cuffari, C1
Thuru, X1
Chavatte, P1
Chamaillard, M1
Treepongkaruna, S1
Pienvichit, P1
Sornmayura, P1
Pornkul, R1
Wisedopas, N1
Phuapradit, P1
Mudter, J1
Neurath, MF1
Bernal, I1
Marín, L1
Navarro, M1
Gassull, MA1
Hagymási, K1
Tulassay, Z1
Kolho, KL1
Ruuska, T1
Savilahti, E1
Swidsinski, A1
Loening-Baucke, V1
Bengmark, S1
Lochs, H1
Dörffel, Y1
Terdiman, JP1
Steinbuch, M1
Blumentals, WA1
Velayos, FS2
Winther, KV1
Tremaine, WJ2
Scott Harmsen, W1
Binder, V1
Munck, LK1
Topaloğlu, R1
Cervený, P1
Kubena, A1
Vlcek, J1
Stasinopoulou, P1
Kaziani, A1
Mantzaris, G1
Roussos, A1
Skoutelis, A1
Lakatos, L1
Levine, JS1
Rijmen, F1
Peh, KH1
Wan, BC1
Assem, ES1
Pearce, FL1
Moffatt, DC1
Cruz-Correa, MR1
Jass, JR1
Lichtenstein, GR2
Montgomery, EA1
Riddell, RH1
Rutter, MD1
Itzkowitz, S1
Subramanian, S1
Rhodes, JM1
Hart, CA1
Tam, B1
Roberts, CL1
Smith, SL1
Corkill, JE1
Winstanley, C1
Virji, M1
Campbell, BJ1
Wong, VK1
Lee, TK1
Yoshida, EM1
Rahimi, R1
Nikfar, S1
Rezaie, A1
Abdollahi, M1
Shah, JA1
Edwards, CM1
Freeman, HJ1
Swaminath, A1
Hawthorne, AB2
Rubin, G1
Lémann, M2
Bruin, KF1
Hommes, DW1
Jansen, J1
Tytgat, GN1
Wouter ten Cate, J1
van Deventer, SJ1
Lauritsen, K3
Laursen, LS2
Bukhave, K2
Hansen, TK1
Rask-Madsen, J2
Sheldon, P1
Pell, P1
Karvonen, AL1
Matikainen, M1
Turunen, U1
Liu, ZC1
McClelland, RA1
Uetrecht, JP1
Rhodes, J1
Coles, GA1
Hirschfeld, S1
Clearfield, HR1
Varela, E1
Nakamaru, K1
Sugai, T1
Kinoshita, N1
Sato, M1
Taniguchi, S1
Kawase, S1
Böhne, P2
Schmidt, M3
Kruis, W7
Grisham, MB2
Jewell, DP3
Devaux, CB1
Christensen, LA2
Rasmussen, SN2
Hansen, SH1
Greenfield, SM1
Punchard, NA1
Teare, JP1
Thompson, RP1
Nichols, TW1
Scheurlen, C1
Erdmann, E1
Sauerbruch, T1
Fehér, J1
Prónai, L1
Schmidt, C1
Kosché, E1
Baumeister, B1
Vetter, H1
Bonner, GF2
World, MJ1
Stevens, PE2
Ashton, MA1
Rainford, DJ1
Lukás, K1
Frol'kis, AV1
Kreisel, W1
Wolf, LM1
Grotz, W1
Grieshaber, M1
Tebano, MT1
Traversa, G1
Da Cas, R1
Loizzo, A1
Sviri, S1
Gafanovich, I1
Kramer, MR1
Tsvang, E1
Ben-Chetrit, E1
Takaya, T1
Sawada, K1
Suzuki, H1
Funaoka, A1
Takada, K2
Cellier, C1
Keljo, DJ1
Sugerman, KS1
Schreiber, S1
Hämling, J1
Zehnter, E1
Howaldt, S1
Daerr, W1
Raedler, A1
De Broe, ME2
Stolear, JC1
Nouwen, EJ1
Elseviers, MM2
Kaiser, GC1
Milov, DE1
Erhart, NA1
Bailey, DJ1
Chadwick, C1
Miner, PB2
Bondesen, S1
Diav-Citrin, O1
Park, YH1
Veerasuntharam, G1
Polachek, H1
Bologa, M1
Pastuszak, A1
Koren, G1
Benbow, AG1
Gould, I1
Botoman, VA1
Botoman, DA1
Stotland, BR1
Cirigliano, MD1
Skhiri, H1
Knebelmann, B1
Martin-Lefevre, L1
Grunfeld, JP1
Wyllie, R1
Sarigol, S1
van den Hazel, SJ1
Batta, AK1
Tint, GS1
Xu, G1
Shefer, S1
Salen, G1
Tennenbaum, R2
Elefant, E2
Simmonds, NJ1
Millar, AD1
Blake, DR1
Rampton, DS4
Eisen, GM1
Farmer, RG1
Saubermann, LJ1
Wolf, JL1
Lowry, PW1
Szumlanski, CL1
Weinshilboum, RM1
Rambaud, JC1
Modigliani, R1
Gendre, JP1
Bokemeyer, B1
Asakura, H1
Sugimura, K1
Geboes, K1
Jouret, A1
Ectors, N1
Weidenhiller, M1
Corrigan, G1
Farrell, RJ1
Murphy, A1
Long, A1
Donnelly, S1
Cherikuri, A1
O'Toole, D1
Mahmud, N1
Keeling, PW1
Weir, DG1
Kelleher, D1
Cristina, G1
Parrello, T1
Morano, S1
Biancone, L1
Pietravalle, P1
Sagratella, E1
Luzza, F1
Di Mario, U1
Dubinsky, MC1
Lamothe, S1
Yang, HY1
Targan, SR1
Sinnett, D1
Théorêt, Y1
Seidman, EG1
Imperiali, G1
Meucci, G1
Alvisi, C1
Fasoli, R1
Ferrara, A1
Girelli, CM1
Rocca, F1
Saibeni, S1
Minoli, G1
Yarze, JC1
Chase, MP1
Fritz, HP1
Herlihy, KJ1
Pearce, CB1
Duncan, HD1
Timmis, L1
Green, JR1
Goldstein, F1
DiMarino, AJ1
Present, DH2
Carty, E1
MacEy, M1
De Vos, M1
Russo, GE1
Bauco, B1
Bosco, M1
Bonello, M1
Bisciglia, MF1
De Paola, A1
Villatico Campbell, S1
Fava, D1
Vitaliano, E1
Trisolini, R1
Dore, R1
Biagi, F1
Luinetti, O1
Pochetti, P1
Carrabino, N1
Luisetti, M1
Faubion, WA1
Stein, RB1
Dassopoulos, T1
Nugent, SG1
Kumar, D1
Evans, DF1
Katz, JA1
Pore, G1
Fraser, JS1
Muller, AF1
Smith, DJ1
Newman, DJ1
Lamb, EJ1
Oshima, T1
Pavlick, K1
Jordan, P1
Manas, K1
Joh, T1
Itoh, M1
Alexander, JS1
Campbell, S1
Iofel, E1
Chawla, A1
Daum, F2
Markowitz, J2
Metge, CJ1
Peterson, S1
Langmead, L1
Dawson, C1
Hawkins, C1
Banna, N1
Loo, S1
Höfer, P2
Gugler, R2
Giaffer, MH1
O'Brien, CJ1
Holdsworth, CD1
Gaginella, TS1
Walsh, RE1
Tolia, V2
Davis, AE1
Patterson, F1
Crouch, R1
Butt, JH1
Rijk, MC1
van Schaik, A1
van Tongeren, JH1
Selve, N1
Pullman, WE2
Elsbury, S1
Kobayashi, M1
Hapel, AJ1
Doe, WF2
Erdkamp, F1
Houben, M1
Ackerman, E1
Breed, W1
van Spreeuwel, J1
Crotty, B2
Rosenberg, WM1
Aronson, JK1
Geier, DL1
Elitsur, Y1
Kovács, A1
Cohen, SA1
Glassman, M1
Holmes, RD1
Piccoli, D1
Rossi, TM1
Treem, WR1
Ulshen, MH1
Winter, HS1
Verspaget, HW1
Aparicio-Pagés, MN1
Verver, S1
Edelbroek, PM1
Hafkenscheid, JC1
Crama-Bohbouth, GE1
Peña, AS1
Weterman, IT1
Lamers, CB1
Fox, CC1
Moore, WC1
Lichtenstein, LM1
Hoang, P1
Dalton, HR1
Thomson, AB1
Mahida, YR1
Lamming, CE1
Gallagher, A1
Kornbluth, AA1
Salomon, P1
Sachar, DB2
Subramani, K1
Kramer, A1
Gray, CE1
Chapman, ML1
Böhme, P1
Tromm, A1
May, B1
Peppercorn, MA2
Williams, CN1
Cotton, P1
Osterwald, HP1
Perrault, J1
O'Brien, JF1
Ruderman, WB1
Williams, JG1
Hallett, MB1
Massoud, N1
Ahnfelt, NO1
Frank-Holmberg, K1
Söderberg, HN1
Paumgartner, G1
Van Rosendaal, GM1
Wu, FC1
Aitken, RJ1
Ferguson, A1
Barden, L1
Lipson, A1
Pert, P1
Walker-Smith, JA1
Järnerot, G1
Brogden, RN1
Sorkin, EM1
Jacobsen, BA1
Zelissen, PM1
van Hattum, J1
Poen, H1
Scholten, P1
Gerritse, R1
te Velde, ER1
Hardy, JG1
Healey, JN1
Reynolds, JR1

Clinical Trials (26)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)[NCT02368743]117 participants (Actual)Observational2015-12-31Completed
Monitoring Serologic Response to SARS-COV-2 / Coronavirus Disease 2019 (COVID-19) in Children, Adolescents, and Young Adults Receiving Biologic Therapies (RECONN)[NCT04838834]472 participants (Actual)Observational2020-05-15Active, not recruiting
Role of Information and Communication Technologies for Health Support in Inflammatory Bowel Diseases: The DAMASCO Trial (Stage I)[NCT04893928]351 participants (Anticipated)Observational2021-05-03Recruiting
Reduction in Length of Hospitalization in Patients With Acute Severe Ulcerative Colitis Treated With Rescue Therapy With Infliximab by the Use of Web-app Constant-Care. One Year Follow-up, Inclusive Colectomy Rate.[NCT04165265]28 participants (Anticipated)Interventional2019-12-03Recruiting
Randomised Placebo-controlled Trial of a Gut Immunomodulatory Agent (Mesalamine) to Tackle Environmental Enteropathy in Acutely Malnourished Children: A Pilot Study.[NCT01841099]Phase 1/Phase 244 participants (Actual)Interventional2013-06-30Completed
Pharmacokinetics of Antimicrobials and Carriage of Antimicrobial Resistance Amongst Hospitalised Children With Severe Acute Malnutrition[NCT02746276]Phase 281 participants (Actual)Interventional2016-04-01Active, not recruiting
First Line Antimicrobials in Children With Complicated Severe Acute Malnutrition[NCT03174236]Phase 32,000 participants (Anticipated)Interventional2017-09-04Active, not recruiting
Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic Evaluation[NCT02994836]Phase 4139 participants (Actual)Interventional2017-04-21Completed
"Azione Chemiopreventiva Della Mesalazina Sul Cancro Del Colon-retto: Studio Pilota Per la Valutazione Degli Effetti Molecolari in Vivo Sulla Via di Segnalazione Proliferativa Della β-catenina (Official Title in Italian Language)"[NCT02077777]Phase 221 participants (Actual)Interventional2012-10-31Completed
Clinical Hypnosis in Pediatric Crohn's Disease[NCT03809195]40 participants (Actual)Interventional2019-02-14Completed
Counseling to Optimize Medication Adherence in Expectant Mothers With Inflammatory Bowel Disease (COACH-IBD)[NCT03091309]220 participants (Anticipated)Interventional2017-10-01Recruiting
Manitoba Inflammatory Bowel Disease Cohort Study[NCT03262649]388 participants (Actual)Observational2002-03-01Completed
[NCT02003807]102 participants (Actual)Observational2013-07-31Completed
Multicentre Controlled, Randomized Clinical Trial to Compare the Efficacy and Safety of Ambulatory Treatment of Mild Acute Diverticulitis Without Antibiotics With the Standard Treatment With Antibiotics[NCT02785549]Phase 4480 participants (Actual)Interventional2016-11-30Completed
Curcumin in Pediatric Inflammatory Bowel Disease: A Forced Dose Titration Study[NCT00889161]Phase 111 participants (Actual)Interventional2009-05-31Completed
Non-Pharmacologic Alternatives for the Treatment of Childhood Obesity in Mexico[NCT03670875]300 participants (Actual)Interventional2021-07-31Completed
Phase 2a Randomised Double-blind Placebo-controlled Trial to Assess Safety, Efficacy of Artesunate & Curcumin in Crohn's Disease Patients, Who Continue to Have Mild to Moderate Disease Activity on an Adequate Dose of Azathioprine[NCT04713631]Phase 240 participants (Anticipated)Interventional2021-01-21Recruiting
The Correlation Between Anemia of Chronic Diseases, Hepcidin and Vitamin D in IBD Patients[NCT03145896]40 participants (Anticipated)Interventional2017-06-01Not yet recruiting
Effect of Aloe Vera in the Inflammation of Patients With Mild Ulcerative Colitis[NCT01783119]Early Phase 160 participants (Anticipated)Interventional2012-08-31Recruiting
Investigating Serotonin Signalling in IBD Patients[NCT01650311]60 participants (Anticipated)Observational2012-07-31Recruiting
A Pilot Study to Evaluate the Applicability of the Crohn's Disease Endoscopy Index of Severity to Data Obtained by the Colonic Capsule Endoscopy in Ileocolonic Crohn's Disease[NCT01183845]Phase 424 participants (Actual)Interventional2009-04-30Completed
Hypnotherapy for Prevention of Relapse in Ulcerative Colitis: a Randomised, Single-blind, Controlled Clinical Trial[NCT00553163]26 participants (Actual)Interventional2007-10-31Terminated (stopped due to Unable to recruit sufficient numbers of patinets in the time available)
An Observational Study of the Immunopathogenesis of and Response to Step-Up Inflammatory Bowel Disease Therapy for Hermansky-Pudlak Syndrome-Associated Colitis[NCT00514982]Phase 20 participants (Actual)Interventional2007-08-07Withdrawn
Decisional Influences and IBD Patients' Medication Use[NCT00968721]55 participants (Actual)Observational2010-06-30Terminated (stopped due to lack of support)
Prevalence of Segmental Colitis Associated With Colic Diverticulosis (SCAD): an Observational Study[NCT04279821]50 participants (Anticipated)Observational2020-02-01Recruiting
Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients[NCT04096222]42 participants (Anticipated)Observational2021-06-29Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Hospital Anxiety and Depression Score-Anxiety, (HADSA) at Week 13

Measure of anxiety, HADS Hospital anxiety and depression scale. HADS questionnaire consists of a 14 question validated questionnaire, developed to measure anxiety and depression in the hospital setting. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 (minimum) to 21 (maximum) for anxiety and 0 (minimum) to 21 (maximum) for depression. Higher scores indicate worse outcome, (NCT00553163)
Timeframe: 13 weeks

Interventionscore on a scale (Median)
UC Patients Given Gut-focussed Hpynotherapy7
UC Patients Given Control Educational Sessions10

Hospital Anxiety and Depression Score-Depression (HADSD)

Measure of depression. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 to 21 for anxiety and 0 to 21 for depression. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 (minimum) to 21 (maximum) for anxiety and (minimum) to 21 (maximum) for depression. Higher scores worse outcome. (NCT00553163)
Timeframe: 13 weeks

Interventionunits on a scale (Median)
UC Patients Given Gut-focussed Hypnotherapy1.5
UC Patients Given Control Educational Sessions4

Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 13

IBDQ (standard measure of IBD patients' Quality of life (QoL) (Irvine et al 1982 approx). The IBDQ is a validated and reliable tool to measure of health-related quality of life in adult patients with IBD. The questionnaire consists of 32 questions scored in four domains: bowel symptoms, emotional health, systemic systems and social function. Scores range from 1 (poorest QoL) to 7 (best QoL). Higher scores indicate better QoL. Lowest score 7, highest score 224. (NCT00553163)
Timeframe: 13 weeks

Interventionunits on a scale (Median)
UC Patients Given Gut-focussed Hypnotherapy195
UC Patients Given Control Educational Sessions192

Perceived Stress Questionnaire-Recent (PSQ-R)

Measure of recent psychological stress. THE PSQ R consists of a 30 question questionnaires: recent, in which the statements used apply to the last month in which used statements apply to the last two years (Appendix 1.3). The score for both recent and general stress levels were stated as the PSQ index ranging from 0 (non-stressed) to 0.99 (highly stressed). Higher scores indicate worse outcome. (NCT00553163)
Timeframe: 13 weeks

Interventionunits on a scale (Median)
UC Patients Given Gut-focussed Hypnotherapy0.3
UC Patients Given Control Educational Sessions0.4

Relapse at 1 Year

The number of patients suffering a relapse was compared between the two treatment groups, and was the primary outcome parameter of this study. (NCT00553163)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
UC Patients Given Gut-focussed Hypnotherapy8
UC Patients Given Control Educational Sessions7

Reviews

148 reviews available for mesalamine and Bowel Diseases, Inflammatory

ArticleYear
COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Inflammatory bowel diseases, 2022, 08-01, Volume: 28, Issue:8

    Topics: Adrenal Cortex Hormones; COVID-19; Humans; Inflammatory Bowel Diseases; Mesalamine; Necrosis; Tumor

2022
5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review.
    European journal of medical research, 2022, Apr-29, Volume: 27, Issue:1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Child; Chronic Disease; Female; Humans; Inflammatory

2022
Pathophysiological Concepts and Management of Pulmonary Manifestation of Pediatric Inflammatory Bowel Disease.
    International journal of molecular sciences, 2022, Jun-30, Volume: 23, Issue:13

    Topics: Child; Humans; Inflammatory Bowel Diseases; Infliximab; Lung; Mesalamine; Proline

2022
Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α.
    The Korean journal of internal medicine, 2022, Volume: 37, Issue:5

    Topics: Adrenal Cortex Hormones; Humans; Immunologic Factors; Inflammatory Bowel Diseases; Mesalamine; Tumor

2022
COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
    Reviews in medical virology, 2023, Volume: 33, Issue:2

    Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; COVID-19; Crohn Disease; Humans; Inflammatory Bowel Di

2023
COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
    Reviews in medical virology, 2023, Volume: 33, Issue:2

    Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; COVID-19; Crohn Disease; Humans; Inflammatory Bowel Di

2023
COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
    Reviews in medical virology, 2023, Volume: 33, Issue:2

    Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; COVID-19; Crohn Disease; Humans; Inflammatory Bowel Di

2023
COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
    Reviews in medical virology, 2023, Volume: 33, Issue:2

    Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; COVID-19; Crohn Disease; Humans; Inflammatory Bowel Di

2023
Myocarditis and inflammatory bowel diseases: A single-center experience and a systematic literature review.
    International journal of cardiology, 2023, 04-01, Volume: 376

    Topics: Adult; Humans; Inflammatory Bowel Diseases; Male; Mesalamine; Myocarditis; Prognosis; Retrospective

2023
Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Inflammatory bowel diseases, 2020, 11-19, Volume: 26, Issue:12

    Topics: Adrenal Cortex Hormones; Digestive System Surgical Procedures; Humans; Immunologic Factors; Infectio

2020
The Association of Mesalamine With Kidney Disease.
    Advances in chronic kidney disease, 2020, Volume: 27, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Monitoring; Humans; Inflammatory Bowel Diseases; Mesal

2020
Effects of 5-aminosalicylates or thiopurines on the progression of low-grade dysplasia in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    International journal of colorectal disease, 2021, Volume: 36, Issue:1

    Topics: Colitis; Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases; Mesalamine; Risk Factors

2021
New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy.
    International journal of molecular sciences, 2020, Sep-05, Volume: 21, Issue:18

    Topics: Administration, Oral; Aminosalicylic Acids; Animals; Colitis; Colon; Drug Delivery Systems; Drug Lib

2020
De-escalation of medical therapy in inflammatory bowel disease.
    Current opinion in pharmacology, 2020, Volume: 55

    Topics: Biological Therapy; Humans; Immunologic Factors; Inflammatory Bowel Diseases; Mesalamine; Safety-Bas

2020
Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease.
    Inflammatory bowel diseases, 2022, 01-05, Volume: 28, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diarrhea; Genetic Background; Genome-W

2022
Pancreatic Disorders in Patients with Inflammatory Bowel Disease.
    Digestive diseases and sciences, 2022, Volume: 67, Issue:2

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Pancreatitis; Azathioprin

2022
Recurrent myocarditis in a patient with active ulcerative colitis: a case report and review of the literature.
    BMJ open gastroenterology, 2021, Volume: 8, Issue:1

    Topics: Adult; Colitis, Ulcerative; Humans; Inflammatory Bowel Diseases; Male; Mesalamine; Myocarditis

2021
Mesalazine and inflammatory bowel disease - From well-established therapies to progress beyond the state of the art.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2021, Volume: 167

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Drug Delivery Systems

2021
Risk Factors for Vitamin D Deficiency in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2021, Volume: 32, Issue:6

    Topics: Biological Products; Colitis; Crohn Disease; Humans; Inflammatory Bowel Diseases; Male; Mesalamine;

2021
Inflammatory bowel disease in liver transplanted patients.
    World journal of gastroenterology, 2017, May-14, Volume: 23, Issue:18

    Topics: Algorithms; Anastomosis, Surgical; Cholangitis, Sclerosing; Colonoscopy; Colorectal Neoplasms; Femal

2017
Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.
    Inflammatory bowel diseases, 2018, 01-18, Volume: 24, Issue:2

    Topics: Cholangitis, Sclerosing; Colonoscopy; Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases; Liv

2018
Inflammatory Bowel Disease in Latin America: A Systematic Review.
    Value in health regional issues, 2018, Volume: 17

    Topics: Cost of Illness; Developing Countries; Humans; Incidence; Inflammatory Bowel Diseases; Latin America

2018
Towards improved control of inflammatory bowel disease.
    Scandinavian journal of immunology, 2019, Volume: 89, Issue:3

    Topics: Antibodies, Monoclonal; Electric Stimulation Therapy; Glucocorticoids; Humans; Inflammatory Bowel Di

2019
Aminosalicylates, thiopurines and methotrexate in inflammatory bowel disease: Is it possible to discontinue the treatment?
    Gastroenterologia y hepatologia, 2019, Volume: 42, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Humans; Immunosuppressive Agents; Inflammator

2019
Mucosal healing in inflammatory bowel disease: Expanding horizon.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2019, Volume: 38, Issue:2

    Topics: Biological Factors; Capsule Endoscopy; Endoscopy, Gastrointestinal; Glucocorticoids; Humans; Immunos

2019
Molecular Profiling of Inflammatory Bowel Disease: Is It Ready for Use in Clinical Decision-Making?
    Cells, 2019, 06-04, Volume: 8, Issue:6

    Topics: Antibodies, Bacterial; CD8-Positive T-Lymphocytes; Clinical Decision-Making; Forkhead Box Protein O3

2019
Innovations in Oral Therapies for Inflammatory Bowel Disease.
    Drugs, 2019, Volume: 79, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Discovery; Heterocyclic Compounds, 3-Ring; Humans; Ind

2019
Recent developments in the treatment of inflammatory bowel disease.
    Journal of digestive diseases, 2013, Volume: 14, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Budesonide; Certolizumab Pegol; Evidence-

2013
Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives.
    Mediators of inflammation, 2013, Volume: 2013

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Disease

2013
IBD medications during pregnancy and lactation.
    Nature reviews. Gastroenterology & hepatology, 2014, Volume: 11, Issue:2

    Topics: Ciprofloxacin; Female; Glucocorticoids; Humans; Inflammatory Bowel Diseases; Lactation; Mesalamine;

2014
5-Aminosalicylic acid and chemoprevention: does it work?
    Digestive diseases (Basel, Switzerland), 2013, Volume: 31, Issue:2

    Topics: Chemoprevention; Colorectal Neoplasms; Evidence-Based Medicine; Humans; Inflammatory Bowel Diseases;

2013
The study of marketed and experimental formulation approaches enabling site-specific delivery of mesalamine in patients with inflammatory bowel disease.
    Recent patents on drug delivery & formulation, 2014, Volume: 8, Issue:1

    Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Drug Deliv

2014
Medical management of inflammatory bowel disease in the elderly: balancing safety and efficacy.
    Clinics in geriatric medicine, 2014, Volume: 30, Issue:1

    Topics: Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Biotransformation; Comorbidity; Cost of Illnes

2014
[Chemoprevention of colorectal cancer in inflammatory bowel disease].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2014, Jan-25, Volume: 63, Issue:1

    Topics: Anti-Inflammatory Agents; Chemoprevention; Colorectal Neoplasms; Folic Acid; Immunosuppressive Agent

2014
Clinical management of inflammatory bowel disease in the organ recipient.
    World journal of gastroenterology, 2014, Apr-07, Volume: 20, Issue:13

    Topics: Azathioprine; Cholangitis, Sclerosing; Colectomy; Colorectal Neoplasms; End Stage Liver Disease; Gra

2014
Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease.
    World journal of gastroenterology, 2014, Apr-07, Volume: 20, Issue:13

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Clinical Trials as Topic; Colon; Fatty Acids, Omega-3; He

2014
The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease.
    Gastrointestinal endoscopy clinics of North America, 2014, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cholagogues and Choleretics;

2014
Inflammatory bowel disease and the elderly: a review.
    Journal of Crohn's & colitis, 2015, Volume: 9, Issue:6

    Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Diagnosi

2015
[Changing paradigm in the management of inflammatory bowel disease].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2015, Volume: 65, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Colitis, Ulcerative; Crohn Disease;

2015
Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis.
    Inflammatory bowel diseases, 2015, Volume: 21, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases;

2015
Lung disease and ulcerative colitis--mesalazine-induced bronchiolitis obliterans with organizing pneumonia or pulmonary manifestation of inflammatory bowel disease?
    Zeitschrift fur Gastroenterologie, 2015, Volume: 53, Issue:9

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Cryptogenic Organizing Pneumoni

2015
New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?
    Inflammatory bowel diseases, 2015, Volume: 21, Issue:12

    Topics: Anti-Inflammatory Agents; Azathioprine; Budesonide; Colitis, Ulcerative; Congresses as Topic; Crohn

2015
Advances in Pediatric Inflammatory Bowel Disease.
    Adolescent medicine: state of the art reviews, 2016,Spring, Volume: 27, Issue:1

    Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antibodies, Monoclonal, Huma

2016
Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
    Oncotarget, 2017, Jan-03, Volume: 8, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Cohort Studies; Colorectal Neoplasms; Huma

2017
Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?
    Alimentary pharmacology & therapeutics, 2009, Mar-01, Volume: 29, Issue:5

    Topics: Aminosalicylic Acids; Drug Therapy, Combination; Humans; Immunologic Factors; Inflammatory Bowel Dis

2009
Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease.
    World journal of gastroenterology, 2009, Mar-28, Volume: 15, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Drug Synergism; Humans;

2009
Reproductive issues in inflammatory bowel disease.
    Medicine and health, Rhode Island, 2009, Volume: 92, Issue:4

    Topics: Adaptation, Psychological; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathio

2009
[The problems of compliance and adherence, using the example of chronic inflammatory bowel disease].
    Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:27

    Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Gluc

2009
Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine.
    Alimentary pharmacology & therapeutics, 2010, Jan-15, Volume: 31, Issue:2

    Topics: Cell Line, Tumor; Chemoprevention; Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases; Intest

2010
The future of inflammatory bowel disease care.
    Reviews in gastroenterological disorders, 2009,Summer, Volume: 9, Issue:3

    Topics: Adalimumab; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal

2009
Optimizing conventional therapies for inflammatory bowel disease.
    Current gastroenterology reports, 2009, Volume: 11, Issue:6

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Glucocorticoids; Humans; Immunologic Factors; Infla

2009
Rheumatic manifestations of inflammatory bowel disease.
    World journal of gastroenterology, 2009, Nov-28, Volume: 15, Issue:44

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Cadherins; Cytokines; Gastroenter

2009
Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease.
    Journal of pediatric gastroenterology and nutrition, 2010, Volume: 50 Suppl 1

    Topics: Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Bone and Bones; Child;

2010
Pancreatitis in inflammatory bowel diseases.
    Journal of clinical gastroenterology, 2010, Volume: 44, Issue:4

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Crohn Dis

2010
Pharmacogenomics in the treatment of inflammatory bowel disease.
    Pharmacogenomics, 2010, Volume: 11, Issue:3

    Topics: Adrenal Cortex Hormones; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transpo

2010
New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut.
    Current medicinal chemistry, 2010, Volume: 17, Issue:17

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Drug Delivery Systems; E

2010
Cost effectiveness of treatments for inflammatory bowel disease.
    PharmacoEconomics, 2011, Volume: 29, Issue:5

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Chronic Di

2011
Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease.
    Drug development and industrial pharmacy, 2011, Volume: 37, Issue:9

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Drug Compounding; Drug D

2011
The clinical implication of drug dependency in children and adults with inflammatory bowel disease: a review.
    Journal of Crohn's & colitis, 2011, Volume: 5, Issue:2

    Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Chi

2011
Inflammatory bowel disease of the elderly: frequently asked questions (FAQs).
    The American journal of gastroenterology, 2011, Volume: 106, Issue:11

    Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Dia

2011
The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
    Arzneimittel-Forschung, 2012, Volume: 62, Issue:2

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Crohn Disease; Drug Delivery

2012
An unusual presentation of inflammatory bowel disease.
    Military medicine, 2012, Volume: 177, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Crohn Disease; Diagnosis, Differential; Erythema Nod

2012
Drugs for inflammatory bowel disease.
    Treatment guidelines from the Medical Letter, 2012, Volume: 10, Issue:115

    Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Anti-Inflammatory Agents, Non-Steroidal; Antitubercula

2012
An aggressive medical approach for inflammatory bowel disease: clinical challenges and therapeutic profiles in a retrospective hospital-based series.
    Current clinical pharmacology, 2012, Volume: 7, Issue:3

    Topics: Adolescent; Adult; Aged; Azathioprine; Cohort Studies; Cyclosporine; Female; Follow-Up Studies; Hosp

2012
Colorectal cancer chemoprevention by mesalazine and its derivatives.
    Journal of biomedicine & biotechnology, 2012, Volume: 2012

    Topics: Cell Survival; Colorectal Neoplasms; DNA Replication; ErbB Receptors; Humans; Inflammatory Bowel Dis

2012
5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations.
    The American journal of gastroenterology, 2012, Volume: 107, Issue:9

    Topics: Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases; Mesalamine

2012
Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights.
    The American journal of gastroenterology, 2012, Volume: 107, Issue:10

    Topics: Abdominal Pain; Acute Disease; Age Distribution; Anti-Infective Agents; Anti-Inflammatory Agents, No

2012
Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights.
    The American journal of gastroenterology, 2012, Volume: 107, Issue:10

    Topics: Abdominal Pain; Acute Disease; Age Distribution; Anti-Infective Agents; Anti-Inflammatory Agents, No

2012
Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights.
    The American journal of gastroenterology, 2012, Volume: 107, Issue:10

    Topics: Abdominal Pain; Acute Disease; Age Distribution; Anti-Infective Agents; Anti-Inflammatory Agents, No

2012
Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights.
    The American journal of gastroenterology, 2012, Volume: 107, Issue:10

    Topics: Abdominal Pain; Acute Disease; Age Distribution; Anti-Infective Agents; Anti-Inflammatory Agents, No

2012
Diarrhea in chronic inflammatory bowel diseases.
    Gastroenterology clinics of North America, 2012, Volume: 41, Issue:3

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidiarrheals; Bacterial Infections

2012
Cutting edge: chemoprevention of colorectal neoplasia in inflammatory bowel disease.
    Inflammation & allergy drug targets, 2013, Volume: 12, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Cell Transformation, Neoplastic; Chemoprevention; Colonoscopy; Co

2013
Inflammatory bowel disease.
    The New England journal of medicine, 2002, Aug-08, Volume: 347, Issue:6

    Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ul

2002
Inflammatory bowel disease.
    The New England journal of medicine, 2002, Aug-08, Volume: 347, Issue:6

    Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ul

2002
Inflammatory bowel disease.
    The New England journal of medicine, 2002, Aug-08, Volume: 347, Issue:6

    Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ul

2002
Inflammatory bowel disease.
    The New England journal of medicine, 2002, Aug-08, Volume: 347, Issue:6

    Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ul

2002
Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid.
    Inflammatory bowel diseases, 2002, Volume: 8, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases;

2002
[Conservative therapy of inflammatory bowel diseases].
    Orvosi hetilap, 2002, Dec-15, Volume: 143, Issue:50

    Topics: Acute Disease; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Chro

2002
Review article: Oral, modified-release mesalazine formulations--proprietary versus generic.
    Alimentary pharmacology & therapeutics, 2003, May-15, Volume: 17, Issue:10

    Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; D

2003
Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 2003, Volume: 18 Suppl 2

    Topics: Adenocarcinoma; Age of Onset; Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Humans;

2003
Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 2003, Volume: 18 Suppl 2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Colorectal Neoplasms; Cyclooxygenase 1; Cycl

2003
Diagnosis and management of dysplasia in patients with inflammatory bowel diseases.
    Gastroenterology, 2004, Volume: 126, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colonoscopy; Colorectal Neoplasms; Humans; Inflammatory Bow

2004
Review article: inflammatory bowel disease--empowering the patient and improving outcome.
    Alimentary pharmacology & therapeutics, 2004, Volume: 20 Suppl 4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Mesalamine; Patient Co

2004
[Association between membranous glomerulonephritis and Crohn's disease].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2004, Volume: 24, Issue:4

    Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Child; Colitis, Ul

2004
Mesalamine delivery systems: do they really make much difference?
    Advanced drug delivery reviews, 2005, Jan-06, Volume: 57, Issue:2

    Topics: Animals; Drug Delivery Systems; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Mesala

2005
[The conservative treatment of nonspecific inflammatory bowel diseases].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2004, Volume: 17 Suppl 1

    Topics: Anti-Inflammatory Agents; Crohn Disease; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseas

2004
5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease.
    World journal of gastroenterology, 2005, Jan-21, Volume: 11, Issue:3

    Topics: Colonic Neoplasms; Humans; Inflammatory Bowel Diseases; Mesalamine

2005
Inflammatory bowel disease.
    Australian family physician, 2005, Volume: 34, Issue:4

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy;

2005
5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.
    Gut, 2005, Volume: 54, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control St

2005
5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2005, Volume: 37, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Clinical Trials as Topic; Colorectal Neopl

2005
Safety of balsalazide therapy in the treatment of inflammatory bowel disease.
    Reviews in gastroenterological disorders, 2005,Summer, Volume: 5, Issue:3

    Topics: Aminosalicylic Acids; Anti-Ulcer Agents; Clinical Trials as Topic; Humans; Inflammatory Bowel Diseas

2005
Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates.
    Digestion, 2006, Volume: 73, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colonoscopy; Colorectal Neoplasms; Humans; Inflamma

2006
Systematic review: the use of mesalazine in inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 2006, Apr-01, Volume: 23, Issue:7

    Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida

2006
Systematic review: the use of mesalazine in inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 2006, Apr-01, Volume: 23, Issue:7

    Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida

2006
Systematic review: the use of mesalazine in inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 2006, Apr-01, Volume: 23, Issue:7

    Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida

2006
Systematic review: the use of mesalazine in inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 2006, Apr-01, Volume: 23, Issue:7

    Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida

2006
Management of diverticular disease is changing.
    World journal of gastroenterology, 2006, May-28, Volume: 12, Issue:20

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Diverticulitis, Col

2006
Inflammatory bowel disease in children: a pediatrician's perspective.
    Minerva pediatrica, 2006, Volume: 58, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Child; Colitis, Ulcerative; Environment; G

2006
PPARgamma as a new therapeutic target in inflammatory bowel diseases.
    Gut, 2006, Volume: 55, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colon; Humans; Inflammatory Bowel Diseases; Ligands; Mesala

2006
Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications.
    Gut, 2007, Volume: 56, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Azathioprine; Cell Survival; Crohn Disease; Huma

2007
Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?
    World journal of gastroenterology, 2006, Oct-14, Volume: 12, Issue:38

    Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Colonic Neoplasms; Humans; Inflammatory Bow

2006
[Inflammatory bowel disease and colorectal cancer].
    Orvosi hetilap, 2006, Oct-15, Volume: 147, Issue:41

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangitis, Sclerosing; Colitis, Ulcerative; Colonoscopy;

2006
5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.
    Inflammatory bowel diseases, 2007, Volume: 13, Issue:5

    Topics: Animals; Dose-Response Relationship, Drug; Humans; Inflammatory Bowel Diseases; Kidney; Kidney Disea

2007
Drug insight: aminosalicylates for the treatment of IBD.
    Nature clinical practice. Gastroenterology & hepatology, 2007, Volume: 4, Issue:3

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Colitis, Ulcerative;

2007
[Medical therapy of inflammatory bowel diseases: Crohn's disease].
    Orvosi hetilap, 2007, Jun-17, Volume: 148, Issue:24

    Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Ster

2007
Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts.
    Inflammatory bowel diseases, 2007, Volume: 13, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cholagogues and Choleretics; Colorectal Neopl

2007
Drug therapy for inflammatory bowel disease in pregnancy and the puerperium.
    Best practice & research. Clinical gastroenterology, 2007, Volume: 21, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antidiarrheals; Fe

2007
Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.
    Inflammatory bowel diseases, 2008, Volume: 14, Issue:2

    Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Humans; I

2008
Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis.
    Reproductive toxicology (Elmsford, N.Y.), 2008, Volume: 25, Issue:2

    Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Anti-Inflammatory Agents, Non-Steroidal;

2008
Optimizing drug therapy in inflammatory bowel disease.
    Current gastroenterology reports, 2007, Volume: 9, Issue:6

    Topics: Absorptiometry, Photon; Adalimumab; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal

2007
Review article: medication non-adherence in ulcerative colitis--strategies to improve adherence with mesalazine and other maintenance therapies.
    Alimentary pharmacology & therapeutics, 2008, Volume: 27, Issue:12

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Health Care Costs; Huma

2008
[Treatment of chronic inflammatory bowel diseases].
    Bulletin de l'Academie nationale de medecine, 2007, Volume: 191, Issue:6

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Ste

2007
Effects of mesalazine on the formation of lipoxygenase and cyclooxygenase products.
    Advances in experimental medicine and biology, 1995, Volume: 371B

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Dinoprostone; Eicosanoids; Humans; In

1995
[Changing treatment of inflammatory bowel diseases].
    Duodecim; laaketieteellinen aikakauskirja, 1994, Volume: 110, Issue:20

    Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, N

1994
Pharmacologic therapy for inflammatory bowel disease.
    American family physician, 1995, Volume: 51, Issue:8

    Topics: Administration, Topical; Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Bacterial Agents; Anti-

1995
[Recent therapeutic modalities in chronic inflammatory bowel diseases: 4- or 5-aminosalicylic acid?].
    Zeitschrift fur Gastroenterologie, 1994, Volume: 32, Issue:11

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid

1994
Oxidants and free radicals in inflammatory bowel disease.
    Lancet (London, England), 1994, Sep-24, Volume: 344, Issue:8926

    Topics: Aminosalicylic Acids; Animals; Free Radicals; Humans; Inflammatory Bowel Diseases; Mesalamine; Oxyge

1994
Salicylates for inflammatory bowel disease.
    Bailliere's clinical gastroenterology, 1994, Volume: 8, Issue:2

    Topics: Aminosalicylic Acids; Controlled Clinical Trials as Topic; Humans; Inflammatory Bowel Diseases; Mesa

1994
Review article: the mode of action of the aminosalicylates in inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 1993, Volume: 7, Issue:4

    Topics: Aminosalicylic Acids; Humans; Inflammatory Bowel Diseases; Mesalamine; Sulfasalazine

1993
Current medical therapy for inflammatory bowel disease.
    Southern medical journal, 1996, Volume: 89, Issue:6

    Topics: Administration, Topical; Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Anti-In

1996
[The treatment of inflammatory intestinal diseases with preparations of 5-aminosalicylic acid].
    Terapevticheskii arkhiv, 1996, Volume: 68, Issue:2

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases;

1996
[Side effects of 5-aminosalicylic acid].
    Gastroenterologie clinique et biologique, 1997, Volume: 21, Issue:5

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Inflammatory Bowel Di

1997
5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link?
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1997, Volume: 12, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Humans; Inflammatory Bowel Diseases; Mesal

1997
Factors influencing the relapse of patients with inflammatory bowel disease.
    The American journal of gastroenterology, 1997, Volume: 92, Issue:12 Suppl

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Humans; Infections; Inflammatory Bowel Disea

1997
Intestinal fate of 5-aminosalicylic acid: regional and systemic kinetic studies in relation to inflammatory bowel disease.
    Pharmacology & toxicology, 1997, Volume: 81 Suppl 2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Humans; Inflammatory Bowel Dis

1997
Epidemiology of toxic nephropathies.
    Advances in nephrology from the Necker Hospital, 1997, Volume: 27

    Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Kidney Dis

1997
Management of inflammatory bowel disease.
    American family physician, 1998, Jan-01, Volume: 57, Issue:1

    Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ul

1998
Medical therapies for inflammatory bowel disease.
    Hospital practice (1995), 1998, May-15, Volume: 33, Issue:5

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Female; Humans

1998
The treatment of inflammatory bowel disease in children.
    Clinical pediatrics, 1998, Volume: 37, Issue:7

    Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Child; Colitis, Ulcerative; Crohn Disease; Fe

1998
Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
    Mediators of inflammation, 1998, Volume: 7, Issue:3

    Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Hum

1998
[Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations].
    Medizinische Klinik (Munich, Germany : 1983), 1999, Feb-15, Volume: 94 Suppl 1

    Topics: Budesonide; Drug Delivery Systems; Humans; Inflammatory Bowel Diseases; Mesalamine; Structure-Activi

1999
New strategies in the management of inflammatory bowel disease.
    Acta clinica Belgica, 1999, Volume: 54, Issue:5

    Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprin

1999
[Present states of development in new drugs and treatment of inflammatory bowel disease].
    Nihon rinsho. Japanese journal of clinical medicine, 1999, Volume: 57, Issue:11

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Glucocorticoids; Humans; I

1999
[DDS preparations of drugs for inflammatory bowel disease].
    Nihon rinsho. Japanese journal of clinical medicine, 1999, Volume: 57, Issue:11

    Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Capsules; De

1999
[Histopathologic diagnosis of the activity of chronic inflammatory bowel disease. Evaluation of the effect of drug treatment. Use of histological scores].
    Gastroenterologie clinique et biologique, 1999, Volume: 23, Issue:10

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biopsy; Colitis, Ulc

1999
Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Mesalamine; Nephritis,

2000
Clinical pharmacokinetics of slow release mesalazine.
    Clinical pharmacokinetics, 2000, Volume: 39, Issue:2

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Digestive Syst

2000
Eosinophilic pleural effusion due to mesalamine. Report of a rare occurrence.
    Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2000, Volume: 17, Issue:3

    Topics: Adult; Eosinophilia; Follow-Up Studies; Humans; Inflammatory Bowel Diseases; Male; Mesalamine; Pleur

2000
Clinical pharmacology of inflammatory bowel disease therapies.
    Current gastroenterology reports, 2000, Volume: 2, Issue:6

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biomarkers; Colitis,

2000
Comparative tolerability of treatments for inflammatory bowel disease.
    Drug safety, 2000, Volume: 23, Issue:5

    Topics: Adrenal Cortex Hormones; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Female; Gas

2000
Evolving treatment strategies for inflammatory bowel disease.
    Annual review of medicine, 2001, Volume: 52

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathiopri

2001
Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.
    Gut, 2001, Volume: 48, Issue:4

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biological Availabi

2001
Inflammatory bowel disease and pregnancy.
    Inflammatory bowel diseases, 2001, Volume: 7, Issue:2

    Topics: Adult; Aminosalicylic Acids; Anti-Bacterial Agents; Colitis, Ulcerative; Crohn Disease; Female; Fert

2001
Sulfasalazine. Multiplicity of action.
    Digestive diseases and sciences, 1992, Volume: 37, Issue:6

    Topics: Aminosalicylic Acids; Animals; Free Radical Scavengers; Humans; Hydroxyeicosatetraenoic Acids; Infla

1992
Outpatient management of inflammatory bowel disease. Let's keep it as simple as possible.
    Postgraduate medicine, 1992, Nov-01, Volume: 92, Issue:6

    Topics: Abdominal Pain; Adrenal Cortex Hormones; Ambulatory Care; Aminosalicylic Acids; Anus Diseases; Diarr

1992
5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease.
    Agents and actions, 1992, Volume: Spec No

    Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Animals; Arachidonic Acid; Disease Models, Animal; Do

1992
New therapeutic agents in the treatment of inflammatory bowel disease.
    The American journal of medicine, 1992, Volume: 93, Issue:2

    Topics: Adjuvants, Immunologic; Administration, Topical; Aminosalicylic Acids; Anti-Bacterial Agents; Anti-I

1992
[New salicylic acid derivatives in the treatment of inflammatory intestinal diseases].
    Orvosi hetilap, 1991, Jun-16, Volume: 132, Issue:24

    Topics: Aminosalicylic Acids; Chronic Disease; Humans; Inflammatory Bowel Diseases; Mesalamine; Sulfasalazin

1991
[Experiences with phase III studies in the area of gastroenterology].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1991, Volume: 97

    Topics: Aminosalicylic Acids; Clinical Trials as Topic; Humans; Inflammatory Bowel Diseases; Mesalamine; Sul

1991
Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 1991, Volume: 5, Issue:5

    Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Inflammatory Bowel Diseases; Mesal

1991
ACTH-induced adrenal hemorrhage: a complication of therapy masquerading as an acute abdomen.
    Journal of clinical gastroenterology, 1990, Volume: 12, Issue:4

    Topics: Abdomen, Acute; Adrenocorticotropic Hormone; Adult; Aminosalicylic Acids; Cortisone; Diagnosis, Diff

1990
Advances in drug therapy for inflammatory bowel disease.
    Annals of internal medicine, 1990, Jan-01, Volume: 112, Issue:1

    Topics: Administration, Oral; Administration, Topical; Adrenocorticotropic Hormone; Aminosalicylic Acids; An

1990
Role of rectal formulations: suppositories.
    Scandinavian journal of gastroenterology. Supplement, 1990, Volume: 172

    Topics: Administration, Rectal; Aminosalicylic Acids; Humans; Inflammatory Bowel Diseases; Mesalamine; Suppo

1990
Newer pharmacologic agents for the therapy of inflammatory bowel disease.
    The Medical clinics of North America, 1990, Volume: 74, Issue:1

    Topics: Adjuvants, Immunologic; Administration, Oral; Aminosalicylic Acids; Anti-Bacterial Agents; Biomechan

1990
Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience.
    Journal of pediatric gastroenterology and nutrition, 1989, Volume: 8, Issue:3

    Topics: Administration, Oral; Adolescent; Aminosalicylic Acids; Chronic Disease; Colitis; Drug Tolerance; Fe

1989
Inflammatory bowel disease.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1989, Jul-15, Volume: 141, Issue:2

    Topics: Administration, Oral; Adrenal Cortex Hormones; Aminosalicylic Acids; Delayed-Action Preparations; Dr

1989
Drug treatment and formation of eicosanoids in patients with chronic inflammatory bowel disease.
    Danish medical bulletin, 1989, Volume: 36, Issue:4

    Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Inflammatory Bowel Diseases; Leuko

1989
Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease.
    Drugs, 1989, Volume: 37, Issue:1

    Topics: Administration, Oral; Administration, Topical; Aminosalicylic Acids; Female; Humans; Inflammatory Bo

1989
Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.
    Drugs, 1989, Volume: 38, Issue:4

    Topics: Aminosalicylic Acids; Humans; Inflammatory Bowel Diseases; Mesalamine

1989
Update on the aminosalicylates: a promise fulfilled.
    Gastroenterology, 1988, Volume: 95, Issue:6

    Topics: Aminosalicylic Acids; Canada; Europe; Humans; Inflammatory Bowel Diseases; Mesalamine; Sulfasalazine

1988

Trials

27 trials available for mesalamine and Bowel Diseases, Inflammatory

ArticleYear
Effects of pentasa-combined probiotics on the microflora structure and prognosis of patients with inflammatory bowel disease.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2019, Volume: 30, Issue:8

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cytokines; Drug Therapy, Combination; Feces; Female;

2019
Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome.
    European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:2 Suppl

    Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; beta-Glucans; Biological Factors; Drug Comb

2017
[Immune response to biological therapy of inflammatory bowel diseases].
    Terapevticheskii arkhiv, 2013, Volume: 85, Issue:12

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Chronic Di

2013
Mesalazine in the initial management of severely acutely malnourished children with environmental enteric dysfunction: a pilot randomized controlled trial.
    BMC medicine, 2014, Aug-14, Volume: 12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child Health Services; Child, Preschool; Double-Blind Metho

2014
Mesalazine in the initial management of severely acutely malnourished children with environmental enteric dysfunction: a pilot randomized controlled trial.
    BMC medicine, 2014, Aug-14, Volume: 12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child Health Services; Child, Preschool; Double-Blind Metho

2014
Mesalazine in the initial management of severely acutely malnourished children with environmental enteric dysfunction: a pilot randomized controlled trial.
    BMC medicine, 2014, Aug-14, Volume: 12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child Health Services; Child, Preschool; Double-Blind Metho

2014
Mesalazine in the initial management of severely acutely malnourished children with environmental enteric dysfunction: a pilot randomized controlled trial.
    BMC medicine, 2014, Aug-14, Volume: 12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child Health Services; Child, Preschool; Double-Blind Metho

2014
Mesalazine in the initial management of severely acutely malnourished children with environmental enteric dysfunction: a pilot randomized controlled trial.
    BMC medicine, 2014, Aug-14, Volume: 12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child Health Services; Child, Preschool; Double-Blind Metho

2014
Mesalazine in the initial management of severely acutely malnourished children with environmental enteric dysfunction: a pilot randomized controlled trial.
    BMC medicine, 2014, Aug-14, Volume: 12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child Health Services; Child, Preschool; Double-Blind Metho

2014
Mesalazine in the initial management of severely acutely malnourished children with environmental enteric dysfunction: a pilot randomized controlled trial.
    BMC medicine, 2014, Aug-14, Volume: 12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child Health Services; Child, Preschool; Double-Blind Metho

2014
Mesalazine in the initial management of severely acutely malnourished children with environmental enteric dysfunction: a pilot randomized controlled trial.
    BMC medicine, 2014, Aug-14, Volume: 12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child Health Services; Child, Preschool; Double-Blind Metho

2014
Mesalazine in the initial management of severely acutely malnourished children with environmental enteric dysfunction: a pilot randomized controlled trial.
    BMC medicine, 2014, Aug-14, Volume: 12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child Health Services; Child, Preschool; Double-Blind Metho

2014
[Serum calprotectin as a marker for determining the activity of the inflammatory process and the effectiveness of therapy in inflammatory bowel disease].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2014, Issue:7

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Biomarkers

2014
Herpes Zoster Vaccine Response in Inflammatory Bowel Disease Patients on Low-dose Immunosuppression.
    Inflammatory bowel diseases, 2016, Volume: 22, Issue:6

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Viral; Cells, Cultured; Female; Herpes Zo

2016
Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?
    Gut, 2018, Volume: 67, Issue:4

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative; Colonoscopy; Colorectal

2018
Plasma histamine levels (H) during adjunctive H1-receptor antagonist treatment with loratadine in patients with active inflammatory bowel disease (IBD).
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2010, Volume: 59 Suppl 2

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Diseas

2010
Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy.
    British journal of pharmacology, 2010, Volume: 160, Issue:5

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Dose-Response Relationship, Drug; Drug

2010
Individually tailored treatment of medication nonadherence.
    Journal of pediatric gastroenterology and nutrition, 2011, Volume: 53, Issue:4

    Topics: Adolescent; Azathioprine; Child; Feasibility Studies; Female; Humans; Inflammatory Bowel Diseases; I

2011
Evaluation of a group-based behavioral intervention to promote adherence in adolescents with inflammatory bowel disease.
    European journal of gastroenterology & hepatology, 2012, Volume: 24, Issue:1

    Topics: Adolescent; Adolescent Behavior; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Behav

2012
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 56, Issue:3

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T

2013
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 56, Issue:3

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T

2013
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 56, Issue:3

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T

2013
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 56, Issue:3

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T

2013
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 56, Issue:3

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T

2013
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 56, Issue:3

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T

2013
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 56, Issue:3

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T

2013
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 56, Issue:3

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T

2013
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 56, Issue:3

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T

2013
Telehealth behavioral treatment for medication nonadherence: a pilot and feasibility study.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:4

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Behavior Therapy; Child; Cost of

2013
Efficacy of Pentasa tablets for the treatment of inflammatory bowel disease.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2003, Volume: 102, Issue:9

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Inflammatory Bowel Diseases; Male; M

2003
Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease.
    Inflammatory bowel diseases, 2004, Volume: 10, Issue:5

    Topics: Administration, Oral; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Chemist

2004
The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
    Alimentary pharmacology & therapeutics, 2005, Oct-01, Volume: 22, Issue:7

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Antimetabolites, Antineoplastic; Dr

2005
5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers.
    Alimentary pharmacology & therapeutics, 2006, Jan-01, Volume: 23, Issue:1

    Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Delay

2006
The safety of mesalamine in human pregnancy: a prospective controlled cohort study.
    Gastroenterology, 1998, Volume: 114, Issue:1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Female; Humans; Inflammatory Bowel D

1998
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.
    Gastroenterology, 2000, Volume: 118, Issue:4

    Topics: Adolescent; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Genotype; Humans; Imm

2000
Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease.
    European journal of gastroenterology & hepatology, 2000, Volume: 12, Issue:4

    Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Breath Tests; Colitis, Ulcera

2000
Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy.
    Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:8

    Topics: Acetylglucosaminidase; Adult; Aged; Aged, 80 and over; Alpha-Globulins; Anti-Inflammatory Agents, No

2001
Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea.
    Scandinavian journal of gastroenterology, 1992, Volume: 27, Issue:10

    Topics: Adult; Aged; Aminosalicylic Acids; Delayed-Action Preparations; Diarrhea; Drug Carriers; Feces; Fema

1992
5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease.
    Agents and actions, 1992, Volume: Spec No

    Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Animals; Arachidonic Acid; Disease Models, Animal; Do

1992
Influence of sulphasalazine and mesalazine on cellular and biochemical oxygen metabolite production. Effect of in vivo administration and an in vitro analysis.
    Scandinavian journal of gastroenterology, 1991, Volume: 26, Issue:7

    Topics: Aminosalicylic Acids; Double-Blind Method; Humans; In Vitro Techniques; Inflammatory Bowel Diseases;

1991
Aminosalicylates: old and new.
    The Mount Sinai journal of medicine, New York, 1990, Volume: 57, Issue:5

    Topics: Administration, Oral; Aminosalicylic Acids; Enema; Humans; Inflammatory Bowel Diseases; Mesalamine;

1990
5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.
    The Netherlands journal of medicine, 1989, Volume: 35 Suppl 1

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Drug Eva

1989
Influence of salazosulphapyridine and 5-aminosalicylic acid on seminal qualities and male sex hormones.
    Scandinavian journal of gastroenterology, 1988, Volume: 23, Issue:9

    Topics: Adult; Aminosalicylic Acids; Gonadal Steroid Hormones; Humans; Inflammatory Bowel Diseases; Male; Me

1988

Other Studies

336 other studies available for mesalamine and Bowel Diseases, Inflammatory

ArticleYear
Brush-border-enzyme-mediated intestine-specific drug delivery. Amino acid prodrugs of 5-aminosalicylic acid.
    Journal of medicinal chemistry, 1993, Dec-24, Volume: 36, Issue:26

    Topics: Amino Acids; Aminopeptidases; Aminosalicylic Acids; Animals; Carboxypeptidases; Colon; Colostomy; Fe

1993
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid with D-phenylalanine for colon specific drug delivery in inflammatory bowel disease.
    Bioorganic & medicinal chemistry letters, 2007, Apr-01, Volume: 17, Issue:7

    Topics: Animals; Chemistry, Pharmaceutical; Colon; Drug Delivery Systems; Drug Design; Hydrochloric Acid; In

2007
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:10

    Topics: Aminosalicylic Acids; Animals; Arthritis; Colitis; Colon; Female; Inflammatory Bowel Diseases; Male;

2009
In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease.
    Bioorganic & medicinal chemistry letters, 2016, 10-01, Volume: 26, Issue:19

    Topics: Humans; In Vitro Techniques; Inflammatory Bowel Diseases; Pyridines

2016
Discovery and structure-activity relationship studies of 2-benzylidene-2,3-dihydro-1H-inden-1-one and benzofuran-3(2H)-one derivatives as a novel class of potential therapeutics for inflammatory bowel disease.
    European journal of medicinal chemistry, 2017, Sep-08, Volume: 137

    Topics: Animals; Benzofurans; Colitis; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discov

2017
Synthesis and biological evaluation of pyridine-linked indanone derivatives: Potential agents for inflammatory bowel disease.
    Bioorganic & medicinal chemistry letters, 2018, 08-01, Volume: 28, Issue:14

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Colitis; Dise

2018
Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease.
    Bioorganic & medicinal chemistry letters, 2021, 06-01, Volume: 41

    Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Coumarins; Disease Models, Animal; Do

2021
Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry.
    Gastroenterology, 2022, Volume: 162, Issue:1

    Topics: Adrenal Cortex Hormones; COVID-19; Humans; Inflammatory Bowel Diseases; Mesalamine; Registries; SARS

2022
Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis.
    British journal of hospital medicine (London, England : 2005), 2021, Oct-02, Volume: 82, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Inflammatory Bowel Diseases; M

2021
Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data.
    Inflammatory bowel diseases, 2022, 10-03, Volume: 28, Issue:10

    Topics: Colitis, Ulcerative; COVID-19; Crohn Disease; Hospitalization; Hospitals; Humans; Inflammatory Bowel

2022
Real world evidence of the association between medication and life expectancy in elderly inflammatory bowel disease: a population-based cohort study.
    BMC gastroenterology, 2022, Jan-04, Volume: 22, Issue:1

    Topics: Aged; Cohort Studies; Female; Humans; Immunologic Factors; Inflammatory Bowel Diseases; Life Expecta

2022
Hemoglobin bio-adhesive nanoparticles as a colon-specific delivery system for sustained release of 5-aminosalicylic acid in the effective treatment of inflammatory bowel disease.
    International journal of pharmaceutics, 2022, Mar-25, Volume: 616

    Topics: Adhesives; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caco-2 Cells; Colitis, Ulcerative; Colo

2022
Emerging inflammatory bowel disease demographics, phenotype, and treatment in South Asia, South-East Asia, and Middle East: Preliminary findings from the Inflammatory Bowel Disease-Emerging Nations' Consortium.
    Journal of gastroenterology and hepatology, 2022, Volume: 37, Issue:6

    Topics: Aged; Asia, Eastern; Asia, Southeastern; Colitis, Ulcerative; Crohn Disease; Cross-Sectional Studies

2022
The role of mesalazine co-treatment in the prevention of recurrence in subjects with subclinical inflammatory bowel disease and perianal fistula who are scheduled for surgical intervention.
    Annali italiani di chirurgia, 2022, Volume: 93

    Topics: Colonoscopy; Humans; Inflammatory Bowel Diseases; Mesalamine; Rectal Fistula; Recurrence; Retrospect

2022
C-reactive protein levels and prevalence of leukopenia in patients with inflammatory bowel disease treated with azathioprine and/or mesalazine: a real-life study.
    Einstein (Sao Paulo, Brazil), 2022, Volume: 20

    Topics: Adult; Azathioprine; C-Reactive Protein; Humans; Inflammatory Bowel Diseases; Leukopenia; Mesalamine

2022
Ulcerative colitis-associated bronchiectasis: A rare extraintestinal manifestation of inflammatory bowel disease: A case report.
    Medicine, 2022, Aug-26, Volume: 101, Issue:34

    Topics: Adult; Azathioprine; Bronchiectasis; Chronic Disease; Colitis, Ulcerative; Cough; Female; Humans; In

2022
Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2023, Volume: 21, Issue:3

    Topics: Adult; Chronic Disease; Colitis, Ulcerative; Crohn Disease; Humans; Inflammatory Bowel Diseases; Inf

2023
Trends in medication use and treatment patterns in Chinese patients with inflammatory bowel disease.
    World journal of gastroenterology, 2022, Aug-14, Volume: 28, Issue:30

    Topics: Adrenal Cortex Hormones; China; Chronic Disease; Colitis, Ulcerative; Crohn Disease; Humans; Immunos

2022
Epidemiological Trends of Pediatric Inflammatory Bowel Disease in Korea: A Multicenter Study of the Last 3 Years Including the COVID-19 Era.
    Journal of Korean medical science, 2022, Sep-26, Volume: 37, Issue:37

    Topics: Azathioprine; Colitis, Ulcerative; COVID-19; Crohn Disease; Humans; Inflammatory Bowel Diseases; Inf

2022
Real-world evidence of quality of life improvement in patients with distal ulcerative colitis treated by mesalazine: the Quartz study.
    European journal of gastroenterology & hepatology, 2022, 12-01, Volume: 34, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Inflammatory Bowel Diseases; M

2022
Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study.
    Alimentary pharmacology & therapeutics, 2022, Volume: 56, Issue:9

    Topics: Biological Products; Chronic Disease; Female; Humans; Infant, Newborn; Inflammatory Bowel Diseases;

2022
Oral administration of human carbonic anhydrase I suppresses colitis in a murine inflammatory bowel disease model.
    Scientific reports, 2022, 10-26, Volume: 12, Issue:1

    Topics: Administration, Oral; Animals; Carbonic Anhydrase I; Colitis; Disease Models, Animal; Humans; Inflam

2022
Repurposing a Drug Targeting Inflammatory Bowel Disease for Lowering Hypertension.
    Journal of the American Heart Association, 2022, 12-20, Volume: 11, Issue:24

    Topics: Animals; Drug Delivery Systems; Drug Repositioning; Dysbiosis; Hypertension; Inflammatory Bowel Dise

2022
In vitro and in vivo evaluation of a pH-, microbiota- and time-based oral delivery platform for colonic release.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2023, Volume: 183

    Topics: Animals; Chitosan; Colon; Drug Delivery Systems; Hydrogen-Ion Concentration; Inflammatory Bowel Dise

2023
Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study.
    The American journal of gastroenterology, 2023, 07-01, Volume: 118, Issue:7

    Topics: Biological Products; Colitis, Ulcerative; Crohn Disease; Humans; Immunologic Factors; Inflammatory B

2023
The Prevalence of Inflammatory Bowel Disease in Greenland.
    Inflammatory bowel diseases, 2023, Dec-05, Volume: 29, Issue:12

    Topics: Colitis, Ulcerative; Crohn Disease; Cross-Sectional Studies; Greenland; Humans; Inflammatory Bowel D

2023
Prevalence and Etiologies of Renal and Urinary Manifestations in a Large Cohort of Children With Inflammatory Bowel Disease.
    Journal of pediatric gastroenterology and nutrition, 2023, 03-01, Volume: 76, Issue:3

    Topics: Adolescent; Child; Colitis, Ulcerative; Crohn Disease; Humans; Inflammatory Bowel Diseases; Kidney;

2023
Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease.
    Nature medicine, 2023, Volume: 29, Issue:3

    Topics: Cross-Sectional Studies; Gastrointestinal Microbiome; Humans; Inflammatory Bowel Diseases; Mesalamin

2023
Patients with elderly onset inflammatory bowel disease have a decreased chance of initiation of all types of medications and increased risk of surgeries-A nationwide cohort study.
    Alimentary pharmacology & therapeutics, 2023, Volume: 58, Issue:1

    Topics: Adrenal Cortex Hormones; Adult; Aged; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Humans; Im

2023
Drug-induced acute pancreatitis due to medications used for inflammatory bowel disease: A VigiBase pharmacovigilance database study.
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2023, Volume: 23, Issue:6

    Topics: Acute Disease; Arthritis, Rheumatoid; Biological Products; Colitis, Ulcerative; Crohn Disease; Human

2023
5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis.
    Scientific reports, 2023, 07-28, Volume: 13, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Mod

2023
An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease.
    PloS one, 2023, Volume: 18, Issue:8

    Topics: Animals; Cholera Vaccines; Colitis; Inflammatory Bowel Diseases; Lipopolysaccharides; Mesalamine; Mi

2023
Designing a microbial fermentation-functionalized alginate microsphere for targeted release of 5-ASA using nano dietary fiber carrier for inflammatory bowel disease treatment.
    Journal of nanobiotechnology, 2023, Sep-23, Volume: 21, Issue:1

    Topics: Alginates; Animals; Dietary Fiber; Fermentation; Humans; Inflammatory Bowel Diseases; Irritable Bowe

2023
Factors contributing to flares of ulcerative colitis in North India- a case-control study.
    BMC gastroenterology, 2023, Sep-28, Volume: 23, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Colitis; Colitis, Ulcerative; Female; Humans; In

2023
The oral bacterial microbiota facilitates the stratification for ulcerative colitis patients with oral ulcers.
    Annals of clinical microbiology and antimicrobials, 2023, Nov-09, Volume: 22, Issue:1

    Topics: Bacteria; Colitis, Ulcerative; Feces; Gastrointestinal Microbiome; Humans; Inflammatory Bowel Diseas

2023
Evaluation of the effect of liposomes loaded with chlorogenic acid in treatment of 2,4,6-trinitrobenzenesulfonic acid-induced murine colitis.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2019, Volume: 70, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Chlorogenic Acid; Colitis; Colon; Disease Models, Animal; Inflamm

2019
The effects of di-butyl phthalate exposure from medications on human sperm RNA among men.
    Scientific reports, 2019, 08-27, Volume: 9, Issue:1

    Topics: Dibutyl Phthalate; DNA Damage; Endocrine Disruptors; Humans; Inflammatory Bowel Diseases; Male; Mesa

2019
Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease.
    International journal of colorectal disease, 2019, Volume: 34, Issue:10

    Topics: Adult; Colitis, Ulcerative; Crohn Disease; Female; Humans; Inflammatory Bowel Diseases; Kaplan-Meier

2019
Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects.
    European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:11

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; C-Reactive Pr

2019
Serum cytokine, chemokine, and growth factor profiles and their modulation in inflammatory bowel disease.
    Medicine, 2019, Volume: 98, Issue:38

    Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Becaplermin; Biomarkers; Case-Contr

2019
5-Aminosalicylic Acid Azo-Coupled with a GPR109A Agonist Is a Colon-Targeted Anticolitic Codrug with a Reduced Risk of Skin Toxicity.
    Molecular pharmaceutics, 2020, 01-06, Volume: 17, Issue:1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Tumor; Chromatography, Liquid; Colitis;

2020
Pregnant women with IBD are more likely to be adherent to biologic therapies than other medications.
    Alimentary pharmacology & therapeutics, 2020, Volume: 51, Issue:5

    Topics: Adult; Biological Factors; Biological Therapy; Canada; Drug Prescriptions; Female; Humans; Inflammat

2020
Errors in the care of inflammatory bowel disease patients: "Errata" Study.
    Gastroenterologia y hepatologia, 2020, Volume: 43, Issue:5

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Ambulatory Care; Colonoscopy; Colorectal Ne

2020
Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
    Scandinavian journal of gastroenterology, 2020, Volume: 55, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Cohort Studies; Colitis, Ulcerative;

2020
Increased neuroendocrine tumours, but small colorectal cancer incidence in patients with inflammatory bowel disease treated by mesalazine.
    European journal of gastroenterology & hepatology, 2020, Volume: 32, Issue:6

    Topics: Colorectal Neoplasms; Humans; Incidence; Inflammatory Bowel Diseases; Matched-Pair Analysis; Mesalam

2020
High-Fat Diet and Antibiotics Cooperatively Impair Mitochondrial Bioenergetics to Trigger Dysbiosis that Exacerbates Pre-inflammatory Bowel Disease.
    Cell host & microbe, 2020, 08-12, Volume: 28, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Diet, High-Fat; Dysbiosis;

2020
Inflammatory bowel disease and inherited colorectal cancer: Is there a genetic link?
    Gastroenterologia y hepatologia, 2021, Volume: 44, Issue:2

    Topics: Adenocarcinoma; Adult; Age of Onset; Anti-Inflammatory Agents; Azathioprine; Breast Neoplasms; Colit

2021
Medicinal products with controlled drug release for local therapy of inflammatory bowel diseases from perspective of pharmaceutical technology.
    Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti, 2020,Summer, Volume: 69, Issue:3

    Topics: Delayed-Action Preparations; Drug Liberation; Humans; Inflammatory Bowel Diseases; Mesalamine; Techn

2020
Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2021, Volume: 19, Issue:2

    Topics: Adolescent; Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Co

2021
Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply.
    Alimentary pharmacology & therapeutics, 2020, Volume: 52, Issue:10

    Topics: Humans; Inflammatory Bowel Diseases; Mesalamine

2020
Letter: rationalising aminosalicylates in inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 2020, Volume: 52, Issue:10

    Topics: Humans; Inflammatory Bowel Diseases; Mesalamine

2020
Chemically modified inulin for intestinal drug delivery - A new dual bioactivity concept for inflammatory bowel disease treatment.
    Carbohydrate polymers, 2021, Jan-15, Volume: 252

    Topics: Anti-Inflammatory Agents; Drug Carriers; Drug Liberation; Humans; Inflammatory Bowel Diseases; Inuli

2021
Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease.
    European journal of gastroenterology & hepatology, 2021, 09-01, Volume: 33, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Inflammatory Bowel Diseases; K

2021
A chromatographic approach to development of 5-aminosalicylate/folic acid fixed-dose combinations for treatment of Crohn's disease and ulcerative colitis.
    Scientific reports, 2020, 11-30, Volume: 10, Issue:1

    Topics: Chromatography; Colitis, Ulcerative; Crohn Disease; Drug Combinations; Folic Acid; Humans; Inflammat

2020
Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation.
    Scientific reports, 2020, 12-07, Volume: 10, Issue:1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; C-Reactive Protein; Crohn Disease; Delayed-Action Pr

2020
Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease.
    Scientific reports, 2020, 12-17, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Des

2020
COVID-19 in IBD: The experience of a single tertiary IBD center.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2021, Volume: 53, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Biological Products;

2021
Thiopurine Monotherapy Is Effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease.
    Digestive diseases and sciences, 2022, Volume: 67, Issue:4

    Topics: Adult; Colitis, Ulcerative; Crohn Disease; Humans; Inflammatory Bowel Diseases; Mesalamine; Retrospe

2022
circRNA expression profiling of colon tissue from mesalazine-treated mouse of inflammatory bowel disease reveals an important circRNA-miRNA-mRNA pathway.
    Aging, 2021, 03-26, Volume: 13, Issue:7

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colon; Disease Models, Animal; Gene Expression Pro

2021
Azathioprine-induced Myelotoxicity After Switching Mesalazine Compound.
    Inflammatory bowel diseases, 2021, Aug-19, Volume: 27, Issue:9

    Topics: Azathioprine; Drug Substitution; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Mesa

2021
A machine learning approach identifies 5-ASA and ulcerative colitis as being linked with higher COVID-19 mortality in patients with IBD.
    Scientific reports, 2021, 08-13, Volume: 11, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, P

2021
Editorial: 5-ASA in IBD patients on biologics-'stop or continue'? Authors' reply.
    Alimentary pharmacology & therapeutics, 2021, Volume: 54, Issue:6

    Topics: Biological Products; Humans; Inflammatory Bowel Diseases; Mesalamine

2021
Comparison of anti-inflammatory activities of an anthocyanin-rich fraction from Portuguese blueberries (Vaccinium corymbosum L.) and 5-aminosalicylic acid in a TNBS-induced colitis rat model.
    PloS one, 2017, Volume: 12, Issue:3

    Topics: Animals; Anthocyanins; Anti-Inflammatory Agents; Antioxidants; Blueberry Plants; Colitis; Colon; Cyc

2017
Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease.
    Journal of Crohn's & colitis, 2017, Jul-01, Volume: 11, Issue:7

    Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Immunosuppressive Agent

2017
Oxidized 5-aminosalicylic acid activates Nrf2-HO-1 pathway by covalently binding to Keap1: Implication in anti-inflammatory actions of 5-aminosalicylic acid.
    Free radical biology & medicine, 2017, Volume: 108

    Topics: Animals; Anti-Inflammatory Agents; Colonic Neoplasms; HCT116 Cells; Heme Oxygenase-1; Humans; Hypoch

2017
Direct health-care cost utilization in Hong Kong inflammatory bowel disease patients in the initial 2 years following diagnosis.
    Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:1

    Topics: Adult; Cohort Studies; Female; Health Care Costs; Health Resources; Hong Kong; Hospitalization; Huma

2018
Combined Treatment with Hyaluronic Acid and Mesalamine Protects Rats from Inflammatory Bowel Disease Induced by Intracolonic Administration of Trinitrobenzenesulfonic Acid.
    Molecules (Basel, Switzerland), 2017, May-30, Volume: 22, Issue:6

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cytokines; Disease Models, Anima

2017
Impact of an Integrated Model of Care on Outcomes of Patients With Inflammatory Bowel Diseases: Evidence From a Population-Based Study.
    Journal of Crohn's & colitis, 2017, Dec-04, Volume: 11, Issue:12

    Topics: Adult; Biological Factors; Delivery of Health Care; Digestive System Surgical Procedures; Drug Presc

2017
Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:3

    Topics: Administrative Claims, Healthcare; Adolescent; Adrenal Cortex Hormones; Adult; Biological Products;

2018
Intestinal organoids containing poly(lactic-co-glycolic acid) nanoparticles for the treatment of inflammatory bowel diseases.
    Journal of biomedical materials research. Part A, 2018, Volume: 106, Issue:4

    Topics: Animals; Inflammatory Bowel Diseases; Intestines; Mesalamine; Mice, Inbred C57BL; Nanoparticles; Org

2018
The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets.
    Scandinavian journal of gastroenterology, 2018, Volume: 53, Issue:2

    Topics: Adolescent; Adult; Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerat

2018
Cutaneous side effects caused by treatment for inflammatory bowel disease.
    Vojnosanitetski pregled, 2016, Volume: 73, Issue:4

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cyclosporine; Drug E

2016
Patterns in use and costs of subsidising 5-aminosalicyclic acid compounds and biologic agents in the treatment of inflammatory bowel disease in Australia.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2018, Volume: 50, Issue:3

    Topics: Australia; Biological Therapy; Humans; Inflammatory Bowel Diseases; Mesalamine

2018
The Frequency of Clinic Visits Was Not Associated with Medication Adherence or Outcome in Children with Inflammatory Bowel Diseases.
    Canadian journal of gastroenterology & hepatology, 2018, Volume: 2018

    Topics: Adalimumab; Adolescent; Ambulatory Care Facilities; Analysis of Variance; Canada; Child; Cohort Stud

2018
Iron Sequestration in Microbiota Biofilms As A Novel Strategy for Treating Inflammatory Bowel Disease.
    Inflammatory bowel diseases, 2018, 06-08, Volume: 24, Issue:7

    Topics: Adult; Animals; Bacterial Physiological Phenomena; Biofilms; Case-Control Studies; Disease Models, A

2018
NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
    Journal of gastroenterology, 2018, Volume: 53, Issue:9

    Topics: Alopecia; Antibodies, Monoclonal; Azathioprine; Biomarkers, Pharmacological; Genetic Predisposition

2018
Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases.
    European journal of clinical investigation, 2018, Volume: 48, Issue:10

    Topics: Adult; Antibodies, Monoclonal; Area Under Curve; Biomarkers; Female; Humans; Immunosuppressive Agent

2018
5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity.
    The Journal of antibiotics, 2018, Volume: 71, Issue:11

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Colonic Neoplasms; Comet Assay; Dose-Re

2018
The effect of anti-TNF therapy on thyroid function in patients with inflammatory bowel disease.
    Endocrine journal, 2018, Nov-29, Volume: 65, Issue:11

    Topics: Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Female; Gastrointestinal A

2018
Inflammatory bowel disease in patients over the age of 70 y. Does the disease duration influence its behavior?
    Scandinavian journal of gastroenterology, 2018, Volume: 53, Issue:9

    Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Comorbidity; Cross-Sectional Studies; Disease Prog

2018
Smoldering Multiple Myeloma Arising in Ulcerative Colitis.
    Chinese medical journal, 2018, Nov-05, Volume: 131, Issue:21

    Topics: Aged; Biopsy; C-Reactive Protein; Colitis, Ulcerative; Colonoscopy; gamma-Globulins; Humans; Immunog

2018
Determination of Mesalamine levels in Human Milk as a Function of Dose.
    Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine, 2019, Volume: 14, Issue:2

    Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Breast Feeding; Female; Humans

2019
Statin Use Is Associated With Improved Outcomes of Patients With Primary Sclerosing Cholangitis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2019, Volume: 17, Issue:9

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cholagogues and Choleretics; Cholangit

2019
Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study.
    Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:6

    Topics: Adult; Cohort Studies; Colectomy; Colitis, Ulcerative; Disease Progression; Europe; Female; Follow-U

2019
5-Aminosalicylic acid.
    Nihon rinsho. Japanese journal of clinical medicine, 2017, Volume: 75, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Mesalamine

2017
pH-Dependent 5-Aminosalicylates Releasing Preparations Do Not Affect Thiopurine Metabolism.
    Digestion, 2019, Volume: 100, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal;

2019
Mesalazine-Induced Acute Focal Bacterial Nephritis-Like Features in Two Paediatric Patients with Ulcerative Colitis.
    Journal of Crohn's & colitis, 2019, 07-25, Volume: 13, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Humans; Inflammatory Bowel Dise

2019
Comparative Efficacy of Chitosan, Pectin Based Mesalamine Colon Targeted Drug Delivery Systems on TNBS-induced IBD Model Rats.
    Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2020, Volume: 19, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Chitosan; Colon; Disease Models, Animal; Drug Delivery Systems; H

2020
Rosacea fulminans - coincidence of the disease with inflammatory bowel disease.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:6

    Topics: Anti-Inflammatory Agents; Budesonide; Dermatologic Agents; Humans; Inflammatory Bowel Diseases; Male

2019
Mesalamine and azathioprine modulate junctional complexes and restore epithelial barrier function in intestinal inflammation.
    Scientific reports, 2019, 02-26, Volume: 9, Issue:1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis; Epithelial Cells; Inflammat

2019
Improvement of the therapeutic treatment of inflammatory bowel diseases following rectal administration of mesalazine-loaded chitosan microparticles vs Asamax
    Carbohydrate polymers, 2019, May-15, Volume: 212

    Topics: Administration, Rectal; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caco-2 Cells; Cell Surviva

2019
Prevalence of Clostridium difficile infection among hospitalized inflammatory bowel disease patients in Greece.
    European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:7

    Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Bacteri

2019
Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease.
    Molecular pharmaceutics, 2019, 06-03, Volume: 16, Issue:6

    Topics: Animals; Colitis; Drug Delivery Systems; Hydrocortisone; Inflammatory Bowel Diseases; Male; Mesalami

2019
Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease.
    World journal of gastroenterology, 2019, May-14, Volume: 25, Issue:18

    Topics: Adolescent; Adult; Aged; Case-Control Studies; Child; China; Drug Therapy, Combination; Feces; Femal

2019
Association of Parkinson's disease and treatment with aminosalicylates in inflammatory bowel disease: a cross-sectional study in a Spain drug dispensation records.
    BMJ open, 2019, 06-19, Volume: 9, Issue:6

    Topics: Age Distribution; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional

2019
Mesalazine and Nephrolithiasis: Leave No Stone Unturned.
    The American journal of gastroenterology, 2019, Volume: 114, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Mesalamine; Nephrolith

2019
No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study.
    Alimentary pharmacology & therapeutics, 2019, Volume: 50, Issue:4

    Topics: Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Colitis, Ulcerative; Crohn Disease; D

2019
Epstein-Barr virus in inflammatory bowel disease-correlation with different therapeutic regimens.
    Inflammatory bowel diseases, 2013, Volume: 19, Issue:8

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Case-Control S

2013
5-aminosalicylate is not protective from neoplasia in ulcerative colitis.
    The American journal of gastroenterology, 2013, Volume: 108, Issue:6

    Topics: Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases; Mesalamine

2013
Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies;

2013
Design and development of novel azo prodrugs using various permutations and combinations of 5- and 4-aminosalicylic acids for inflammatory bowel disease: a colon-targeted approach.
    Inflammation & allergy drug targets, 2013, Volume: 12, Issue:5

    Topics: Aminosalicylic Acid; Animals; Azo Compounds; Colitis; Colon; Drug Design; Female; Humans; Inflammato

2013
Cyanidin-3-glucoside suppresses cytokine-induced inflammatory response in human intestinal cells: comparison with 5-aminosalicylic acid.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Anthocyanins; Anti-Inflammatory Agents; Cell Line; Cell Nucleus; Cell Survival; Cyclooxygenase 2; Cy

2013
Commentary: 5-ASA switches in IBD, adherence and flares.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Substitution; Female; Humans; Inflammatory Bowel Disea

2013
Commentary: 5-ASA switches in IBD, adherence and flares--authors' reply.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Substitution; Female; Humans; Inflammatory Bowel Disea

2013
Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications.
    Gastroenterology, 2014, Volume: 146, Issue:1

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aminosalicylic Acids; Azathioprine; Congenital Abnormali

2014
Letter: switches of 5-aminosalicylates in ulcerative colitis, risk of relapse and ascertainment bias.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Substitution; Female; Humans; Inflammatory Bowel Disea

2014
Letter: switches of 5-aminosalicylates in ulcerative colitis, risk of relapse and ascertainment bias--authors' reply.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Substitution; Female; Humans; Inflammatory Bowel Disea

2014
Methaemoglobinaemia and renal failure following mesalazine for treatment of inflammatory bowel disease.
    Journal of Crohn's & colitis, 2014, Volume: 8, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Inflammatory Bowel Diseases; Mesalamine; Me

2014
Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia.
    Expert review of gastroenterology & hepatology, 2014, Volume: 8, Issue:3

    Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Australia; Female; Follo

2014
Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis.
    Journal of managed care & specialty pharmacy, 2014, Volume: 20, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Inflammatory Bowel Diseases; Male; M

2014
New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.
    PloS one, 2014, Volume: 9, Issue:4

    Topics: Adult; Amino Acid Transport Systems; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cells, C

2014
"Add-on" is scientifically more accurate than "placebo control" in multiple inflammatory bowel disease (IBD) trials.
    Journal of Crohn's & colitis, 2014, Volume: 8, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Genetic Predisposition to Disease

2014
Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
    The Annals of pharmacotherapy, 2014, Volume: 48, Issue:10

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Case-Control Studies; Drug Therapy, Co

2014
Combination therapy with an immunomodulator and anti-TNFα agent improves bone mineral density in IBD patients.
    Journal of Crohn's & colitis, 2014, Volume: 8, Issue:12

    Topics: Absorptiometry, Photon; Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; A

2014
Dissolution of mesalazine modified release tablets under standard and bio-relevant test conditions.
    The Journal of pharmacy and pharmacology, 2015, Volume: 67, Issue:2

    Topics: Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Liberation; Humans; Hydrogen-Ion Concen

2015
Frequency and associated factors of hair loss among patients with inflammatory bowel disease.
    World journal of gastroenterology, 2015, Jan-07, Volume: 21, Issue:1

    Topics: Adult; Alopecia; Anti-Inflammatory Agents; Biological Products; Chi-Square Distribution; Cross-Secti

2015
Environmental enteropathy and malnutrition: do we know enough to intervene?
    BMC medicine, 2014, Oct-14, Volume: 12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Inflammatory Bowel Diseases; Male; Malnutri

2014
Inflammatory bowel disease in pediatric patients: Characteristics of newly diagnosed patients from the CEDATA-GPGE Registry.
    Deutsches Arzteblatt international, 2015, Feb-20, Volume: 112, Issue:8

    Topics: Age Distribution; Anti-Inflammatory Agents; Child; Child Health; Child, Preschool; Diet Therapy; End

2015
Gene ablation of carnitine/organic cation transporter 1 reduces gastrointestinal absorption of 5-aminosalicylate in mice.
    Biological & pharmaceutical bulletin, 2015, Volume: 38, Issue:5

    Topics: Animals; Biological Availability; Biological Transport, Active; Carnitine; HEK293 Cells; Humans; Inf

2015
The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy.
    Scandinavian journal of gastroenterology, 2015, Volume: 50, Issue:12

    Topics: Adult; Female; Humans; Immunosuppressive Agents; Immunotherapy; Inflammatory Bowel Diseases; Latent

2015
Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine.
    Inflammatory bowel diseases, 2015, Volume: 21, Issue:12

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Crohn Diseas

2015
Cardiac MRI-confirmed mesalamine-induced myocarditis.
    BMJ case reports, 2015, Sep-04, Volume: 2015

    Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Chest Pain; Dyspnea; Follow

2015
Author's reply to Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients: disease activity as an influencing factor.
    Scandinavian journal of gastroenterology, 2016, Volume: 51, Issue:3

    Topics: Female; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Latent Tuberculosis; Male; Me

2016
Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients: Disease activity as an influencing factor.
    Scandinavian journal of gastroenterology, 2016, Volume: 51, Issue:3

    Topics: Female; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Latent Tuberculosis; Male; Me

2016
Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease.
    Journal of Crohn's & colitis, 2016, Volume: 10, Issue:2

    Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Child; DNA; F

2016
EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
    Danish medical journal, 2015, Volume: 62, Issue:12

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Denmark; Diet Th

2015
Patients and gastroenterologists' perceptions of treatments for inflammatory bowel diseases: do their perspectives match?
    Scandinavian journal of gastroenterology, 2016, Volume: 51, Issue:9

    Topics: Adolescent; Adult; Aged; Attitude of Health Personnel; Azathioprine; Female; Focus Groups; Gastroent

2016
[Not a cure, but a normal life].
    MMW Fortschritte der Medizin, 2016, Feb-04, Volume: 158, Issue:2

    Topics: Azathioprine; Biological Products; Budesonide; Cell Adhesion Molecules; Drug Therapy, Combination; H

2016
Clinical course and outcomes of diagnosing Inflammatory Bowel Disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy.
    BMC gastroenterology, 2016, Mar-15, Volume: 16

    Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Age of Onset; Anti-Bacterial Agents; Anti-Inflammat

2016
Treat to target-what is realistic in Australian practice today?
    Journal of gastroenterology and hepatology, 2016, Volume: 31 Suppl 1

    Topics: Antibodies, Monoclonal, Humanized; Australia; Humans; Immunologic Factors; Inflammatory Bowel Diseas

2016
Development of a zero-order sustained-release tablet containing mesalazine and budesonide intended to treat the distal gastrointestinal tract in inflammatory bowel disease.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2016, Volume: 103

    Topics: Budesonide; Delayed-Action Preparations; Humans; Inflammatory Bowel Diseases; Mesalamine; Tablets

2016
Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease.
    Journal of digestive diseases, 2016, Volume: 17, Issue:6

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Colectomy; Colitis, Ulcerat

2016
Treatment Options and Outcomes of Pediatric IBDU Compared with Other IBD Subtypes: A Retrospective Multicenter Study from the IBD Porto Group of ESPGHAN.
    Inflammatory bowel diseases, 2016, Volume: 22, Issue:6

    Topics: Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; C

2016
Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study.
    The American journal of gastroenterology, 2016, Volume: 111, Issue:8

    Topics: Adalimumab; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Clostridioides difficile;

2016
Mucoadhesive microparticulates based on polysaccharide for target dual drug delivery of 5-aminosalicylic acid and curcumin to inflamed colon.
    Colloids and surfaces. B, Biointerfaces, 2016, Sep-01, Volume: 145

    Topics: Animals; Chitosan; Colitis; Colon; Curcumin; Drug Carriers; Inflammatory Bowel Diseases; Mesalamine;

2016
Effects of Mesalazine on Morphological and Functional Changes in the Indomethacin-Induced Inflammatory Bowel Disease (Rat Model of Crohn's Disease).
    Pathology oncology research : POR, 2017, Volume: 23, Issue:1

    Topics: Animals; Crohn Disease; Disease Models, Animal; Glucuronates; Indomethacin; Inflammation; Inflammato

2017
The Effects of Active IBD During Pregnancy in the Era of Novel IBD Therapies.
    The American journal of gastroenterology, 2016, Volume: 111, Issue:9

    Topics: Abortion, Spontaneous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Colitis, Ulce

2016
Steroid dependency and trends in prescribing for inflammatory bowel disease - a 20-year national population-based study.
    Alimentary pharmacology & therapeutics, 2016, Volume: 44, Issue:5

    Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Drug

2016
Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
    The American journal of gastroenterology, 2016, Volume: 111, Issue:10

    Topics: Adrenal Cortex Hormones; Age of Onset; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroi

2016
A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease.
    Environment international, 2016, Volume: 95

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Dibutyl Phthalate; Humans; Infla

2016
Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases.
    Digestive diseases and sciences, 2016, Volume: 61, Issue:11

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Ste

2016
Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases.
    International immunopharmacology, 2016, Volume: 40

    Topics: Aminosalicylic Acids; Animals; Caprylates; Colitis; Colon; Dextran Sulfate; Drug Discovery; Drug Eva

2016
Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease.
    European journal of internal medicine, 2017, Volume: 37

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Biomarkers; Carotid Arteries; Carot

2017
Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:2

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Child; Child, Preschool; Female; Humans; Immunolog

2017
Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    The American journal of gastroenterology, 2017, Volume: 112, Issue:1

    Topics: Adalimumab; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antirheumatic Agents; Colitis,

2017
The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:4

    Topics: Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Co

2017
IBD-Like Features in Syndromic Diarrhea/Trichohepatoenteric Syndrome.
    Journal of pediatric gastroenterology and nutrition, 2017, Volume: 64, Issue:1

    Topics: Anti-Inflammatory Agents; Biological Therapy; Colitis; Colon; Diarrhea; Diarrhea, Infantile; Facies;

2017
Synthesis and in vitro Bioactivity Evaluation of New Galactose and Fructose Ester Derivatives of 5-Aminosalicylic Acid.
    Chemistry & biodiversity, 2017, Volume: 14, Issue:4

    Topics: 3T3 Cells; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; E

2017
Clinicians' adherence to international guidelines in the clinical care of adults with inflammatory bowel disease.
    Scandinavian journal of gastroenterology, 2017, Volume: 52, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Australia; Colo

2017
Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis.
    Alimentary pharmacology & therapeutics, 2008, Sep-01, Volume: 28, Issue:5

    Topics: Acute Disease; Adult; Antimetabolites; Azathioprine; Cohort Studies; Female; Humans; Inflammatory Bo

2008
Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis.
    World journal of gastroenterology, 2008, Jun-14, Volume: 14, Issue:22

    Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cholangitis, Scler

2008
Extreme thrombocytosis--an unusual presentation of inflammatory bowel disease.
    Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:13

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Female; Humans; Inflammat

2008
Adverse events of IBD therapies.
    Inflammatory bowel diseases, 2008, Volume: 14 Suppl 2

    Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents; Gastrointestinal Agents; H

2008
Which are the 5-ASA compound side effects and how is it possible to avoid them?
    Inflammatory bowel diseases, 2008, Volume: 14 Suppl 2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Diarrhea; Dose-Response Relationship, Drug; Female; Humans;

2008
Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study.
    Gastroenterologia y hepatologia, 2008, Volume: 31, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Creatinine; Female; Follow-Up Studies; Humans; Inflammatory

2008
Mesenteric ischemia is a cause of resistance to treatment in IBD.
    Inflammatory bowel diseases, 2009, Volume: 15, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colonoscopy; Humans; Inflammatory Bowel Diseases; Ischemia;

2009
Alpha-defensins and clostridium difficile recent growing concerns in inflammatory bowel disease.
    The American journal of gastroenterology, 2008, Volume: 103, Issue:12

    Topics: alpha-Defensins; Anti-Inflammatory Agents; Bacterial Proteins; Bacterial Toxins; Clostridioides diff

2008
Inflammatory bowel disease classification through multigene analysis: fact or fiction?
    Expert review of molecular diagnostics, 2009, Volume: 9, Issue:1

    Topics: Biomarkers; Gene Expression Regulation; Genome; Humans; Inflammatory Bowel Diseases; Mesalamine; Mul

2009
Advances in inflammatory bowel disease: are patients taking their medicines? Interview by Paul C. Adams.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2009, Volume: 23, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Canada; Drug Costs; Humans; Inflammatory Bowel Diseases; Me

2009
Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression.
    Inflammatory bowel diseases, 2009, Volume: 15, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Disk Diffusion Antimicrobial Tests; Enterobacteriaceae; Gen

2009
Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
    Digestion, 2009, Volume: 79, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites; Azathioprine; China; Drug Ther

2009
Chemoprevention of colorectal cancer in inflammatory bowel disease.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2009, Volume: 41, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Comorbidity; Gene Expression; Humans;

2009
Hypereosinophilia due to mesalazine treatment.
    Journal of clinical gastroenterology, 2009, Volume: 43, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Humans; Hypereosinophilic Syndrome; Inflammatory Bow

2009
Medical therapy of IBD in 2009.
    Medicine and health, Rhode Island, 2009, Volume: 92, Issue:3

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; C

2009
Novel polymeric film coatings for colon targeting: Drug release from coated pellets.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2009, Jun-28, Volume: 37, Issue:3-4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Capsules; Cellulose; Colon; Delayed-Action Preparations; Dr

2009
Macroscopic and histopathological examination of the gastric mucosa in dogs with inflammatory bowel disease (IBD) treated with mesalazine.
    Polish journal of veterinary sciences, 2009, Volume: 12, Issue:2

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Female; Gastric Mucosa; Inflam

2009
Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 2009, Oct-15, Volume: 30, Issue:8

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; DNA; Drug Interactions; Female; Genoty

2009
Mesalamine protects against colorectal cancer in inflammatory bowel disease.
    Digestive diseases and sciences, 2010, Volume: 55, Issue:6

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Case-Control Studies; Chi-S

2010
Barriers to oral medication adherence for adolescents with inflammatory bowel disease.
    Journal of pediatric psychology, 2010, Volume: 35, Issue:6

    Topics: Administration, Oral; Adolescent; Azathioprine; Family; Female; Humans; Inflammatory Bowel Diseases;

2010
Inflammatory bowel disease in young people: the case for transitional clinics.
    Inflammatory bowel diseases, 2010, Volume: 16, Issue:6

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monocl

2010
Managing the risks of IBD therapy.
    Current gastroenterology reports, 2009, Volume: 11, Issue:6

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Glucocorticoids; Humans; Im

2009
Nitrated oleic acid up-regulates PPARgamma and attenuates experimental inflammatory bowel disease.
    Free radical biology & medicine, 2010, Feb-15, Volume: 48, Issue:4

    Topics: Animals; Cell Culture Techniques; Fatty Acids; Female; Free Radicals; Gene Expression Regulation, En

2010
Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease.
    Inflammatory bowel diseases, 2010, Volume: 16, Issue:8

    Topics: Acute Disease; Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; A

2010
Health-related quality of life of youth with inflammatory bowel disease: a comparison with published data using the PedsQL 4.0 generic core scales.
    Inflammatory bowel diseases, 2010, Volume: 16, Issue:6

    Topics: Adolescent; Adult; Child; Female; Humans; Inflammatory Bowel Diseases; Interpersonal Relations; Male

2010
On the dynamics of nitrite, nitrate and other biomarkers of nitric oxide production in inflammatory bowel disease.
    Nitric oxide : biology and chemistry, 2010, Feb-15, Volume: 22, Issue:2

    Topics: Animals; Biomarkers; Disease Models, Animal; Inflammatory Bowel Diseases; Male; Mesalamine; Nitrates

2010
Brief report: Barriers to treatment adherence in pediatric inflammatory bowel disease.
    Journal of pediatric psychology, 2010, Volume: 35, Issue:9

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Female; Humans; Immunosuppressive

2010
How do patients with inflammatory bowel disease want their biological therapy administered?
    BMC gastroenterology, 2010, Jan-10, Volume: 10

    Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz

2010
In vivo analysis of gut function and disease changes in a zebrafish larvae model of inflammatory bowel disease: a feasibility study.
    Inflammatory bowel diseases, 2010, Volume: 16, Issue:7

    Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal;

2010
Understanding of chemoprophylaxis and concordance in inflammatory bowel disease.
    World journal of gastroenterology, 2010, Feb-07, Volume: 16, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholagogues and Choleretics; Colorectal Neoplasms; Humans;

2010
Relapsing tubulointerstitial nephritis in an adolescent with inflammatory bowel disease without aminosalicylate exposure.
    Clinical nephrology, 2010, Volume: 73, Issue:3

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Crohn Disease; Diagnosis, Differential;

2010
IBD and IBS: novel mechanisms and future practice. Preface.
    Digestive diseases (Basel, Switzerland), 2009, Volume: 27 Suppl 1

    Topics: Animals; Congresses as Topic; Gastrointestinal Tract; Humans; Inflammatory Bowel Diseases; Irritable

2009
[Portal hypertension in patients with inflammatory bowel disease].
    Gastroenterologia y hepatologia, 2010, Volume: 33, Issue:4

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Ascites; Crohn Disease; Female;

2010
Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approach.
    Pharmacoepidemiology and drug safety, 2010, Volume: 19, Issue:5

    Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; Female; Gastro

2010
High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine.
    International journal of clinical pharmacology and therapeutics, 2010, Volume: 48, Issue:4

    Topics: Adolescent; Aminosalicylic Acids; Azathioprine; Biotransformation; Child; Child, Preschool; Drug The

2010
Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy.
    Revista espanola de enfermedades digestivas, 2010, Volume: 102, Issue:10

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathiopr

2010
Enzymatically degraded Eurylon 6 HP-PG: ethylcellulose film coatings for colon targeting in inflammatory bowel disease patients.
    The Journal of pharmacy and pharmacology, 2010, Volume: 62, Issue:12

    Topics: Amylose; Anti-Inflammatory Agents, Non-Steroidal; Bacteria; Cellulose; Colon; Delayed-Action Prepara

2010
Pregnancy and IBD treatment: this challenging interplay from a patients' perspective.
    Journal of Crohn's & colitis, 2010, Volume: 4, Issue:2

    Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Azathioprine; Cross-Sectional Studies; Fem

2010
IBD: Stress causes flares of IBD--how much evidence is enough?
    Nature reviews. Gastroenterology & hepatology, 2011, Volume: 8, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Helicobacter pylori; Huma

2011
The actin-bundling protein fascin is overexpressed in inflammatory bowel disease and may be important in tissue repair.
    BMC gastroenterology, 2011, Feb-23, Volume: 11

    Topics: Actins; Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Butyrates; Carrier Proteins; Cell L

2011
5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
    The American journal of gastroenterology, 2011, Volume: 106, Issue:4

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cohort Studies; Colitis, Ulcer

2011
Inflammatory bowel disease unclassified.
    Journal of Zhejiang University. Science. B, 2011, Volume: 12, Issue:4

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anastomosis, Surgical; Biopsy; Colitis, Ulcerative

2011
Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease.
    Gut, 2012, Volume: 61, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cohort Studies; Colorectal Neoplasms;

2012
Protective effect of aqueous extract of Bombax malabaricum DC on experimental models of inflammatory bowel disease in rats and mice.
    Indian journal of experimental biology, 2011, Volume: 49, Issue:5

    Topics: Acetic Acid; Animals; Bombax; Colitis; Disease Models, Animal; Female; India; Indomethacin; Inflamma

2011
The causes of finger clubbing: a list worth learning.
    The American journal of medicine, 2011, Volume: 124, Issue:7

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiac Surgical Procedures; Diagnosis, Differential

2011
Thrombosis with inflammatory bowel disease--bleed, clot or break.
    QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:8

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Hematoma; Hematuria; Heparin, Low-Mo

2012
Role of 5-aminosalicylate in preventing colorectal cancer.
    The American journal of gastroenterology, 2011, Volume: 106, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Female; Humans; Inflammatory Bowel Di

2011
Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.
    World journal of gastroenterology, 2011, Aug-14, Volume: 17, Issue:30

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Humans; Immunosuppressive Agents; Inflammator

2011
Mesalazine. Now authorised for children, but no suitable form.
    Prescrire international, 2011, Volume: 20, Issue:119

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Humans; Inflammatory Bowel Diseases; Mes

2011
Thorax as an extraintestinal target for inflammatory bowel disease.
    Tuberkuloz ve toraks, 2011, Volume: 59, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Inflammatory Bowel Diseases; Lung Diseases;

2011
Solitary rectal ulcer syndrome in children and adolescents.
    Journal of pediatric gastroenterology and nutrition, 2012, Volume: 54, Issue:2

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Female; Follow-Up Studies; Humans; Infla

2012
Asymptomatic urinary anomalies, hematuria and proteinuria, in patients with inflammatory bowel disease. Preliminary study.
    Romanian journal of internal medicine = Revue roumaine de medecine interne, 2011, Volume: 49, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Diagnosis, Diffe

2011
Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease.
    The American journal of gastroenterology, 2012, Volume: 107, Issue:2

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Female; Hu

2012
Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity.
    Digestive diseases and sciences, 2012, Volume: 57, Issue:9

    Topics: Aged; Aged, 80 and over; Female; Humans; Inflammatory Bowel Diseases; Male; Mesalamine; Nutritional

2012
Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease.
    Journal of Crohn's & colitis, 2012, Volume: 6, Issue:4

    Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Endoscopy, Gastrointestinal; Humans; Inflammatory B

2012
[Quality of life in inflammatory bowel disease patients].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2011, Issue:9

    Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Female; Humans; Inflammatory Bowel Diseases;

2011
The MMAS-8, a screening tool for determining nonadherent behavior, should not be dismissed in IBD.
    The American journal of gastroenterology, 2012, Volume: 107, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Female; Humans; Immunosuppressive A

2012
The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients.
    European journal of gastroenterology & hepatology, 2012, Volume: 24, Issue:8

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Azathioprine; Bone M

2012
Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study.
    Gut, 2013, Volume: 62, Issue:5

    Topics: Adolescent; Adult; Aged; Atherosclerosis; Case-Control Studies; Cohort Studies; Denmark; Female; Fol

2013
[Optimization of cell therapy in patients with inflammatory bowel diseases].
    Terapevticheskii arkhiv, 2012, Volume: 84, Issue:8

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cell Transplantation; Colitis, Ulcerative; Glucocort

2012
5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: a nationwide survey.
    Journal of Crohn's & colitis, 2013, Volume: 7, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Creatinine; Cross-Sectional Studies; France; Gastroenterolo

2013
[5-Aminosalicylate derivatives].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 1

    Topics: Humans; Inflammatory Bowel Diseases; Mesalamine

2012
[Current status of new drug development for inflammatory bowel diseases].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 1

    Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal,

2012
[Chemoprevention of colorectal cancer associated with IBD].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 1

    Topics: Azathioprine; Colorectal Neoplasms; Crohn Disease; Folic Acid; Humans; Inflammatory Bowel Diseases;

2012
Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
    Therapeutic drug monitoring, 2012, Volume: 34, Issue:6

    Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; China; Drug Interactions;

2012
Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice.
    Life sciences, 2013, Apr-09, Volume: 92, Issue:12

    Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents; Budesonide; Colitis; Colon; Cyclosporine; D

2013
Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.
    Gut, 2002, Volume: 51, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Liver Inju

2002
Which 5-ASA?
    Gut, 2002, Volume: 51, Issue:4

    Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Enema; Humans; Inflammatory Bowel Diseases

2002
Is your patient taking the medicine? A simple assay to measure compliance with 5-aminosalicylic acid-containing compounds.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Chromatography, High Pressure Liquid; Feasibility S

2002
Autonomic imbalance during the day in patients with inflammatory bowel disease in remission. Evidence from spectral analysis of heart rate variability over 24 hours.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2002, Volume: 34, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Autonomic Nervous System Diseases; Chronobiology Disorders;

2002
The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria.
    Inflammatory bowel diseases, 2003, Volume: 9, Issue:1

    Topics: Amino Acids; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Desul

2003
How safe are the safest IBD drugs?
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Gastrointestinal A

2003
Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 2003, Jul-15, Volume: 18, Issue:2

    Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Delayed-Action

2003
Distinct elevation of levels of anti-Caenorhabditis elegans antibody in sera of patients with inflammatory bowel disease.
    Clinical and diagnostic laboratory immunology, 2003, Volume: 10, Issue:5

    Topics: Adult; Aged; Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antigens; Caen

2003
Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England.
    European journal of gastroenterology & hepatology, 2003, Volume: 15, Issue:12

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; Data Collection; England; F

2003
Mesalazine is safe for the treatment of IBD.
    Gut, 2004, Volume: 53, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Mesalamine; Sulfasalaz

2004
[Colitis therapy becomes more acceptable for patients. Rectal foam instead of enema].
    MMW Fortschritte der Medizin, 2003, Nov-20, Volume: 145, Issue:47

    Topics: Administration, Rectal; Anti-Inflammatory Agents; Dosage Forms; Enema; Humans; Inflammatory Bowel Di

2003
5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study.
    Gastroenterology, 2004, Volume: 126, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control St

2004
[5-aminosalicylates and colorectal cancer: preventive role in chronic inflammatory bowel disease?].
    Gastroenterologie clinique et biologique, 2004, Volume: 28, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases;

2004
Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis.
    Inflammatory bowel diseases, 2004, Volume: 10, Issue:3

    Topics: Adult; Aminosalicylic Acid; Drug Tolerance; Enema; Female; Humans; Inflammatory Bowel Diseases; Male

2004
Is mesalazine really safe for use in breastfeeding mothers?
    Gut, 2005, Volume: 54, Issue:1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Breast Feeding; Female; Humans; Infant; Inflammatory

2005
5-ASA therapy and renal function in inflammatory bowel disease.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Kidney Diseases; Mesal

2005
[Chronic inflammatory bowel diseases. Update on evidence-based therapy].
    MMW Fortschritte der Medizin, 2005, Apr-28, Volume: 147, Issue:17

    Topics: Administration, Oral; Administration, Rectal; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Ant

2005
Occult inflammatory small-bowel disease: not so occult anymore.
    Scandinavian journal of gastroenterology, 2005, Volume: 40, Issue:3

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Diagnostic Errors; Endoscopy

2005
Is non-adherence to blame?
    Inflammatory bowel diseases, 2005, Volume: 11, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Inflammatory Bowel Diseases; Male; Mesalami

2005
Adherence to treatment in inflammatory bowel disease.
    Revista espanola de enfermedades digestivas, 2005, Volume: 97, Issue:4

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Female; Gastroin

2005
Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model.
    Pharmaceutical research, 2005, Volume: 22, Issue:8

    Topics: Algorithms; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Transport, Active; Caco-2 C

2005
Safety of high doses of mesalazine during pregnancy.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Inflammatory Bowel Diseases; Mesalamine; Pr

2005
[Primary chemoprevention of colorectal cancer in patients with inflammatory bowel diseases].
    Likars'ka sprava, 2005, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Colorectal Neoplasms; Humans; Inflammatory

2005
Inflammatory bowel disease and drug intake.
    Inflammatory bowel diseases, 2005, Volume: 11, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Female; Humans; Inflammatory Bowel Dis

2005
Mesalamine-induced pneumonitis during therapy for chronic inflammatory bowel disease: a pediatric case report.
    Journal of pediatric gastroenterology and nutrition, 2005, Volume: 41, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Diagnosis, Differential; Female; Humans; Inflammator

2005
Mesalazine-associated acute tubulointerstitial nephritis in a patient with spondylarthropathy.
    The New Zealand medical journal, 2005, Sep-16, Volume: 118, Issue:1222

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Creatinine; Humans; Inflammatory Bowel Disea

2005
Free radical scavenging reactions of sulfasalazine, 5-aminosalicylic acid and sulfapyridine: mechanistic aspects and antioxidant activity.
    Free radical research, 2005, Volume: 39, Issue:11

    Topics: Aminosalicylic Acids; Anions; Antioxidants; Electrons; Free Radical Scavengers; Free Radicals; Gluta

2005
Distal adenomatous polyps are rare in patients with inflammatory bowel disease.
    Postgraduate medical journal, 2006, Volume: 82, Issue:963

    Topics: Adenomatous Polyps; Antimetabolites, Antineoplastic; Azathioprine; Case-Control Studies; Colorectal

2006
Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2006, Volume: 20, Issue:3

    Topics: Adult; Aged; Amidohydrolases; Animals; Arachidonic Acids; Benzenesulfonates; Colitis; Colitis, Ulcer

2006
Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid?
    World journal of gastroenterology, 2006, Feb-07, Volume: 12, Issue:5

    Topics: Adolescent; Adult; Aged; Colitis, Ulcerative; Creatinine; Crohn Disease; Female; Humans; Inflammator

2006
5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.
    Inflammatory bowel diseases, 2006, Volume: 12, Issue:4

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biomarkers; Child; C

2006
Inflammatory bowel disease in Thai children: presentations and outcomes of treatment.
    Asian Pacific journal of allergy and immunology, 2006, Volume: 24, Issue:1

    Topics: Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Child; C

2006
Medication-taking behavior in a cohort of patients with inflammatory bowel disease.
    Digestive diseases and sciences, 2006, Volume: 51, Issue:12

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cohort Studies; Female; Humans; Immuno

2006
Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease.
    Acta paediatrica (Oslo, Norway : 1992), 2007, Volume: 96, Issue:1

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Child; Ch

2007
Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis.
    Inflammatory bowel diseases, 2007, Volume: 13, Issue:1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Bacteria; Bacterial Adhesion; Colitis;

2007
5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
    Inflammatory bowel diseases, 2007, Volume: 13, Issue:4

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Colorectal Neoplasms; Female; H

2007
Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota.
    The American journal of gastroenterology, 2007, Volume: 102, Issue:4

    Topics: Adult; Case-Control Studies; Colonoscopy; Colorectal Neoplasms; Denmark; Female; Gastrointestinal Ag

2007
Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:11

    Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diagnosis,

2007
Nonadherence in inflammatory bowel disease: results of factor analysis.
    Inflammatory bowel diseases, 2007, Volume: 13, Issue:10

    Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers;

2007
Parallel manifestation of Crohn's disease and acute pericarditis: a report of two cases.
    International journal of colorectal disease, 2007, Volume: 22, Issue:9

    Topics: Acute Disease; Adult; Crohn Disease; Female; Humans; Inflammatory Bowel Diseases; Male; Mesalamine;

2007
Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism.
    The American journal of gastroenterology, 2007, Volume: 102, Issue:12

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Female; Humans; In

2007
Effect of sulphasalazine and balsalazide on histamine release from mast cells.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2007, Volume: 56 Suppl 1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Gastrointestinal Agents; Histamine Rele

2007
Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamine.
    Inflammatory bowel diseases, 2008, Volume: 14, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cells, Cultured; Colonic Neoplasms; E

2008
Estimating the economic burden of inflammatory bowel disease in Canada: physician office visits and mesalamine prescriptions dispensed as surrogate markers.
    The American journal of gastroenterology, 2007, Volume: 102, Issue:11

    Topics: Adolescent; Adult; Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Canada; Child; Female;

2007
Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.
    European journal of gastroenterology & hepatology, 2008, Volume: 20, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Dose-Response Relationship, Drug; Drug Intera

2008
Natural history and long-term clinical behavior of segmental colitis associated with diverticulosis (SCAD syndrome).
    Digestive diseases and sciences, 2008, Volume: 53, Issue:9

    Topics: Abdominal Pain; Adult; Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis; Dia

2008
Modulation of cytokine release from human monocytes by drugs used in the therapy of inflammatory bowel diseases.
    European journal of gastroenterology & hepatology, 1995, Volume: 7, Issue:8

    Topics: Aminosalicylic Acids; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non

1995
Comparison of the effects of sulphasalazine, 5-aminosalicylic acid and sulphapyridine on the humoral response to antigen in vivo.
    Advances in experimental medicine and biology, 1995, Volume: 371B

    Topics: Administration, Oral; Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibo

1995
Oxidation of 5-aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Possible role in the treatment of inflammatory bowel diseases.
    Drug metabolism and disposition: the biological fate of chemicals, 1995, Volume: 23, Issue:2

    Topics: Amino Acids; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Biotransformation; Gluta

1995
An alternative view of 5-ASA formulations.
    Gut, 1995, Volume: 36, Issue:4

    Topics: Aminosalicylic Acids; Chemistry, Pharmaceutical; Humans; Inflammatory Bowel Diseases; Kidney Disease

1995
[5-ASA versus sulfasalazine].
    Acta gastroenterologica Latinoamericana, 1994, Volume: 25, Issue:5

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases;

1994
[Effect of mesalazine, an agent for the treatment of idiopathic inflammatory bowel disease, on reactive oxygen metabolites and LTB4 formation].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1994, Volume: 104, Issue:6

    Topics: Aminosalicylic Acids; Animals; Depression, Chemical; Dosage Forms; Dose-Response Relationship, Drug;

1994
Mesalazine during pregnancy.
    Lancet (London, England), 1994, Dec-17, Volume: 344, Issue:8938

    Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Infant, Newb

1994
Disposition of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid in fetal and maternal body fluids during treatment with different 5-aminosalicylic acid preparations.
    Acta obstetricia et gynecologica Scandinavica, 1994, Volume: 73, Issue:5

    Topics: Aminosalicylic Acids; Drug Monitoring; Female; Fetal Blood; Fetus; Humans; Inflammatory Bowel Diseas

1994
Experience with Eudragit-S coated mesalamine (Asacol) in inflammatory bowel disease: adverse events.
    Journal of clinical gastroenterology, 1994, Volume: 18, Issue:2

    Topics: Acrylic Resins; Aminosalicylic Acids; Humans; Inflammatory Bowel Diseases; Mesalamine; Polymethacryl

1994
Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPase. A possible diarrhogenic factor?
    The Clinical investigator, 1993, Volume: 71, Issue:4

    Topics: Aminosalicylic Acids; Binding, Competitive; Colon, Sigmoid; Diarrhea; Humans; Ileum; Inflammatory Bo

1993
[The role of free radical scavengers in gastrointestinal diseases].
    Orvosi hetilap, 1993, Mar-28, Volume: 134, Issue:13

    Topics: Aminosalicylic Acids; Antioxidants; Ascorbic Acid; Free Radical Scavengers; Gastrointestinal Disease

1993
Bioavailability of controlled release mesalazine (5-ASA) preparations.
    Journal of gastroenterology, 1995, Volume: 30 Suppl 8

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Delayed-Acti

1995
Arachidonic acid metabolism and intracellular calcium concentration in inflammatory bowel disease.
    European journal of gastroenterology & hepatology, 1995, Volume: 7, Issue:9

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Biopsy; Calcium; Ce

1995
Mesalazine-associated interstitial nephritis.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1996, Volume: 11, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroid

1996
5-aminosalicylates in inflammatory bowel disease--the more the merrier?
    European journal of gastroenterology & hepatology, 1995, Volume: 7, Issue:11

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; H

1995
[Aminosalicylates in the treatment of idiopathic inflammatory bowel disease].
    Vnitrni lekarstvi, 1996, Volume: 42, Issue:2

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases;

1996
Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease.
    European journal of gastroenterology & hepatology, 1996, Volume: 8, Issue:5

    Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, N

1996
Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome.
    Alimentary pharmacology & therapeutics, 1996, Volume: 10, Issue:4

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Drug Utilization; Gastrointestinal Ag

1996
Mesalamine-induced hypersensitivity pneumonitis. A case report and review of the literature.
    Journal of clinical gastroenterology, 1997, Volume: 24, Issue:1

    Topics: Alveolitis, Extrinsic Allergic; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Drug

1997
Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs.
    Journal of drug targeting, 1997, Volume: 4, Issue:5

    Topics: Administration, Oral; Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsul

1997
Pancreatitis in patients with inflammatory bowel disease.
    Journal of pediatric gastroenterology and nutrition, 1997, Volume: 25, Issue:1

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Azathioprine;

1997
Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate.
    Gut, 1997, Volume: 40, Issue:6

    Topics: Adult; Alkaline Phosphatase; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Dose-Res

1997
Massive pericardial effusion in a child following the administration of mesalamine.
    Journal of pediatric gastroenterology and nutrition, 1997, Volume: 25, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Dose-Response Relationship, Drug; Echocardiography;

1997
Mesalazine preparations.
    Lancet (London, England), 1997, Nov-01, Volume: 350, Issue:9087

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Mesalamine

1997
Mesalazine preparations.
    Lancet (London, England), 1998, Jan-03, Volume: 351, Issue:9095

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Mesalamine

1998
Nephrotic syndrome associated with inflammatory bowel disease treated by mesalazine.
    Nephron, 1998, Volume: 79, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Inflammatory Bowel Diseases; Mesalamine; Mi

1998
Synthesis and intestinal metabolism of ursodeoxycholic acid conjugate with an antiinflammatory agent, 5-aminosalicylic acid.
    Journal of lipid research, 1998, Volume: 39, Issue:8

    Topics: Amidohydrolases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Transport, Active; Clo

1998
Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules.
    Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:11

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chi-Square Distribution; Drug Administration Schedul

1998
Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies.
    Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agen

1999
Health-related quality of life in inflammatory bowel disease.
    PharmacoEconomics, 1996, Volume: 10, Issue:4

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Health Status; Humans; Inflammatory B

1996
Mesalamine: safe at first look.
    Inflammatory bowel diseases, 1999, Volume: 5, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Female; Humans; Inflammatory Bowel Diseases

1999
Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction.
    Gastroenterology, 1999, Volume: 116, Issue:6

    Topics: Aminosalicylic Acids; Anti-Ulcer Agents; Antirheumatic Agents; Azathioprine; Drug Interactions; Drug

1999
[Pregnancy outcome in inflammatory bowel diseases].
    Gastroenterologie clinique et biologique, 1999, Volume: 23, Issue:5

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; Female;

1999
Claversal dissolution.
    Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Humans; Hydrogen-Ion Concentra

1999
Hypersensitivity to 5-ASA suppositories.
    Digestive diseases and sciences, 1999, Volume: 44, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Hypersensitivity; Humans; Inflammatory Bowel Diseases;

1999
High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy.
    Gastroenterology, 2000, Volume: 118, Issue:2

    Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azathioprine; Colectomy; Colon; Cycl

2000
Altered IgG(4) renal clearance in patients with inflammatory bowel diseases. Evidence for a subclinical impairment of protein charge renal selectivity.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2000, Volume: 15, Issue:4

    Topics: Administration, Oral; Adult; Albuminuria; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antin

2000
Segmental colitis associated with diverticula: a prospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII).
    The American journal of gastroenterology, 2000, Volume: 95, Issue:4

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis; Colonoscopy; Diverticulit

2000
Hematological monitoring in patients receiving aminosalicylates.
    The American journal of gastroenterology, 2000, Volume: 95, Issue:4

    Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents; Drug Monitoring; Humans; Inf

2000
Diarrhea as a side effect of mesalamine treatment for inflammatory bowel disease.
    Journal of clinical gastroenterology, 2000, Volume: 31, Issue:1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diarrhea; Female; Humans; Inflammatory Bowel Disease

2000
Interaction of 6-mercaptopurine and azathioprine with 5-aminosalicylic acid agents.
    Gastroenterology, 2000, Volume: 119, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Drug Interactions; Humans; Inflammatory Bowel

2000
Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:9

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Dose-Response Relationsh

2000
Pyelonephritis caused by mesalazine.
    Nephron, 2000, Volume: 86, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Cell Count; Blood Sedimentation; Hematuria; Hu

2000
Glucocorticoids and IL-10, but not 6-MP, 5-ASA or sulfasalazine block endothelial expression of MAdCAM-1: implications for inflammatory bowel disease therapy.
    Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:8

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion Molecules; Cells, Cultured; Dexameth

2001
Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy.
    European journal of gastroenterology & hepatology, 2001, Volume: 13, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug T

2001
Management of inflammatory bowel disease during pregnancy and nursing.
    Seminars in gastrointestinal disease, 2001, Volume: 12, Issue:4

    Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Breast Feeding; Ce

2001
Mesalamine intolerance mimics symptoms of active inflammatory bowel disease.
    Journal of pediatric gastroenterology and nutrition, 2002, Volume: 34, Issue:1

    Topics: Abdominal Pain; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Diarrhea; Female; Humans; Infla

2002
Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:12

    Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents,

2001
Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cells, Cultured; Colonoscopy; Dose-Res

2002
Superoxide, hydroxyl and fatty acid radical scavenging by aminosalicylates. Direct evaluation with electron spin resonance spectroscopy.
    Biochemical pharmacology, 1992, Jan-22, Volume: 43, Issue:2

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Chromatography, High Pressure Liquid; Electron Spin Reson

1992
Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.
    Alimentary pharmacology & therapeutics, 1992, Volume: 6, Issue:1

    Topics: Aminosalicylic Acids; Drug Hypersensitivity; Female; Humans; Inflammatory Bowel Diseases; Male; Mesa

1992
Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease.
    The American journal of gastroenterology, 1992, Volume: 87, Issue:8

    Topics: Adolescent; Aminosalicylic Acids; Child; Chronic Disease; Desensitization, Immunologic; Diarrhea; Do

1992
The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model.
    British journal of cancer, 1992, Volume: 66, Issue:5

    Topics: Adenocarcinoma; Aminosalicylic Acids; Animals; Cocarcinogenesis; Colonic Neoplasms; Dimethylhydrazin

1992
Chronic intrajejunal TNBS application in TNBS-sensitized rats: a new model of chronic inflammatory bowel diseases.
    Agents and actions, 1992, Volume: Spec No

    Topics: Aminosalicylic Acids; Animals; Disease Models, Animal; Female; Immunization; Inflammatory Bowel Dise

1992
Enhanced mucosal cytokine production in inflammatory bowel disease.
    Gastroenterology, 1992, Volume: 102, Issue:2

    Topics: Aminosalicylic Acids; Cyclosporine; Fluorescent Antibody Technique; Granulocyte Colony-Stimulating F

1992
Pancreatitis induced by mesalamine.
    The Netherlands journal of medicine, 1992, Volume: 41, Issue:1-2

    Topics: Acute Disease; Adult; Aminosalicylic Acids; Female; Humans; Inflammatory Bowel Diseases; Mesalamine;

1992
Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.
    Gut, 1992, Volume: 33, Issue:10

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Northe

1992
IL-2 production by intestinal lamina propria cells in normal inflamed and cancer-bearing colons.
    Clinical and experimental immunology, 1992, Volume: 88, Issue:1

    Topics: Aminosalicylic Acids; Colonic Neoplasms; Cyclosporine; Humans; Hydrocortisone; Inflammatory Bowel Di

1992
The effect of 5-aminosalicylic acid on the mucosal immune system.
    Gastroenterology, 1992, Volume: 102, Issue:3

    Topics: Aminosalicylic Acids; Antigens, Surface; Cell Division; Gene Expression; Humans; Immunity; Inflammat

1992
Immunology of inflammatory bowel disease: summary of the proceedings of the Subcommittee on Immunosuppressive Use in IBD.
    Journal of pediatric gastroenterology and nutrition, 1991, Volume: 12, Issue:4

    Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Humans; Immunologic Factors; Immunosuppressive Agent

1991
Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid.
    Digestive diseases and sciences, 1991, Volume: 36, Issue:2

    Topics: Adult; Aged; Aminosalicylic Acids; Basophils; Cells, Cultured; Colon; Female; Histamine Release; Hum

1991
Salicylates used in inflammatory bowel disease and colchicine impair interferon-gamma induced HLA-DR expression.
    Gut, 1992, Volume: 33, Issue:1

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cell Line; Colchicine; Colon; Epithelium; Flow Cytometry;

1992
5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease.
    Gut, 1991, Volume: 32, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Colitis, Ulcerative; Colon; Crohn Disease; Dex

1991
Is radical scavenging necessary in the treatment of inflammatory bowel disease?
    Gastroenterology, 1991, Volume: 100, Issue:2

    Topics: Aminosalicylic Acids; Free Radical Scavengers; Humans; Inflammatory Bowel Diseases; Mesalamine

1991
[5-aminosalicylic acid-associated pancreatitis].
    Deutsche medizinische Wochenschrift (1946), 1991, Jul-12, Volume: 116, Issue:28-29

    Topics: Acute Disease; Aminosalicylic Acids; Humans; Inflammatory Bowel Diseases; Mesalamine; Pancreatitis

1991
1989 Henry Baker lecture. Inflammatory bowel disease: back to the future.
    The American journal of gastroenterology, 1990, Volume: 85, Issue:4

    Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Awards and Prizes; Colorectal Neoplasms; Gastroentero

1990
New approaches may aid patients with inflammatory bowel disease.
    JAMA, 1990, Jun-20, Volume: 263, Issue:23

    Topics: Aminosalicylic Acids; Cyclosporins; Fish Oils; Humans; Hydroxychloroquine; Inflammatory Bowel Diseas

1990
Management of inflammatory bowel disease. Proceedings of an international symposium on mesalazine. frankfurt, 23-25 March 1988.
    Scandinavian journal of gastroenterology. Supplement, 1990, Volume: 172

    Topics: Aminosalicylic Acids; Humans; Inflammatory Bowel Diseases; Mesalamine

1990
Pharmaceutic development: mesalazine.
    Scandinavian journal of gastroenterology. Supplement, 1990, Volume: 172

    Topics: Aminosalicylic Acids; Chemical Phenomena; Chemistry; Dosage Forms; Drug Administration Routes; Human

1990
Macrotransaminase of aspartate aminotransferase (AST): a benign cause of elevated AST activity.
    The Journal of pediatrics, 1990, Volume: 117, Issue:3

    Topics: Adolescent; Aminosalicylic Acids; Aspartate Aminotransferases; Female; Humans; Inflammatory Bowel Di

1990
The reaction of 5-amino-salicylic acid with hypochlorite. Implications for its mode of action in inflammatory bowel disease.
    Biochemical pharmacology, 1989, Jan-01, Volume: 38, Issue:1

    Topics: Aminosalicylic Acids; Fluorescence; Humans; Hypochlorous Acid; Inflammatory Bowel Diseases; Luminesc

1989
Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease.
    Gastroenterology, 1989, Volume: 97, Issue:1

    Topics: Acetylation; Aminosalicylic Acids; Chromatography, High Pressure Liquid; Colon; Feces; Humans; Infla

1989
Inflammatory bowel disease and male infertility: effects of sulfasalazine and 5-aminosalicylic acid on sperm-fertilizing capacity and reactive oxygen species generation.
    Fertility and sterility, 1989, Volume: 52, Issue:5

    Topics: Adult; Aminosalicylic Acids; Animals; Cricetinae; Female; Free Radicals; Humans; Infertility, Male;

1989
Mesalazine in childhood inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 1989, Volume: 3, Issue:6

    Topics: Adolescent; Aminosalicylic Acids; Child; Child, Preschool; Colitis, Ulcerative; Crohn Disease; Femal

1989
Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 1987, Volume: 1, Issue:4

    Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Female; Humans; Inflammatory

1987